

23.05.2020

**12:00 - 12:15**    **Type: Opening/closure**    **Channel 1**  
**Title: Opening and welcome**  
Chair(s): Sibylle Loibl, DE; Giuseppe Curigliano, IT

12:00 - 12:15    **Welcome to the Congress**

**12:00 - 20:00**    **Type: ePoster**    **ePosters**  
**Title: ePoster**

12:00 - 12:00    **Biomarkers and translational research and precision medicine**

12:00 - 12:00    **4P - Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)&#x2b;/HER2&#x2b; breast cancer (BC)**  
T. Pascual<sup>1</sup>, A. Fernandez-Martinez<sup>2</sup>, M. Tanioka<sup>2</sup>, M.V. Dieci<sup>3</sup>, S. Pernas Simon<sup>4</sup>, J. Gavila Gregori<sup>5</sup>, V. Guarneri<sup>6</sup>, J. Cortés<sup>7</sup>, P. Villagrasa<sup>8</sup>, M.J. Vidal<sup>9</sup>, B. Adamo<sup>9</sup>, M. Muñoz<sup>9</sup>, G. Griguolo<sup>3</sup>, A. Llombart Cussac<sup>10</sup>, M. Oliveira<sup>11</sup>, L. Paré<sup>8</sup>, L. Carey<sup>12</sup>, C. Perou<sup>13</sup>, A. Prat<sup>14</sup>, <sup>1</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>2</sup>UNC Lineberger Comprehensive Cancer Center - University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>3</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, <sup>5</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>6</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>SOLTI, Barcelona, ES, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>11</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>12</sup>UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, <sup>13</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00    **5P - Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)**  
O. Martinez Saez<sup>1</sup>, T. Pascual<sup>1</sup>, F. Brasó-Maristany<sup>2</sup>, N. Chic<sup>3</sup>, B. González-Farré<sup>1</sup>, E. Sanfeliu<sup>1</sup>, A. Rodríguez<sup>1</sup>, D. Martínez<sup>2</sup>, P. Galván<sup>2</sup>, A. Rodriguez Hernandez<sup>4</sup>, F. Schettini<sup>5</sup>, B. Conte<sup>6</sup>, M.J. Vidal<sup>1</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, R. Moreno<sup>1</sup>, E. Ciruelos<sup>7</sup>, I. Faull<sup>8</sup>, J. Odegaard<sup>9</sup>, A. Prat<sup>4</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>IDIBAPS, Barcelona, ES, <sup>3</sup>Hospital Clinic, Barcelona, ES, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>8</sup>Guardant Health, Barcelona, ES, <sup>9</sup>Guardant Health, Redwood City, US

12:00 - 12:00    **6P - Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER&#x2b;/HER2-negative advanced breast cancer (ABC)**

F. Galardi<sup>1</sup>, C. Biagioni<sup>1</sup>, F. De Luca<sup>1</sup>, G. Curigliano<sup>2</sup>, A.M. Minisini<sup>3</sup>, M. Bonechi<sup>1</sup>, E. Moretti<sup>4</sup>, E. Risi<sup>5</sup>, I. Migliaccio<sup>4</sup>, A. McCartney<sup>4</sup>, M. Benelli<sup>4</sup>, D. Romagnoli<sup>1</sup>, V. Conti<sup>6</sup>, L. Biganzoli<sup>5</sup>, A. Di Leo<sup>5</sup>, L. Malorni<sup>7</sup>, <sup>1</sup>Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, <sup>4</sup>Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, <sup>5</sup>Nuovo Ospedale di Prato, Prato, IT, <sup>6</sup>Children's Hospital A. Meyer, Firenze, ITALY, Firenze, IT, <sup>7</sup>Hospital of Prato, Azienda USL Toscana Centro, Prato, IT

12:00 - 12:00

**7P - Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial**

G. Wan, F. Cao, X. Cai, X. Yu, Z. Zuo, Y. Song, T. Xu, Y. Li, Y. Yu, X. Wang, X. Wang, Hubei University of Medicine, Shiyan, CN

12:00 - 12:00

**8P - Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)**

G. Griguolo<sup>1</sup>, G. Serna<sup>2</sup>, T. Pascual<sup>3</sup>, R. Fasani<sup>2</sup>, N. Chic<sup>4</sup>, L. Paré<sup>5</sup>, S. Pernas<sup>6</sup>, M. Muñoz<sup>3</sup>, M. Oliveira<sup>7</sup>, M. Vidal<sup>4</sup>, A. Llombart Cussac<sup>8</sup>, J. Cortés<sup>9</sup>, P. Galván<sup>10</sup>, B. Bermejo<sup>11</sup>, N. Martínez<sup>12</sup>, R. López<sup>13</sup>, S. Morales<sup>14</sup>, P. Villagrasa<sup>5</sup>, A. Prat<sup>15</sup>, P. Nuciforo<sup>2</sup>, <sup>1</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>4</sup>Hospital Clinic, Barcelona, ES, <sup>5</sup>SOLTI, Barcelona, ES, <sup>6</sup>Institut Catala d'Oncologia, Hospitalet de Llobregat, ES, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>10</sup>IDIBAPS, Barcelona, ES, <sup>11</sup>Hospital Clínico Universitario de Valencia / INCLIVA / CIBERONC, Valencia, ES, <sup>12</sup>Ramon y Cajal Hospital, Madrid, ES, <sup>13</sup>Hospital Clínico Universitario de Santiago / CIBERONC, Santiago de Compostela, ES, <sup>14</sup>Hospital Universitario Arnau de Vilanova, LLEIDA, ES, <sup>15</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00

**9P - The histopathologic profile of pregnancy associated breast cancer; particularly aggressive breast cancer subtype. Analysis of the Dutch National Registry**

B. Suelmann<sup>1</sup>, E. Van Der Wall<sup>1</sup>, C. Van Dooijweert<sup>2</sup>, S. Linn<sup>3</sup>, P. Van Diest<sup>2</sup>, <sup>1</sup>UMC-University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>UMC - university medical center Utrecht, Utrecht, NL, <sup>3</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

12:00 - 12:00

**10P - Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer**

F. Le Du<sup>1</sup>, F. Takeo<sup>2</sup>, M. Park<sup>2</sup>, K. Hess<sup>2</sup>, D. Liu<sup>2</sup>, R. Jackson<sup>2</sup>, C. Mylander<sup>3</sup>, M. Rosman<sup>3</sup>, A. Raghavendra<sup>2</sup>, L. Tafra<sup>3</sup>, N. Ueno<sup>2</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Anne Arundel Medical Center, Annapolis, US

12:00 - 12:00

**11P - BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC)**

G. Bianchini<sup>1</sup>, M. De Laurentiis<sup>2</sup>, G. Arpino<sup>3</sup>, A. Zambelli<sup>4</sup>, F. Puglisi<sup>5</sup>, L. Del Mastro<sup>6</sup>, M. Colleoni<sup>7</sup>, F. Montemurro<sup>8</sup>, G. Bianchi<sup>9</sup>, I. Paris<sup>10</sup>, G. Allegrini<sup>11</sup>, L. Amaducci<sup>12</sup>, M. Cazzaniga<sup>13</sup>, M. Orditura<sup>14</sup>, C. Zamagni<sup>15</sup>, S. Bianchetti<sup>16</sup>, D. Castelletti<sup>16</sup>, M. Benelli<sup>17</sup>, M. Callari<sup>18</sup>, L. Malorni<sup>19</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT, <sup>3</sup>Università Federico II, Naples, IT, <sup>4</sup>Presidio Ospedaliero Papa Giovanni XXIII, Bergamo, IT, <sup>5</sup>Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, <sup>9</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>10</sup>Università Cattolica del Sacro Cuore, Rome, IT, <sup>11</sup>Az Osp ULS 5 - Ospedale Pontedera, Pontedera, IT, <sup>12</sup>P.O. Ospedale degli Infermi, Romagna, IT, <sup>13</sup>Azienda Ospedaliera S. Gerardo, Monza, IT, <sup>14</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>15</sup>AOU Policlinico S. Orsola-Malpighi, F. Addarii, Bologna, IT, <sup>16</sup>Novartis Farma Italy, Origgio, IT, <sup>17</sup>Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, <sup>18</sup>University of Cambridge, Li Ka Shing Centre, Cambridge, GB, <sup>19</sup>Hospital of Prato, Azienda USL Toscana Centro, Prato, IT

12:00 - 12:00 **12P - Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R&#x2b;L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial**

N. Chic<sup>1</sup>, B. González-Farré<sup>2</sup>, L. Paré<sup>3</sup>, T. Pascual<sup>4</sup>, C. Saura Manich<sup>5</sup>, C. Hernando Melia<sup>6</sup>, M. Muñoz<sup>2</sup>, P. Fernandez<sup>7</sup>, D. Martínez<sup>8</sup>, E. Sanfeliu<sup>2</sup>, F. Brasó-Maristany<sup>9</sup>, X. González-Farré<sup>10</sup>, M. Oliveira<sup>11</sup>, M. Gil-Gil<sup>12</sup>, P. Celiz<sup>13</sup>, E. Ciruelos<sup>14</sup>, P. Villagrasa<sup>3</sup>, J. Gavila Gregori<sup>15</sup>, A. Prat<sup>16</sup>, <sup>1</sup>Hospital Clinic, Barcelona, ES, <sup>2</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>3</sup>SOLTI, Barcelona, ES, <sup>4</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>7</sup>Hospital Germans Trias i Pujol, Badalona, ES, <sup>8</sup>Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, <sup>9</sup>IDIBAPS, Barcelona, ES, <sup>10</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>11</sup>Vall d' Hebron University Hospital, Barcelona, ES, <sup>12</sup>Institut Catala d' Oncologia, L'Hospitalet de Llobregat, ES, <sup>13</sup>SOLTI HQ, Barcelona, ES, <sup>14</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>15</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>16</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **13P - HER2 low testing in breast cancer: How to optimize detection**

F. Cecchi<sup>1</sup>, D. Carrolle<sup>2</sup>, M. Gustavson<sup>1</sup>, S. Sridhar<sup>1</sup>, M. De Los Reyes<sup>1</sup>, S. Thyparambil<sup>3</sup>, A. Bhalkikar<sup>3</sup>, W.-L. Liao<sup>3</sup>, S. Coats<sup>1</sup>, T. Hembrough<sup>1</sup>, <sup>1</sup>AstraZeneca USA, Gaithersburg, US, <sup>2</sup>AstraZeneca USA, cambridge, GB, <sup>3</sup>mProbe, Gaithersburg, US

12:00 - 12:00 **14P - Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma**

N. Palazón Carrión<sup>1</sup>, C. Jiménez Cortegana<sup>2</sup>, M.L. Sánchez León<sup>2</sup>, F. Henao Carrasco<sup>3</sup>, E. Nogales Fernandez<sup>1</sup>, V. Sánchez Margalet<sup>1</sup>, L. De La Cruz Merino<sup>2</sup>, <sup>1</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>2</sup>Hospital Universitario Virgen Macarena, sevilla, la macarena, ES, <sup>3</sup>Hospital Universitario Virgen Macarena, Sevilla, ES

12:00 - 12:00 **15P - The CelTIL score as an early predictor of anti-tumour response following**



**neoadjuvant therapy (NAT): A SOLTI biomarker analysis**

B. González-Farré<sup>1</sup>, P. Nuciforo<sup>2</sup>, L. Pare Brunet<sup>3</sup>, J. Cortés<sup>4</sup>, A. Llombart Cussac<sup>5</sup>, J. Gavila Gregori<sup>6</sup>, E. Sanfeliu<sup>1</sup>, N. Chic<sup>7</sup>, M. Vidal<sup>7</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, P. Galván<sup>8</sup>, D. Martínez<sup>8</sup>, P. Villagrasa<sup>9</sup>, T. Pascual<sup>1</sup>, A. Prat<sup>3</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>6</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>7</sup>Hospital Clinic, Barcelona, ES, <sup>8</sup>IDIBAPS, Barcelona, ES, <sup>9</sup>SOLTI, Barcelona, ES

12:00 - 12:00 **17P - Dysregulation of immune checkpoint proteins in newly diagnosed early breast cancer patients**

B. Rapoport<sup>1</sup>, A. Theron<sup>2</sup>, H. Steel<sup>2</sup>, S. Nayler<sup>3</sup>, C. Benn<sup>4</sup>, N. Hlatswayo<sup>2</sup>, L. Kwofie<sup>2</sup>, L. Heyman<sup>1</sup>, T. Smit<sup>1</sup>, L. Jooste<sup>1</sup>, F. Moosa<sup>1</sup>, R. Anderson<sup>2</sup>, <sup>1</sup>The Medical Oncology Centre of Rosebank, Johannesburg, ZA, <sup>2</sup>University of Pretoria Faculty of Health Sciences, Pretoria, ZA, <sup>3</sup>Drs Gritzman & Thatcher Inc Laboratories & Wits Donald Gordon Medical Centre, Randburg, ZA, <sup>4</sup>Head of Netcare breast care Centre, Johannesburg, ZA

12:00 - 12:00 **18P - Inter-tumour heterogeneity in breast cancers: The dynamic evolution of cancer genome during the metastatic process**

C. Fumagalli<sup>1</sup>, A. Ranghiero<sup>2</sup>, S. Gandini<sup>2</sup>, F. Corso<sup>2</sup>, S. Taormina<sup>2</sup>, E. De Camilli<sup>2</sup>, G. Viale<sup>3</sup>, M. Barberis<sup>3</sup>, E. Guerini Rocco<sup>4</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>European Institute of Oncology, Milan, IT, <sup>3</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup>University of Milan, Milan, IT

12:00 - 12:00 **19P - PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study**

V. Guarneri<sup>1</sup>, M.V. Dieci<sup>2</sup>, G. Bisagni<sup>3</sup>, A. Brandes<sup>4</sup>, A. Frassoldati<sup>5</sup>, L. Cavanna<sup>6</sup>, A. Musolino<sup>7</sup>, F. Giotta<sup>8</sup>, A. Rimanti<sup>9</sup>, O. Garrone<sup>10</sup>, E. Bertone<sup>11</sup>, K. Cagossi<sup>12</sup>, O. Nanni<sup>13</sup>, F. Piacentini<sup>14</sup>, E. Orvieto<sup>15</sup>, M. Curtarello<sup>16</sup>, N. Chic<sup>17</sup>, R. D'Amico<sup>18</sup>, A. Prat<sup>19</sup>, P.F. Conte<sup>1</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>Azienda USL-IRCCS, Reggio Emilia, IT, <sup>4</sup>Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, IT, <sup>5</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>6</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>7</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>8</sup>Istituto Oncologico Bari, Bari, IT, <sup>9</sup>University Hospital of Parma, Parma, IT, <sup>10</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>11</sup>Sant'Anna Hospital, Torino, IT, <sup>12</sup>Ramazzini Hospital, Carpi, IT, <sup>13</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>14</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>15</sup>Ulss 5 Polesana, Rovigo, IT, <sup>16</sup>Veneto Institute of Oncology IRCCS, padova, IT, <sup>17</sup>Hospital Clinic, Barcelona, ES, <sup>18</sup>University of Modena, Modena, IT, <sup>19</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **21P - Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)**

J. Litton<sup>1</sup>, L. Zhao<sup>1</sup>, J. White<sup>1</sup>, B. Arun<sup>2</sup>, E. Ravenberg<sup>1</sup>, X. Song<sup>1</sup>, J. Zhang<sup>1</sup>, S. Moulder<sup>1</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The M. D. Anderson Cancer Center, Houston, US

- 12:00 - 12:00 **23P - Clinical, pathological and gene expression features of HER2-low breast cancer**  
F. Schettini<sup>1</sup>, N. Chic<sup>2</sup>, F. Brasó-Maristany<sup>3</sup>, L. Paré<sup>4</sup>, T. Pascual<sup>5</sup>, B. Conte<sup>6</sup>, O. Martinez Saez<sup>5</sup>, B. Adamo<sup>5</sup>, M. Vidal<sup>2</sup>, A. Fernandez-Martinez<sup>7</sup>, B. González-Farré<sup>5</sup>, E. Sanfeliu<sup>5</sup>, G. Perrone<sup>8</sup>, P. Villagrasa<sup>4</sup>, J. Gavila Gregori<sup>9</sup>, C. Barrios<sup>10</sup>, A. Lluch<sup>11</sup>, M. Martin Jimenez<sup>12</sup>, S. De Placido<sup>13</sup>, A. Prat<sup>14</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>2</sup>Hospital Clinic, Barcelona, ES, <sup>3</sup>IDIBAPS, Barcelona, ES, <sup>4</sup>SOLTI, Barcelona, ES, <sup>5</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>UNC Lineberger Comprehensive Cancer Center - University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>8</sup>Campus Bio-Medico University, Rome, IT, <sup>9</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>10</sup>Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre, BR, <sup>11</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>12</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>13</sup>University of Naples Federico II, Naples, IT, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **24P - The influence of metabolic syndrome on the risk of breast cancer: A study analysing nationwide data from the Korean National Health Insurance Service**  
K.-T. Hwang, Boramae Medical Center, Seoul, KR
- 12:00 - 12:00 **25P - Breast cancers with heterogeneous HER2 amplification show a diverse distribution of driver and passenger somatic mutations and copy number variations**  
M. Van Bockstal<sup>1</sup>, M.C. Agahozo<sup>2</sup>, R. Van Marion<sup>2</sup>, P. Atmodimedjo<sup>2</sup>, H. Sleddens<sup>2</sup>, W. Dinjens<sup>2</sup>, L. Visser<sup>3</sup>, E. Lips<sup>4</sup>, J. Wesseling<sup>4</sup>, C. Van Deurzen<sup>5</sup>, <sup>1</sup>Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>5</sup>Erasmus University Medical Center, Rotterdam, NL
- 12:00 - 12:00 **28P - Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer**  
R. Erber<sup>1</sup>, A. Hartmann<sup>2</sup>, P. Fasching<sup>3</sup>, R. Stöhr<sup>2</sup>, M. Beckmann<sup>3</sup>, M. Zentgraf<sup>2</sup>, M. Ruebner<sup>4</sup>, H. Huebner<sup>4</sup>, J. Fischer<sup>5</sup>, E. Guerini Rocco<sup>6</sup>, G. Viale<sup>7</sup>, A. Cayre<sup>8</sup>, F. Penault-Llorca<sup>8</sup>, T. Caniego Casa<sup>9</sup>, J. Palacios Calvo<sup>9</sup>, P. Jank<sup>10</sup>, C. Denkert<sup>11</sup>, L. Khoury<sup>12</sup>, T. Mairinger<sup>12</sup>, F. Ferrazzi<sup>2</sup>, <sup>1</sup>Universitaetsklinikum Erlangen - Pathologisches Institut, Erlangen, DE, <sup>2</sup>University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>3</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>4</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, DE, <sup>5</sup>Qualitätssicherungs-Initiative Pathologie QuIP GmbH, Berlin, DE, <sup>6</sup>University of Milan, Milan, IT, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>9</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>10</sup>Uniklinikum Giessen und Marburg (UKGM), Marburg, DE, <sup>11</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>12</sup>MVZ Helios Hospital Emil von Behring GmbH, Berlin, DE

- 12:00 - 12:00 **29P - Key cancer gene expression features of hereditary breast cancer in the Kazakh population**  
N. Omarbayeva<sup>1</sup>, D. Kaidarova<sup>1</sup>, A. Abdrakhmanova<sup>1</sup>, G. Zhunussova<sup>2</sup>, S. Abdikerim<sup>3</sup>, L. Djansugurova<sup>3</sup>, <sup>1</sup>Kazakh Reserch Institute of Oncology & Radiology, Almaty, KZ, <sup>2</sup>Institute of general genetics and cytology, Almaty, KZ, <sup>3</sup>Institute of general genetics and cytology, almaty, KZ
- 12:00 - 12:00 **30P - In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients**  
S. D'Oronzo<sup>1</sup>, D. Lovero<sup>2</sup>, R. Palmirotta<sup>2</sup>, P. Cafforio<sup>2</sup>, J. Brown<sup>3</sup>, S. Wood<sup>4</sup>, M. Cives<sup>5</sup>, M. Tucci<sup>1</sup>, L. Stucci<sup>1</sup>, R. Coleman<sup>3</sup>, F. Silvestris<sup>1</sup>, <sup>1</sup>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, IT, <sup>2</sup>University of Bari Aldo Moro, Bari, IT, <sup>3</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>4</sup>University of Sheffield, Sheffield, GB, <sup>5</sup>University of Bari, Bari, IT
- 12:00 - 12:00 **31P - BRCA1/2 gene mutation detection in 2686 Chinese clinical samples based on NGS HANDLE technology**  
F. Zhang<sup>1</sup>, B. Jin<sup>2</sup>, L. Zhang<sup>2</sup>, A. Zhang<sup>2</sup>, H. Ge<sup>2</sup>, M. Mueser<sup>2</sup>, L. Ruan<sup>2</sup>, <sup>1</sup>AmoyDx Medical Institute, Xiamen, CN, <sup>2</sup>Amoy Diagnostics Co., Ltd., Xiamen, CN
- 12:00 - 12:00 **32P - The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer**  
E. Zattarin<sup>1</sup>, C. Fabbroni<sup>2</sup>, F. Ligorio<sup>1</sup>, F. Nichetti<sup>2</sup>, R. Lobefaro<sup>1</sup>, L. Rivoltini<sup>2</sup>, G. Capri<sup>1</sup>, G. Bianchi<sup>1</sup>, F.G.M. De Braud<sup>1</sup>, C. Vernieri<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 12:00 - 12:00 **33P - Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers**  
A. Quintana<sup>1</sup>, V. Peg<sup>2</sup>, T. Moline<sup>2</sup>, A. Prat<sup>3</sup>, L. Paré<sup>4</sup>, P. Galván<sup>5</sup>, G. Villacampa<sup>2</sup>, R. Dientsmann<sup>2</sup>, J. Perez<sup>6</sup>, E. Muñoz<sup>2</sup>, M. Martí<sup>7</sup>, J. Blanco-Heredia<sup>8</sup>, C. Dos Anjos<sup>8</sup>, M. Vazquez<sup>9</sup>, L. De Mattos<sup>8</sup>, J. Cortés<sup>10</sup>, <sup>1</sup>Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES, <sup>2</sup>HOSPITAL VALL D'HEBRON, BARCELONA, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>SOLTI, Barcelona, ES, <sup>5</sup>IDIBAPS, Barcelona, ES, <sup>6</sup>IOB Institute of Oncology, Quironsalud group, Barcelona, ES, <sup>7</sup>Universidad Autónoma de Barcelona, Bellaterra, ES, <sup>8</sup>Hospital Universitari Trias i Pujol, Badalona, ES, <sup>9</sup>Barcelona Supercomputing Center, Barcelona, ES, <sup>10</sup>Vall d'Hebron University Hospital, Barcelona, ES
- 12:00 - 12:00 **34P - Comprehensive clinical and molecular portraits of grade 3 ER+ HER2- breast cancer**  
K. Wang<sup>1</sup>, S. Franch-Expósito<sup>2</sup>, L. Li<sup>3</sup>, T. Xiang<sup>4</sup>, J. Wu<sup>3</sup>, G. Ren<sup>4</sup>, <sup>1</sup>The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, CN, <sup>2</sup>Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, <sup>3</sup>Fudan University Shanghai Cancer Center, Fudan University, Shanghai, CN, <sup>4</sup>The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN



- 12:00 - 12:00 **35P - The role of interplay between microRNA-133a and Mre11 in breast cancer**  
L.-C. Kao, F.-M. Chen, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City, TW
- 12:00 - 12:00 **36P - Molecular subtypes in Tunisian breast cancer**  
M. Frikha<sup>1</sup>, S. Zouari<sup>2</sup>, N. Fourati<sup>2</sup>, M. Kallel<sup>2</sup>, F. Elloumi<sup>2</sup>, M. Bahri<sup>2</sup>, W. Siala<sup>2</sup>, T. Boudawara<sup>2</sup>, A. Khanfir<sup>2</sup>, W. Mnejja<sup>1</sup>, J. Daoud<sup>2</sup>, <sup>1</sup>University of Sfax - Hopital Habib Bourguiba, Sfax, TN, <sup>2</sup>Hopital Habib Bourguiba - Sfax University, Sfax, TN
- 12:00 - 12:00 **37P - A pooled analysis of the clinical utility of genomic signatures in young women with breast cancer**  
A. Ferrigno<sup>1</sup>, C. De La Garza-Ramos<sup>2</sup>, M. Lambertini<sup>3</sup>, R. Barragan-Carrillo<sup>4</sup>, H. Azim Jr<sup>2</sup>, C. Villarreal-Garza<sup>1</sup>, <sup>1</sup>Hospital Zambrano Hellion Tecnológico de Monterrey, San Pedro Garza Garcia, MX, <sup>2</sup>Tecnologico de Monterrey, San Pedro Garza Garcia, MX, <sup>3</sup>University of Genova, Genova, IT, <sup>4</sup>National Institute of Medical Sciences and Nutrition, Mexico City, MX
- 12:00 - 12:00 **38P - Morphological heterogeneity in ductal carcinoma in situ of the breast**  
C. Stanciu Pop<sup>1</sup>, M.-C. Nollevaux<sup>1</sup>, M. Berlière<sup>2</sup>, F. Duhoux<sup>3</sup>, M. Van Bockstal<sup>3</sup>, <sup>1</sup>CHU UCL Namur - Site Godinne, Yvoir, BE, <sup>2</sup>Cliniques Universitaires Saint Luc, Belgium, BE, <sup>3</sup>Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE
- 12:00 - 12:00 **39P - Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel**  
I. Alvarez Lopez<sup>1</sup>, E. González<sup>2</sup>, L. Manso<sup>3</sup>, J.L. Alonso<sup>4</sup>, J. Cruz-Hernández<sup>5</sup>, V. Carañana Ballerini<sup>6</sup>, I. Gallegos<sup>7</sup>, M. Quindós Varela<sup>8</sup>, J. Illaramendi<sup>9</sup>, E. Vicente<sup>10</sup>, A.I. Ballesteros Garcia<sup>11</sup>, F. Ayala De La Pena<sup>12</sup>, A. Perelló<sup>13</sup>, J. Vidal<sup>14</sup>, A. Llombart Cussac<sup>14</sup>, <sup>1</sup>Hospital Donostia, San Sebastian, ES, <sup>2</sup>Hospital Universitario Virgen de las Nieves, Granada, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, ES, <sup>5</sup>Salamanca University Healthcare Complex, Salamanca, ES, <sup>6</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>7</sup>Hospital General Segovia, Segovia, ES, <sup>8</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>9</sup>Hospital de Navarra, Pamplona, ES, <sup>10</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>11</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>12</sup>Hospital Universitario Morales Meseguer, Murcia, ES, <sup>13</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>14</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES
- 12:00 - 12:00 **40P - Analysis of clinical pathological association with somatic mutations through next-generation sequencing**  
S. Jung, Kosin Univeristy Gospel Hospital, Busan, KR
- 12:00 - 12:00 **41P - A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)**  
L. Manso<sup>1</sup>, P. Villagrasa<sup>2</sup>, N. Chic<sup>3</sup>, J.M. Cejalvo<sup>4</sup>, Y. Izarzugaza<sup>5</sup>, B. Cantos<sup>6</sup>, S. Blanch<sup>7</sup>, M. Juan<sup>8</sup>, B. González-Farré<sup>9</sup>, R. Laeufle<sup>10</sup>, G. Nuovo<sup>11</sup>, G. Wilkinson<sup>12</sup>, M. Coffey<sup>12</sup>, A.

González<sup>8</sup>, D. Martínez<sup>13</sup>, L. Paré<sup>2</sup>, F. Salvador<sup>14</sup>, X. González-Farré<sup>15</sup>, A. Prat<sup>16</sup>, J. Gavila Gregori<sup>17</sup>, <sup>1</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>2</sup>SOLTI, Barcelona, ES, <sup>3</sup>Hospital Clinic, Barcelona, ES, <sup>4</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>5</sup>Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, <sup>6</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, <sup>7</sup>Instituto Valenciano de Oncología, Valencia, ES, <sup>8</sup>Hospital Clinic de Barcelona, Barcelona, ES, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Oncolytics biotech inc, Calgary, CA, <sup>11</sup>Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, Powell OHIO, US, <sup>12</sup>Oncolytics Biotech Inc., Calgary, CA, <sup>13</sup>IDIBAPS, Barcelona, ES, <sup>14</sup>SOLTI HQ, Barcelona, ES, <sup>15</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>16</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>17</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES

12:00 - 12:00

**42P - Expression of WNT, Hedgehog and NOTCH signaling pathways in HER-2 overexpressed and triple negative subtypes of breast cancer with high and low content of cancer stem cells**

S. Demidov<sup>1</sup>, S. Sazonov<sup>2</sup>, A. Brilliant<sup>3</sup>, Y. Brilliant<sup>3</sup>, <sup>1</sup>City Clinical Hospital 40 (Mau Gkb 40)-Surgery Department, Ekaterinburg, RU, <sup>2</sup>Ural State Medical University, Ekaterinburg, RU, <sup>3</sup>Institute of Medical Cell Technologies, Ekaterinburg, RU

12:00 - 12:00

**43P - PDL1 protein expression is a prognostic factor in triple negative breast cancer**

J. Yue<sup>1</sup>, P. Yuan<sup>2</sup>, A. Zhu<sup>2</sup>, N. Hu<sup>2</sup>, X. Wang<sup>2</sup>, W. Wang<sup>3</sup>, Z. Wang<sup>3</sup>, <sup>1</sup>Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>3</sup>Beijing Hospital, National Center of Gerontology, Beijing, CN

12:00 - 12:00

**44P - Obesity is associated with a late-stage diagnosis in triple-negative breast cancer**

A. Aranda-Gutierrez<sup>1</sup>, A. Ferrigno<sup>2</sup>, M. Moncada-Madrado<sup>2</sup>, A. Gomez-Picos<sup>2</sup>, C. De La Garza-Ramos<sup>2</sup>, F. Mesa-Chavez<sup>2</sup>, H. Diaz-Perez<sup>2</sup>, S. Cardona<sup>2</sup>, R. Ortiz-Lopez<sup>3</sup>, C. Villarreal-Garza<sup>2</sup>, <sup>1</sup>Hospital Zambrano Hellion, Monterrey, MX, <sup>2</sup>Hospital Zambrano Hellion Tecnológico de Monterrey, San Pedro Garza Garcia, MX, <sup>3</sup>Tecnologico de Monterrey, Monterrey, MX

12:00 - 12:00

**45P - Characterizing the impact of pathogenic BRCA mutations on tissue-specific gene expression and pre-mRNA splicing**

P. Bak-Gordon, IMM Instituto de Medicina Molecular, Lisbon, PT

12:00 - 12:00

**46P - Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore are associated with pathological CR in patients receiving neo-adjuvant chemotherapy**

B. Rapoport<sup>1</sup>, J. Galon<sup>2</sup>, S. Nayler<sup>3</sup>, B. Mlecnik<sup>2</sup>, A. Fugon<sup>4</sup>, C. Benn<sup>5</sup>, M. Martel<sup>4</sup>, T. Cronje<sup>6</sup>, T. Smit<sup>1</sup>, F. Moosa<sup>1</sup>, L. Jooste<sup>1</sup>, R. Anderson<sup>7</sup>, <sup>1</sup>The Medical Oncology Centre of Rosebank, Johannesburg, ZA, <sup>2</sup>Laboratory of Integrative Cancer Immunology, Paris, FR, <sup>3</sup>Drs Gritzman & Thatcher Inc Laboratories & Wits Donald Gordon Medical Centre, Randburg, ZA, <sup>4</sup>HaliDx, Marseille, FR, <sup>5</sup>Head of Netcare breast care Centre,



Johannesburg, ZA, <sup>6</sup>University of Pretoria, Pretoria, ZA, <sup>7</sup>University of Pretoria Faculty of Health Sciences, Pretoria, ZA

- 12:00 - 12:00 **47P - Androgen receptor expression and survival in triple negative breast cancer**  
L. Moyano<sup>1</sup>, J. Soto<sup>1</sup>, M. Garmendia<sup>2</sup>, <sup>1</sup>Instituto Nacional del Cancer, Santiago, CL, <sup>2</sup>Institute of Nutrition and Food Technology, Universidad de Chile., SANTIAGO, CL
- 12:00 - 12:00 **48P - Association of a genomic index of sensitivity to endocrine therapy with disease-free survival in breast cancer**  
P. Singh<sup>1</sup>, I. Bedrosian<sup>1</sup>, M.J. Ha<sup>1</sup>, Y. Shen<sup>1</sup>, L. Du<sup>1</sup>, R. Gould<sup>1</sup>, F. Symmans<sup>2</sup>, <sup>1</sup>University of Texas M.D. Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **49P - BRCA mutation testing rates among breast cancer patients meeting testing criteria: A single-centre experience**  
M. Boianu, N. Daaboul, G. Speranza, C. Prady, S. Soldera, S. Martel, Hopital Charles - Le Moyne, Greenfield Park, CA
- 12:00 - 12:00 **50P - Cardiosafe nano-formulation of doxorubicin allows coadministration with trastuzumab in neoadjuvant setting improving antitumor efficacy and preventing trastuzumab-mediated cardiotoxicity in HER2<sup>+</sup> murine model of breast cancer**  
S. Mazzucchelli<sup>1</sup>, F. Andreato<sup>1</sup>, A. Bonizzi<sup>1</sup>, M. Sevieri<sup>1</sup>, M. Truffi<sup>1</sup>, L. Sitia<sup>1</sup>, R. Ottria<sup>1</sup>, F. Silva<sup>1</sup>, P. Zerbi<sup>1</sup>, D. Prospero<sup>2</sup>, F. Corsi<sup>1</sup>, <sup>1</sup>Università degli Studi di Milano, Milan, IT, <sup>2</sup>Università degli studi di Milano- Bicocca, Milano, IT
- 12:00 - 12:00 **51P - Evolution of low HER2 expressions between primary and metastatic breast cancer**  
P. Tarantino<sup>1</sup>, E. Nicolò<sup>2</sup>, P. Zagami<sup>3</sup>, F. Giugliano<sup>2</sup>, P. Trillo A.<sup>2</sup>, A. Marra<sup>4</sup>, D. Trapani<sup>4</sup>, S. Morganti<sup>4</sup>, L. Mazzeo<sup>2</sup>, C. Criscitiello<sup>3</sup>, A. Esposito<sup>5</sup>, G. Curigliano<sup>3</sup>, <sup>1</sup>European Institute of Oncology (IEO), Milan, IT, <sup>2</sup>IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, IT, <sup>3</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>5</sup>ecancer, Bristol, GB
- 12:00 - 12:00 **52P - Characterising clinicopathological and biological parameters predictive of outcome for patients diagnosed with invasive lobular carcinoma**  
P. Simpson<sup>1</sup>, A. McCart Reed<sup>1</sup>, J. Kutasovic<sup>1</sup>, C. Coorey<sup>1</sup>, L. Kuo<sup>1</sup>, H. Nguyen<sup>1</sup>, W. Pei<sup>1</sup>, J. Ong<sup>1</sup>, A. Sokolova<sup>1</sup>, E. Evans<sup>2</sup>, A. Porter<sup>2</sup>, S. Lakhani<sup>1</sup>, <sup>1</sup>University of Queensland, Brisbane, AU, <sup>2</sup>The Wesley Hospital, Brisbane, AU
- 12:00 - 12:00 **53P - Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer**  
S. Pasricha<sup>1</sup>, D. Bansal<sup>1</sup>, A. Jajodia<sup>1</sup>, K. Choudhary<sup>2</sup>, G. Gupta<sup>1</sup>, A. Sharma<sup>1</sup>, A. Sharma<sup>1</sup>, G. Durga<sup>1</sup>, M. Kamboj<sup>1</sup>, A. Kumar<sup>1</sup>, S. Bothra<sup>1</sup>, M. Chhanna<sup>3</sup>, V.P.B. Koyyala<sup>1</sup>, A. Russo<sup>4</sup>, D.C. Doval<sup>1</sup>, A. Mehta<sup>2</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>3</sup>Princess

Margaret Cancer Center, Toronto, CA, <sup>4</sup>University of Palermo, Palermo, IT

- 12:00 - 12:00 **54P - Establishment and characterization of luminal A breast PDX models from patients with acquired resistance to CDK 4/6 inhibitors**  
M. Wick, J. Flores, A. Moriarty, M. Beeram, K. Papadopoulos, South Texas Accelerated Research Therapeutics (START), San Antonio, US
- 12:00 - 12:00 **55P - Role of radiomics for predicting immunophenotypes in male breast cancer**  
V.P.B. Koyyala<sup>1</sup>, A. Jajodia<sup>1</sup>, S. Pasricha<sup>1</sup>, A. Gupta<sup>2</sup>, A. Chaturvedi<sup>1</sup>, A. Rao<sup>3</sup>, R. Tripathi<sup>1</sup>, M. Kamboj<sup>1</sup>, M. Mayerhoefer<sup>4</sup>, D. Leithner<sup>5</sup>, H. Prosch<sup>6</sup>, M. Chllamma<sup>7</sup>, M. La Mantia<sup>8</sup>, A. Russo<sup>9</sup>, D.C. Doval<sup>1</sup>, A. Mehta<sup>3</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>The Indian Institute of Information Technology, Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>Medical University of Vienna, vienna, AT, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>Medical University of Vienna, HOUSTON, AT, <sup>7</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>8</sup>University of Palermo, palermo, IT, <sup>9</sup>University of Palermo, Palermo, IT
- 12:00 - 12:00 **57P - Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients**  
P. Tolosa Ortega<sup>1</sup>, J.M. Cejalvo<sup>2</sup>, S. Moragon Terencio<sup>1</sup>, L. Carril-Ajuria<sup>3</sup>, B. Bermejo<sup>4</sup>, Á. Ruiz<sup>3</sup>, C. Hernando Melia<sup>1</sup>, A. Sánchez-Torre<sup>3</sup>, M.T. Martínez<sup>2</sup>, M. Herrera<sup>3</sup>, V. Gambardella<sup>1</sup>, L. Lema<sup>3</sup>, D. Roda<sup>1</sup>, E. Bernal<sup>3</sup>, P. Rentero-Garrido<sup>1</sup>, A. Lluch<sup>2</sup>, E. Ciruelos<sup>5</sup>, A. Cervantes<sup>1</sup>, L. Manso<sup>3</sup>, <sup>1</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>3</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup>Hospital Clínico Universitario de Valencia / INCLIVA / CIBERONC, Valencia, ES, <sup>5</sup>University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **58P - Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients**  
T. De La Motte Rouge<sup>1</sup>, F. Le Du<sup>1</sup>, J. Corne<sup>2</sup>, F. Godey<sup>1</sup>, H. Bourien<sup>1</sup>, A. Brunot<sup>1</sup>, L. Crouzet<sup>1</sup>, C. Perrin<sup>1</sup>, C. Lefeuvre-Plesse<sup>3</sup>, V. Dieras<sup>1</sup>, V. Quillien<sup>1</sup>, <sup>1</sup>Centre Eugène - Marquis, Rennes, FR, <sup>2</sup>Centre Eugène Marquis, RENNES, FR, <sup>3</sup>Centre Eugène Marquis, Rennes, FR
- 12:00 - 12:00 **59P - Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC)**  
S. Di Cosimo<sup>1</sup>, M. Silvestri<sup>1</sup>, M. Dugo<sup>1</sup>, M. Vismara<sup>1</sup>, C. Reduzzi<sup>1</sup>, G. Pruneri<sup>2</sup>, S. Folli<sup>1</sup>, V. Cappelletti<sup>1</sup>, M.G. Daidone<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale Tumori (INT) Milan, Milan, IT
- 12:00 - 12:00 **60P - Prognosis and survival of single hormone receptor positive breast cancer comparing to double HR positive and triple-negative breast cancers**  
K. Oualla<sup>1</sup>, L. Nouiakh<sup>1</sup>, O. Zouiten<sup>1</sup>, L. Amaadour<sup>2</sup>, Z. Benbrahim<sup>1</sup>, S. Arifi<sup>1</sup>, N. Mellas<sup>2</sup>, <sup>1</sup>CHU - University Hospital of Hassan II, Fez, MA, <sup>2</sup>University Hospital of Hassan II, Fez, MA

- 12:00 - 12:00 **62P - XRCC1 (Arg194Trp), Palb2 T1100T (3300T→G), HMMR (V353A), TNF (aG308A) polymorphisms as diagnostic markers of breast cancer in the Kyrgyz ethnic group**  
A. Semetei Kyzy<sup>1</sup>, E. Makimbetov<sup>2</sup>, J. Isakova<sup>3</sup>, <sup>1</sup>International school of medicine-International University of Kyrgyzstan (IUK), Bishkek, KG, <sup>2</sup>Kyrgyz Russian Slavic University, Bishkek, KG, <sup>3</sup>Research Institute of Molecular Biology and Medicine, Bishkek, KG
- 12:00 - 12:00 **63P - Study of single nucleotide polymorphism of thymocyte selection associated high mobility group box 3 and fibroblast growth factor receptor 2 genes in breast cancer patients**  
A. Alhanafy, M. Hammoudah, A. Dawood, M. Abouelenin, Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG
- 12:00 - 12:00 **64P - Comprehensive genomic analysis of primary triple negative breast cancer prior to neoadjuvant chemotherapy**  
M. Drobnienė<sup>1</sup>, R. Sabaliauskaite<sup>1</sup>, E. Zurauskas<sup>2</sup>, R. Meskauskas<sup>2</sup>, B. Brasiuniene<sup>1</sup>, S. Jarmalaite<sup>1</sup>, <sup>1</sup>National Cancer Institute, Vilnius, LT, <sup>2</sup>National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, LT
- 12:00 - 12:00 **65P - Investigating the molecular connection between hormone receptor status and ploidy management in breast cancer**  
S. Nath, Saroj Gupta Cancer Centre & Research Institute, Kolkata, IN
- 12:00 - 12:00 **66P - Impact of EPclin on adjuvant therapeutic decision-making and comparison of EPclin to PREDICT tool**  
H. Bourien<sup>1</sup>, V. Quillien<sup>1</sup>, F. Godey<sup>1</sup>, C. Perrin<sup>1</sup>, F. Le Du<sup>1</sup>, A. Brunot<sup>1</sup>, L. Crouzet<sup>1</sup>, T. De La Motte Rouge<sup>1</sup>, V. Dieras<sup>1</sup>, C. Lefeuvre-Plesse<sup>2</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>Centre Eugène Marquis, Rennes, FR
- 12:00 - 12:00 **67P - Digital analysis of distant and cancer-associated adipocytes in breast cancer**  
E. Isnaldi<sup>1</sup>, F. Richard<sup>1</sup>, M. De Schepper<sup>1</sup>, D. Vincent<sup>2</sup>, S. Leduc<sup>1</sup>, M. Maetens<sup>1</sup>, T. Geukens<sup>1</sup>, G. Floris<sup>3</sup>, G. Rouas<sup>4</sup>, F. Rothé<sup>4</sup>, F. Cardoso<sup>5</sup>, M. Piccart<sup>4</sup>, C. Sotiriou<sup>4</sup>, G. Zoppoli<sup>6</sup>, E. Biganzoli<sup>7</sup>, D. Larsimont<sup>4</sup>, C. Desmedt<sup>8</sup>, <sup>1</sup>KU Leuven - VIB Campus Gasthuisberg, Leuven, BE, <sup>2</sup>Institut Jules Bordet, Bruxelles, BE, <sup>3</sup>UZ Leuven, Leuven, BE, <sup>4</sup>Institute Jules Bordet, Brussels, BE, <sup>5</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>6</sup>University of Genova-DIMI, Genova, IT, <sup>7</sup>University of Milan, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT, <sup>8</sup>KU Leuven, Leuven, BE
- 12:00 - 12:00 **68P - Deciphering the interplay between nuclear RNA export factors and long non-coding RNAs in breast cancer metabolism**  
C. Klec<sup>1</sup>, D. Schwarzenbacher<sup>2</sup>, B. Gottschalk<sup>3</sup>, R. Margit<sup>2</sup>, F. Prinz<sup>2</sup>, T. Bauernhofer<sup>4</sup>, H. Stoeger<sup>5</sup>, W. Graier<sup>3</sup>, M. Pichler<sup>2</sup>, <sup>1</sup>Medical University Graz-Center for Medical Research, Graz, AT, <sup>2</sup>Medical University of Graz, Graz, AT, <sup>3</sup>Gottfried Schatz Research Center, Graz, AT, <sup>4</sup>University Hospital Graz, Graz, AT, <sup>5</sup>LKH-Univ. Klinikum Graz, Graz, AT



- 12:00 - 12:00 **69P - TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort**  
H. Pla<sup>1</sup>, Á. Díaz-Lagares<sup>2</sup>, A. Hernandez<sup>1</sup>, G. Oliveras<sup>3</sup>, F. Pérez-Bueno<sup>3</sup>, M. Esteller<sup>4</sup>, T. Puig<sup>5</sup>, S. Palomeras<sup>5</sup>, G. Viñas<sup>1</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO), Dr. Josep Trueta Hospital, Girona, ES, <sup>2</sup>Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS), CIBERONC, Santiago de Compostela., ES, <sup>3</sup>Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, ES, <sup>4</sup>Josep Carreras Leukaemia Research Institute (IJC), Badalona, ES, <sup>5</sup>TargetsLab, University of Girona, Girona, ES
- 12:00 - 12:00 **70P - Genetic polymorphisms of ESR1 are associated with hormone resistance to aromatase inhibitors therapy in patients with metastatic luminal breast cancer (MLBC)**  
T. Tarasenko, L. Syvak, N. Verovkina, S. Lyalkin, National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA
- 12:00 - 12:00 **71P - Role of radiomics in predicting molecular phenotypes of female breast cancer**  
A. Jajodia<sup>1</sup>, A. Gupta<sup>2</sup>, A. Mehta<sup>3</sup>, A. Chaturvedi<sup>1</sup>, A. Rao<sup>3</sup>, G. Gupta<sup>3</sup>, D.C. Doval<sup>1</sup>, A. Bp<sup>3</sup>, P. Medisetty<sup>4</sup>, S. Bommera<sup>1</sup>, V.P.B. Koyyala<sup>1</sup>, S. Pasricha<sup>1</sup>, M. Mayerhoefer<sup>5</sup>, H. Prosch<sup>6</sup>, M. Chllamma<sup>7</sup>, M. La Mantia<sup>8</sup>, A. Russo<sup>8</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>The Indian Institute of Information Technology, Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>BSAH - Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, IN, <sup>5</sup>Medical University of Vienna, vienna, AT, <sup>6</sup>Medical University of Vienna, HOUSTON, AT, <sup>7</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>8</sup>University of Palermo, Palermo, IT
- 12:00 - 12:00 **72P - Non-mass like enhancement patterns on MR mammography and their pathological correlation**  
A. Parashar<sup>1</sup>, A. Jajodia<sup>2</sup>, A. Chaturvedi<sup>2</sup>, A. Rao<sup>3</sup>, A. Mehta<sup>3</sup>, D.C. Doval<sup>2</sup>, A. Bp<sup>3</sup>, P. Medisetty<sup>4</sup>, V.P.B. Koyyala<sup>2</sup>, S. Pasricha<sup>2</sup>, M. La Mantia<sup>5</sup>, M. Chllamma<sup>6</sup>, D. Leithner<sup>7</sup>, M. Mayerhoefer<sup>8</sup>, A. Russo<sup>5</sup>, H. Prosch<sup>9</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, <sup>2</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>BSAH - Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, IN, <sup>5</sup>University of Palermo, Palermo, IT, <sup>6</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>Medical University of Vienna, vienna, AT, <sup>9</sup>Medical University of Vienna, HOUSTON, AT
- 12:00 - 12:00 **73P - microRNA expression profiles of single hormone receptor-positive breast cancers**  
M. Kunc<sup>1</sup>, M. Popeda<sup>1</sup>, A. Szalkowska<sup>2</sup>, M. Niemira<sup>2</sup>, A. Lacko<sup>3</sup>, B. Radecka<sup>4</sup>, M. Braun<sup>5</sup>, J. Pikiel<sup>6</sup>, M. Litwiniuk<sup>7</sup>, K. Pogoda<sup>8</sup>, A. Szwajkosz<sup>9</sup>, E. Izycka-Swieszewska<sup>1</sup>, A. Zaczek<sup>1</sup>, W. Biernat<sup>10</sup>, E. Senkus-Konefka<sup>1</sup>, <sup>1</sup>Medical University of Gdansk, Gdansk, PL, <sup>2</sup>Medical University of Bialystok, Bialystok, PL, <sup>3</sup>Wroclaw Medical University, Wroclaw, PL, <sup>4</sup>Opolskie Centrum Onkologii Oddzial Onkologii Klinicznej Tadeusz Koszarowski, Opole, PL, <sup>5</sup>Medical University of Lodz, Lodz, PL, <sup>6</sup>Szpital Morski, Gdynia, PL, <sup>7</sup>Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>8</sup>The

Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>9</sup>Beskid Oncology Center, Bielsko-Biala, PL, <sup>10</sup>Medical University of Gdansk, Gdańsk, PL

- 12:00 - 12:00 **74P - Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy**  
B. Kotowicz<sup>1</sup>, P. Winter<sup>1</sup>, M. Fuksiewicz<sup>1</sup>, A. Jagiello-Gruszfeld<sup>2</sup>, Z. Nowecki<sup>3</sup>, M. Kowalska<sup>4</sup>, <sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>2</sup>Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, <sup>3</sup>Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, <sup>4</sup>National Cancer Institute, Warsaw, PL
- 12:00 - 12:00 **75P - Clinical and pathological feature of primary lung cancer in patients with primary breast cancer**  
T. Zeng, W. Li, Y. Yin, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **76P - Retrospective study about the prevalence of (TILs) tumour infiltrating lymphocytes in non-metastatic triple negative breast cancer patients and its prognostic value**  
A. Kamal, H. Elghazaly, M. El-Mahdy, A. Adel, N. Abdel-Kader, Mataria Teaching Hospital, Cairo, EG
- 12:00 - 12:00 **79P - Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastatic breast cancer patients**  
C. Suppan<sup>1</sup>, Q. Zhou<sup>2</sup>, R. Graf<sup>2</sup>, V. Klocker<sup>3</sup>, A. Terbuch<sup>3</sup>, N. Dandachi<sup>3</sup>, E. Heitzer<sup>2</sup>, M. Balic<sup>4</sup>, <sup>1</sup>Medical University of Graz, Graz, AT, <sup>2</sup>Medical University of Graz, Graz, AT, <sup>3</sup>LKH-Univ. Klinikum Graz, Graz, AT, <sup>4</sup>LKH-Univ.Klinikum Graz - Universitätsklinik für Innere Medizin, Graz, AT
- 12:00 - 12:00 **Early Breast cancer: Adjuvant therapy**
- 12:00 - 12:00 **82P - A multinational study of real-world treatment patterns among patients with early stage HR<sup>+</sup>/HER2<sup>-</sup> breast cancer (BC)**  
C. Criscitiello<sup>1</sup>, D. Spurden<sup>2</sup>, A. Rider<sup>3</sup>, R. Williams<sup>4</sup>, M. Corsaro<sup>5</sup>, J. Pike<sup>4</sup>, E. Law<sup>6</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Pfizer UK, Tadworth, GB, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Bollington, GB, <sup>5</sup>Pfizer, Milan, IT, <sup>6</sup>Pfizer Inc, New York, US
- 12:00 - 12:00 **83P - Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2<sup>+</sup>; HR<sup>+</sup> breast cancer after trastuzumab-based therapy on patient outcomes**  
M. Martin Jimenez<sup>1</sup>, M. Gnant<sup>2</sup>, B. Ejlerlsen<sup>3</sup>, J. Mansi<sup>4</sup>, M. Ruiz-Borrego<sup>5</sup>, E. Jakobsen<sup>6</sup>, C.K. Osborne<sup>7</sup>, R. Birhiray<sup>8</sup>, B. Zhang<sup>9</sup>, A. Wong<sup>9</sup>, B. Moy<sup>10</sup>, F. Holmes<sup>11</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>2</sup>Medizinische Universität Wien, Vienna, AT, <sup>3</sup>Rigshospitalet, University of Copenhagen, Copenhagen, DK, <sup>4</sup>Guy's and St.

Thomas' Hospital NHS Trust, London, GB, <sup>5</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>6</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>7</sup>Baylor College of Medicine, Houston, US, <sup>8</sup>Hematology / Oncology of Indiana, Indianapolis, US, <sup>9</sup>PUMA Biotechnology, Los Angeles, US, <sup>10</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>11</sup>Texas Oncology, Fort Worth, US

12:00 - 12:00

**84P - Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials**

E. Aravantinou Fatorou<sup>1</sup>, G.-A. Koliou<sup>2</sup>, F. Zagouri<sup>2</sup>, L. Kostadima<sup>2</sup>, H. Gogas<sup>2</sup>, D. Pectasides<sup>2</sup>, I. Binas<sup>2</sup>, A. Koutras<sup>2</sup>, G. Aravantos<sup>2</sup>, A. Psyrris<sup>2</sup>, G.L. Lazaridis<sup>2</sup>, D. Bafaloukos<sup>2</sup>, E. Saloustros<sup>2</sup>, C. Karanikiotis<sup>2</sup>, I.B. Bombolaki<sup>2</sup>, E. Razis<sup>2</sup>, A. Koumariou<sup>2</sup>, P. Papakostas<sup>2</sup>, P. Kosmidis<sup>2</sup>, G. Fountzilias<sup>3</sup>, <sup>1</sup>251 Hellenic Airforce General Hospital, Athens, GR, <sup>2</sup>Hellenic Cooperative Oncology Group ( HeCOG), Athens, GR, <sup>3</sup>Papageorgiou Hospital - Aristotle University of Thessaloniki, Thessaloniki, GR

12:00 - 12:00

**85P - Racial differences in predictive value of 21-gene recurrence score assay: A population-based study using the SEER database**

J. Jung<sup>1</sup>, H. Kim<sup>2</sup>, K.-T. Hwang<sup>3</sup>, <sup>1</sup>Seoul Medical Center, Seoul, KR, <sup>2</sup>Seoul Metropolitan Government Seoul National Hospital Boramae Medical Center, Seoul, KR, <sup>3</sup>Boramae Medical Center, Seoul, KR

12:00 - 12:00

**86P - Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2<sup>+</sup> early breast cancer (BC) treated within the GAIN-2 trial**

M. Reinisch<sup>1</sup>, M. Untch<sup>2</sup>, T. Reimer<sup>3</sup>, R. Mahlberg<sup>4</sup>, M. Aydogdu<sup>5</sup>, T. Hitschold<sup>6</sup>, C. Jackisch<sup>7</sup>, F. Marmé<sup>8</sup>, H.-J. Lück<sup>9</sup>, E. Ladda<sup>10</sup>, S. Schmatloch<sup>11</sup>, M. Schmidt<sup>12</sup>, P. Klare<sup>13</sup>, B. Sinn<sup>14</sup>, E. Stickeler<sup>15</sup>, S. Seiler<sup>16</sup>, J. Rey<sup>16</sup>, N. Klutinus<sup>17</sup>, V. Möbus<sup>18</sup>, S. Loibl<sup>16</sup>, <sup>1</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>2</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>3</sup>Klinikum Südstadt Rostock, Rostock, DE, <sup>4</sup>Klinikum Mutterhaus der Borromäerinnen, Trier, DE, <sup>5</sup>Klinikum Bremen-Mitte, Bremen, DE, <sup>6</sup>Klinikum Worms, Worms, DE, <sup>7</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>8</sup>UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>9</sup>Gynäkologisch-onkologische Praxis, Hamburg, DE, <sup>10</sup>Onkologische Praxis Neumarkt, Neumarkt, DE, <sup>11</sup>Elisabeth Krankenhaus Kassel, Kassel, DE, <sup>12</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>13</sup>Praxisklinik Berlin, Berlin, DE, <sup>14</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>15</sup>Universitätsklinikum Aachen (UKA), Aachen, Germany, DE, <sup>16</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>17</sup>HELIOS Klinikum Pforzheim, Pforzheim, DE, <sup>18</sup>Universitätsklinikum Frankfurt, Frankfurt, DE

12:00 - 12:00

**87P - Patient-reported and cancer-specific health-related quality of life among patients with early stage HR<sup>+</sup>/HER2- breast cancer (BC)**

C. Criscitiello<sup>1</sup>, D. Spurden<sup>2</sup>, A. Rider<sup>3</sup>, R. Williams<sup>4</sup>, M. Corsaro<sup>5</sup>, J. Pike<sup>4</sup>, E. Law<sup>6</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Pfizer UK, Tadworth, GB, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Bollington, GB, <sup>5</sup>Pfizer, Milan, IT, <sup>6</sup>Pfizer Inc, New York, US

12:00 - 12:00



**88P - Latent class analysis (LCA) to identify and describe clinically relevant subgroups in a multinational study of patients with HR<sup>+</sup>/HER2<sup>-</sup> early breast cancer (eBC)**

A. Rider<sup>1</sup>, D. Spurden<sup>2</sup>, R. Williams<sup>3</sup>, M. Corsaro<sup>4</sup>, J. Pike<sup>3</sup>, E. Law<sup>5</sup>, C. Criscitiello<sup>6</sup>,  
<sup>1</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>2</sup>Pfizer UK, Tadworth, GB,  
<sup>3</sup>Adelphi Real World, Bollington, GB, <sup>4</sup>Pfizer, Milan, IT, <sup>5</sup>Pfizer Inc, New York, US, <sup>6</sup>IEO -  
Istituto Europeo di Oncologia, Milan, IT

12:00 - 12:00 **89P - Tamoxifen versus aromatase inhibitors as adjuvant therapy in premenopausal women with hormone receptor-positive breast cancer: Effects on sexuality and the female reproductive system**

A. Skolariki<sup>1</sup>, A. Boutis<sup>1</sup>, E. Kosmidis<sup>2</sup>, <sup>1</sup>Theagenio Cancer Hospital, Thessaloniki, GR,  
<sup>2</sup>Aristotle University of Thessaloniki, Thessaloniki, GR

12:00 - 12:00 **90P - Patient-reported outcomes among patients with HR<sup>+</sup>/HER2<sup>-</sup> early breast cancer: A systematic literature review**

E. Salvo<sup>1</sup>, J. Cueto<sup>2</sup>, E. Law<sup>2</sup>, C. Aniceto Da Silva<sup>1</sup>, C. Cameron<sup>3</sup>, I. Samjoo<sup>1</sup>, <sup>1</sup>Eversana,  
Burlington, CA, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Eversana, Nova Scotia, CA

12:00 - 12:00 **91P - Gene expression profiling in localised luminal N<sup>+</sup> breast cancer: Efficacy and utility of 50 gene expression platform in adjuvant treatment decision making**

P. Tolosa Ortega<sup>1</sup>, A. Sánchez-Torre<sup>2</sup>, L. Carril-Ajuria<sup>2</sup>, M. Herrera<sup>2</sup>, Á. Ruiz<sup>2</sup>, E. Bernal<sup>2</sup>,  
L. Lema<sup>2</sup>, L. Manso<sup>2</sup>, E. Ciruelos<sup>3</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia,  
ES, <sup>2</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>3</sup>University Hospital 12 De  
Octubre, Madrid, ES

12:00 - 12:00 **93P - Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer**

B. Liu<sup>1</sup>, X. Guan<sup>2</sup>, Y. Wang<sup>2</sup>, X. Sun<sup>3</sup>, Z. Yi<sup>2</sup>, W. Wang<sup>2</sup>, L. Li<sup>2</sup>, J. Zhai<sup>2</sup>, H. Li<sup>4</sup>, F. Ma<sup>2</sup>,  
<sup>1</sup>CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National  
Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union  
Medical College, Beijing, CN, <sup>3</sup>Cancer Hospital of Huanxing, Beijing, CN, <sup>4</sup>Beijing  
Anzhen Hospital, Capital Medical University, Beijing, CN

12:00 - 12:00 **94P - Integration of clinicopathological and genomic data and adjuvant treatment decisions in premenopausal women with recurrence scores between 16 and 25**

M. Alsendi<sup>1</sup>, M. Lucas<sup>1</sup>, W. Darwish<sup>2</sup>, M. Higgins<sup>3</sup>, C. Kelly<sup>3</sup>, <sup>1</sup>The Mater Misericordiae  
University Hospital, Dublin, IE, <sup>2</sup>Letterkenny General Hospital, Letterkenny, IE, <sup>3</sup>Mater  
Misericordiae hospital, Dublin, IE

12:00 - 12:00 **95TiP - Gruppo Italiano Mammella (GIM) 10 &#x2013; CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR<sup>+</sup>) early breast cancer (EBC)**

M. Lambertini<sup>1</sup>, V. Guarneri<sup>2</sup>, E.R. Caremoli<sup>3</sup>, A. Rocca<sup>4</sup>, F. Montemurro<sup>5</sup>, M. De

Laurentiis<sup>6</sup>, M. Giordano<sup>7</sup>, S. De Placido<sup>8</sup>, G. Bisagni<sup>9</sup>, O. Garrone<sup>10</sup>, A. Ferzi<sup>11</sup>, F. Giovanardi<sup>12</sup>, F. Cognetti<sup>13</sup>, L. Amaducci<sup>14</sup>, A. Bernardo<sup>15</sup>, L. Livi<sup>16</sup>, C. Bighin<sup>17</sup>, F. Poggio<sup>1</sup>, A. Ballestrero<sup>18</sup>, L. Del Mastro<sup>19</sup>, <sup>1</sup>University of Genova, Genova, IT, <sup>2</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>ASST Papa Giovanni XXIII, Bergamo, IT, <sup>4</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>5</sup>Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, <sup>6</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, IT, <sup>7</sup>Ospedale Sant'Anna, Como, IT, <sup>8</sup>University of Naples Federico II, Naples, IT, <sup>9</sup>Azienda USL-IRCCS, Reggio Emilia, IT, <sup>10</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>11</sup>Ospedale Civile, Legnano, IT, <sup>12</sup>AUSL.RE, Guastalla, IT, <sup>13</sup>Istituto Nazionale Tumori Regina Elena, Roma, IT, <sup>14</sup>P.O. Ospedale degli Infermi, Romagna, IT, <sup>15</sup>Fondazione S. Maugeri IRCCS, Pavia, IT, <sup>16</sup>AUC Careggi, Florence, IT, <sup>17</sup>IRCCS Ospedale Policlinico San Martino - University of Genova, Genova, IT, <sup>18</sup>Università degli Studi di Genova and Ospedale Policlinico San Martino IRCCS, Genova, IT, <sup>19</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

12:00 - 12:00 **Early Breast cancer: Neoadjuvant therapy**

12:00 - 12:00 **99P - Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer**

G. Vernaci<sup>1</sup>, E. Cumerlato<sup>2</sup>, G. Griguolo<sup>3</sup>, D. Massa<sup>2</sup>, A. Menichetti<sup>3</sup>, F. Miglietta<sup>3</sup>, G. Tasca<sup>3</sup>, E. Savarino<sup>2</sup>, P.F. Conte<sup>1</sup>, V. Guarneri<sup>1</sup>, M.V. Dieci<sup>3</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>University of Padova, Padova, IT, <sup>3</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

12:00 - 12:00 **101P - Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[&#x2b;] early breast cancer (EBC). A substudy of the PHERGain trial**

A. Llombart Cussac<sup>1</sup>, A. Prat<sup>2</sup>, J.M. Pérez-García<sup>3</sup>, J. Mateos<sup>4</sup>, T. Pascual<sup>5</sup>, S. Escrivà-De-Romani<sup>6</sup>, A. Stradella<sup>7</sup>, M. Ruiz-Borrego<sup>8</sup>, B. Bermejo De Las Heras<sup>9</sup>, M. Keyaerts<sup>10</sup>, M. Sampayo-Cordero<sup>11</sup>, A. Malfettone<sup>11</sup>, R. Cortés<sup>12</sup>, P. Galván<sup>13</sup>, J. Cortés<sup>14</sup>, G. Gebhart<sup>10</sup>, <sup>1</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>2</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>3</sup>IOB, Institute of Oncology, QuironSalud Group; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, Madrid and Barcelona, ES, <sup>4</sup>IEC, Barcelona, ES, <sup>5</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>6</sup>Hospital Universitari Vall Hebrón, Barcelona, ES, <sup>7</sup>ICO l'Hospitalet, Barcelona, ES, <sup>8</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>9</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>10</sup>Institute Jules Bordet, Brussels, BE, <sup>11</sup>MedSIR - Medica Scientia Innovation Research, Barcelona, ES, <sup>12</sup>Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, ES, <sup>13</sup>IDIBAPS, Barcelona, ES, <sup>14</sup>Vall d'Hebron University Hospital, Barcelona, ES

12:00 - 12:00 **102P - Predictive models associated with the presence of pathological complete response following neoadjuvant chemotherapy for breast cancer**

Y. Xie, West China Medical Center of Sichuan University, Chengdu, CN

12:00 - 12:00 **103P - Loss of HER2 after neoadjuvant treatment of HER2[&#x2b;] early breast**

**cancer**

S. Morales<sup>1</sup>, A. Gasol Cudos<sup>2</sup>, A. Rodriguez Galindo<sup>1</sup>, A. Velasco<sup>1</sup>, C. Canosa Morales<sup>1</sup>, D.-R. Sánchez Guzmán<sup>1</sup>, J. Melé Olivé<sup>1</sup>, <sup>1</sup>Hospital Universitario Arnau de Vilanova, LLEIDA, ES, <sup>2</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES

12:00 - 12:00

**104P - Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)**

W. Rhodes<sup>1</sup>, S. Gautam<sup>1</sup>, A. Haiderali<sup>2</sup>, M. Huang<sup>3</sup>, J. Sieluk<sup>4</sup>, K. Skinner<sup>1</sup>, L. Schwartzberg<sup>5</sup>, <sup>1</sup>Concerto HealthAI, Memphis, US, <sup>2</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>3</sup>Merck & Co., Inc. - Upper Gwynedd Site, North Wales, US, <sup>4</sup>MSD - Merck Sharp & Dohme, North Wales, US, <sup>5</sup>West Cancer Center, Germantown, US

12:00 - 12:00

**105P - Lower-dose apatinib combined with nanoparticle albumin-bound paclitaxel and carboplatin as a neoadjuvant regimen for triple negative breast cancer: A prospective, single-arm, phase II study**

Y. Yin, W. Li, X. Zha, J. Wang, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN

12:00 - 12:00

**107P - Preservation of ovarian function with goserelin in young breast cancer patients: Does it hamper the effect of neoadjuvant chemotherapy?**

S.Y. Wang, S. Wang, Peking University People's Hospital, Beijing, CN

12:00 - 12:00

**109P - Role of MRI and histopathological classification in pre-treatment identification of non-responders to neoadjuvant chemotherapy in breast cancer**

B. Vertakova Krakovska<sup>1</sup>, L. Vanovcanova<sup>2</sup>, V. Lehotska<sup>2</sup>, I. Waczulikova<sup>3</sup>, K. Gocarova<sup>1</sup>, <sup>1</sup>Oncological Institute of St. Elizabeth-Onkologický ústav sv. Alžbety, s.r.o., Bratislava, SK, <sup>2</sup>Comenius University, Medical Faculty, Bratislava, SK, <sup>3</sup>Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava, Bratislava, SK

12:00 - 12:00

**110P - Primary endocrine therapy of breast cancer: Is there a good radiological technique to define pathological response?**

J. Lopez Velazco<sup>1</sup>, M. Otaño<sup>2</sup>, L. Larburu<sup>2</sup>, A. Lahuerta<sup>2</sup>, K. Elorriaga<sup>2</sup>, V. Segur<sup>2</sup>, J.C. Irizabal<sup>2</sup>, A. Martinez<sup>2</sup>, L. Jáuregui<sup>2</sup>, J.A. Alberro<sup>2</sup>, L. Álvarez<sup>2</sup>, I. Etxabe<sup>2</sup>, M. Huarte<sup>2</sup>, M. M. Caffarel<sup>3</sup>, A. Urruticoechea Ribate<sup>2</sup>, <sup>1</sup>Onkologiko Donostia - Kutxa Fundaziona, San Sebastian, ES, <sup>2</sup>Onkologiko Donostia - Kutxa Fundaziona, DONOSTIA, ES, <sup>3</sup>Instituto de Investigación Sanitaria Biodonostia, DONOSTIA, ES

12:00 - 12:00

**111P - Evaluating the protective effect of metformine on cancer: A retrospective cohort analysis**

N. Honoré<sup>1</sup>, A. Van Der Elst<sup>1</sup>, D. D'Augusto<sup>2</sup>, E. Seront<sup>3</sup>, <sup>1</sup>UCLouvain Brussels Woluwe, Brussels, BE, <sup>2</sup>Jolimont Group, La Louvière, BE, <sup>3</sup>Centre Hospitalier Jolimont-Lobbes, Haine Saint Paul, BE

12:00 - 12:00

**112TiP - SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR<sup>+</sup>)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)**

E. Ciruelos<sup>1</sup>, X. González-Farré<sup>2</sup>, A. Perelló<sup>3</sup>, E. Alba<sup>4</sup>, P. Palacios-Ozores<sup>5</sup>, J. Salvador-



Bofil<sup>6</sup>, M. Merino<sup>7</sup>, P. Villagrasa<sup>8</sup>, P. Celiz<sup>9</sup>, T. Pascual<sup>10</sup>, A. Prat<sup>11</sup>, S. Pernas Simon<sup>12</sup>,  
<sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>3</sup>Hospital Universitari Son Espases, Palma de Mallorca, ES, <sup>4</sup>Hospital Virgen de la Victoria, Málaga, ES, <sup>5</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>6</sup>Hospital Virgen del Rocío, Sevilla, ES, <sup>7</sup>Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, ES, <sup>8</sup>SOLTI, Barcelona, ES, <sup>9</sup>SOLTI HQ, Barcelona, ES, <sup>10</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>11</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>12</sup>Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES

- 12:00 - 12:00 **Early Breast cancer: Surgery and radiotherapy**
- 12:00 - 12:00 **113P - Impact of local recurrence on disease-specific survival in breast cancer patients who underwent breast-conserving surgery**  
D. Tiezzi<sup>1</sup>, L. De Mattos<sup>2</sup>, L. Orlandini<sup>1</sup>, F.J. Candido Dos Reis<sup>3</sup>, H. Carrara<sup>1</sup>, O. Rueda<sup>4</sup>, C. Caldas<sup>4</sup>, J. Andrade<sup>1</sup>, <sup>1</sup>Hospital das Clínicas de Ribeirão Preto, Ribeirao Preto, BR, <sup>2</sup>Hospital Universitari Trias i Pujol, Badalona, ES, <sup>3</sup>Ribeirão Preto Medical School, Ribeirao Preto, BR, <sup>4</sup>Cancer Research UK & University of Cambridge UK, Cambridge, GB
- 12:00 - 12:00 **114P - Non-metastatic metaplastic breast cancer; clinicopathological characteristics and treatment outcomes: A single institution experience**  
A. Erjan, A. Dayyat, KHCC - King Hussein Cancer Center, Amman, JO
- 12:00 - 12:00 **115P - Factors associated with mastectomy in women with small residual tumour after neoadjuvant chemotherapy for breast cancer**  
E. Bernell<sup>1</sup>, A. Duinmeijer<sup>2</sup>, R. Altena<sup>2</sup>, T. Foukakis<sup>2</sup>, H. Fredholm<sup>2</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Karolinska Institutet, Karolinska University hospital, Stockholm, SE
- 12:00 - 12:00 **116P - Is young age an independent adverse prognostic factor in carcinoma breast? A single institute retrospective comparative study from South India**  
A. K.P., RCC - Regional Cancer Centre, Thiruvananthapuram, IN
- 12:00 - 12:00 **117P - Pregnancy-associated breast cancer (PABC): Demographics and outcome analysis from a lower and middle income country (LMIC)**  
J. Bajpai<sup>1</sup>, S. Dandekar<sup>2</sup>, V. Simha<sup>3</sup>, T. Shylasree<sup>2</sup>, R. Sarin<sup>2</sup>, V. Bansal<sup>4</sup>, J. Ghosh<sup>2</sup>, S. Rath<sup>2</sup>, N. Nair<sup>2</sup>, S. Gulia<sup>2</sup>, A. Patil<sup>5</sup>, S. Gupta<sup>6</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>Tata Memorial Centre, Mumbai, IN, <sup>3</sup>PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN, <sup>4</sup>Wadia Hospital, Mumbai, IN, <sup>5</sup>Tata Memorial Centre, Mumbai, IR, <sup>6</sup>Tata Memorial Hospital Centre, Mumbai, IN
- 12:00 - 12:00 **118P - Should DIBH (deep inspiration breath-hold) be the standard of care in LBC (left breast cancer)?**  
M.G. Garcia Alvarez<sup>1</sup>, C. Peraza Fernandez<sup>1</sup>, C. Rodrigues<sup>2</sup>, M. Mateos Dominguez<sup>1</sup>, M. Montijano Linde<sup>1</sup>, I. Marrone<sup>1</sup>, L. Tinoco Gil<sup>1</sup>, E. López Ramirez<sup>3</sup>, <sup>1</sup>GenesisCare, H. San

Francisco de Asís, Madrid, ES, <sup>2</sup>Genesiscare, Windsor, GB, <sup>3</sup>Genesiscare, Madrid, ES

- 12:00 - 12:00 **120P - Synchronous breast cancers with dissimilar radiological appearances**  
S. Ganeswaran<sup>1</sup>, A. Palmer<sup>2</sup>, E. Millar<sup>3</sup>, <sup>1</sup>St George Hospital, Kogarah, AU, <sup>2</sup>BreastScreen NSW South Eastern Sydney Illawarra, Kogarah, AU, <sup>3</sup>NSW Health Pathology, Kogarah, AU
- 12:00 - 12:00 **121P - Can axillary surgery be avoided in patients with breast pathologic complete response after neoadjuvant systemic therapy? A real-world study in China**  
R. Chen, Y. Li, S. Li, Q. Zhu, X. Shi, X. Zha, J. Wang, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **122P - A comparison of margin involvement and re-excision rates with the use of Klinitray; versus standard suture specimen orientation in wide local excision surgery for breast cancer**  
T. Clarke<sup>1</sup>, K. Edwards<sup>2</sup>, J. Piper<sup>2</sup>, <sup>1</sup>York Hospital, York, GB, <sup>2</sup>York District Hospital, York, GB
- 12:00 - 12:00 **123P - Cosmetic outcome after vacuum-assisted excision is good and independent of the amount of resected tissue**  
E. Van De Voort, T. Klem, G. Struik, A. Ghandi, R. Sinke, SFVG - St Franciscus Gasthuis, Rotterdam, NL
- 12:00 - 12:00 **125P - Prognostic factors in phyllodes tumours (PT) of the breast: A single-institution cohort**  
E. Di Liso<sup>1</sup>, M. Bottosso<sup>2</sup>, V. Tsvetkova<sup>3</sup>, M. Lo Mele<sup>4</sup>, M.V. Dieci<sup>5</sup>, C. Falci<sup>6</sup>, G. Faggioni<sup>5</sup>, G. Tasca<sup>5</sup>, C.A. Giorgi<sup>6</sup>, T. Giarratano<sup>6</sup>, E. Mioranza<sup>7</sup>, A.P. Dei Tos<sup>8</sup>, V. Guarneri<sup>6</sup>, P.F. Conte<sup>6</sup>, <sup>1</sup>Istituto Oncologico Veneto, padova, IT, <sup>2</sup>Istituto Oncologico Veneto, PADOVA, IT, <sup>3</sup>University of Study of Verona, Verona, IT, <sup>4</sup>University of Study of Padua, Padova, IT, <sup>5</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>7</sup>Istituto Oncologico Veneto IRCCS, PADOVA, IT, <sup>8</sup>University of Padua, School of Medicine, Padova, IT
- 12:00 - 12:00 **126TiP - Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG 101 - TAXIS): A multicenter randomized phase III trial**  
W. Weber<sup>1</sup>, G. Henke<sup>2</sup>, K. Ribi<sup>3</sup>, S. Hayoz<sup>4</sup>, S. Seiler<sup>5</sup>, C. Maddox<sup>6</sup>, T. Ruhstaller<sup>7</sup>, D. Zwahlen<sup>8</sup>, S. Muenst<sup>1</sup>, M. Ackerknecht<sup>1</sup>, F. Fitzal<sup>9</sup>, Z. Matrai<sup>10</sup>, M. Újhelyi<sup>11</sup>, C. Kurzeder<sup>1</sup>, L. Lelièvre<sup>12</sup>, C. Tausch<sup>13</sup>, J. Heil<sup>14</sup>, M. Knauer<sup>7</sup>, <sup>1</sup>University Hospital Basel, Basel, CH, <sup>2</sup>University Hospital St. Gallen, St. Gallen, CH, <sup>3</sup>SAKK Coordinating Center, Switzerland, Bern, CH, <sup>4</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>5</sup>SAKK Coordinating Center, Bern, CH, <sup>6</sup>ETOP - European Thoracic Oncology Platform, Bern, CH, <sup>7</sup>Brustzentrum Ostschweiz AG, St. Gallen, CH, <sup>8</sup>Cantonal Hospital Winterthur, Winterthur, CH, <sup>9</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>10</sup>National Institute of Oncology Hungary, Budapest, HU, <sup>11</sup>National Institute of Oncology, Hungary, Budapest, HU, <sup>12</sup>Centre du sein CHUV, Lausanne, CH, <sup>13</sup>Brust-Zentrum, Zurich, CH, <sup>14</sup>University Hospital Heidelberg, Heidelberg, DE

12:00 - 12:00 **Immunotherapy**

12:00 - 12:00 **129P - Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort**

Y. Novik<sup>1</sup>, N. Klar<sup>2</sup>, S. Zamora<sup>1</sup>, M. Kwa<sup>1</sup>, J. Speyer<sup>1</sup>, R. Oratz<sup>1</sup>, F. Muggia<sup>3</sup>, M. Meyers<sup>1</sup>, T. Hochman<sup>4</sup>, J. Goldberg<sup>4</sup>, S. Adams<sup>5</sup>, <sup>1</sup>NYU Cancer Institute NYU Medical School, New York, US, <sup>2</sup>NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, US, <sup>3</sup>Private Practice - Dr. Franco Muggia, Mamaroneck, US, <sup>4</sup>NYU Langone Medical Center, New York City, US, <sup>5</sup>NYU Cancer Institute NYU Medical School, New York City, US

12:00 - 12:00 **131P - Abrogation of paclitaxel chemo-resistance via epigenetic immune checkpoints regulation in triple negative breast cancer**

S. El Shihy<sup>1</sup>, R. Abdeltawab<sup>2</sup>, H. El Tayebi<sup>3</sup>, <sup>1</sup>GUC - German University in Cairo, Cairo, EG, <sup>2</sup>Ain Shams University, Cairo, EG, <sup>3</sup>GUC - German University in Cairo, New Cairo, EG

12:00 - 12:00 **132P - MALAT-1 ruling the miR-182/PIG-C/MSLN triad in triple negative breast cancer**

A. Samir<sup>1</sup>, F. Barsoum<sup>1</sup>, R. Abdeltawab<sup>2</sup>, H. El Tayebi<sup>3</sup>, <sup>1</sup>GUC - German University in Cairo, Cairo, DE, <sup>2</sup>Ain Shams University, Cairo, EG, <sup>3</sup>GUC - German University in Cairo, New Cairo, EG

12:00 - 12:00 **133TiP - A phase II trial of nivolumab &#x2b; palbociclib &#x2b; anastrozole in postmenopausal women with ER&#x2b;/HER2&#x2013; primary breast cancer: CheckMate 7A8**

S. Tolaney<sup>1</sup>, G. Jerusalem<sup>2</sup>, R. Salgado<sup>3</sup>, X. Liu<sup>4</sup>, T. Chen<sup>4</sup>, H. Zhang<sup>4</sup>, M. Roberts<sup>4</sup>, D. Zardavas<sup>4</sup>, A. Prat<sup>5</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>3</sup>St-Augustinus Ziekenhuis, Wilrijk, BE, <sup>4</sup>Bristol-Myers Squibb, Lawrence, US, <sup>5</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **134TiP - A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER&#x2b;/HER2&#x2212; primary breast cancer: CheckMate 7FL**

G. Curigliano<sup>1</sup>, H. Mcarthur<sup>2</sup>, N. Harbeck<sup>3</sup>, L. Pusztai<sup>4</sup>, S. Delaloge<sup>5</sup>, K. Letrent<sup>6</sup>, T. Chen<sup>6</sup>, B. Li<sup>6</sup>, K. Tatsuoka<sup>6</sup>, D. Zardavas<sup>6</sup>, S. Loi<sup>7</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>Ludwig Maximilians University (LMU) Hospital, Munich, DE, <sup>4</sup>Yale School of Medicine, New Haven, US, <sup>5</sup>Gustave Roussy, Villejuif, FR, <sup>6</sup>Bristol-Myers Squibb, Lawrence, US, <sup>7</sup>Peter MacCallum Cancer Centre, Melbourne, AU

12:00 - 12:00 **135TiP - GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer**

L. Voorwerk<sup>1</sup>, H. Horlings<sup>1</sup>, M. Dongen<sup>2</sup>, I. Kemper<sup>2</sup>, I. Mandjes<sup>2</sup>, J. Boers<sup>3</sup>, C. Schröder<sup>3</sup>, V. Tjan-Heijnen<sup>4</sup>, A. Jager<sup>5</sup>, T. Schumacher<sup>6</sup>, C. Blank<sup>2</sup>, K. De Visser<sup>1</sup>, S.



Linn<sup>6</sup>, M. Kok<sup>6</sup>, <sup>1</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>4</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>5</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>6</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

12:00 - 12:00 **Metastatic Breast cancer**

12:00 - 12:00 **141P - Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer**

P. Schmid<sup>1</sup>, A. Haiderali<sup>2</sup>, J. Mejia<sup>3</sup>, Z. Guo<sup>3</sup>, X. Zhou<sup>3</sup>, A. Martin-Nguyen<sup>4</sup>, J. Cortés<sup>5</sup>, E. Winer<sup>6</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>3</sup>Merck, North Wales, US, <sup>4</sup>MSD-Merck Sharp & Dohme, Kenilworth, US, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Dana Farber Cancer Institute, Boston, US

12:00 - 12:00 **142P - Quality-adjusted survival with ribociclib plus fulvestrant (R&#x2b;F) versus placebo plus fulvestrant (P&#x2b;F) in postmenopausal women (PMW) HR&#x2b;/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial**

G. Jerusalem<sup>1</sup>, T. Delea<sup>2</sup>, M. Martin Jimenez<sup>3</sup>, M. De Laurentiis<sup>4</sup>, A. Nusch<sup>5</sup>, J.T. Beck<sup>6</sup>, A. Chan<sup>7</sup>, S.-A. Im<sup>8</sup>, P. Neven<sup>9</sup>, A. Lonshteyn<sup>2</sup>, D. Chandiwana<sup>10</sup>, B. Lanoue<sup>10</sup>, P. Fasching<sup>11</sup>, <sup>1</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>2</sup>Policy Analysis Inc. (PAI), Brookline, US, <sup>3</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, IT, <sup>5</sup>Practice for Hematology and Internal Oncology, Velbert, DE, <sup>6</sup>Highlands Oncology Group, Fayetteville, US, <sup>7</sup>Breast Cancer Centre WA & Curtin University, Perth, AU, <sup>8</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>9</sup>Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, BE, <sup>10</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>11</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE

12:00 - 12:00 **143P - Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study**

Z. Kahan<sup>1</sup>, M. Gil-Gil<sup>2</sup>, M. Ruiz-Borrego<sup>3</sup>, E. Carrasco<sup>4</sup>, E. Ciruelos<sup>5</sup>, M. Muñoz<sup>6</sup>, B. Bermejo De Las Heras<sup>7</sup>, M. Margeli Vila<sup>8</sup>, A. Anton<sup>9</sup>, M. Casas<sup>4</sup>, L. Calvo<sup>10</sup>, J. De La Haba<sup>11</sup>, M. Ramos<sup>12</sup>, I. Alvarez Lopez<sup>13</sup>, E. Gal-Yam<sup>14</sup>, E. Gautier<sup>15</sup>, M. Corsaro<sup>16</sup>, G. Rodrigálvarez<sup>4</sup>, C. Zielinski<sup>17</sup>, M. Martin Jimenez<sup>18</sup>, <sup>1</sup>University of Szeged, Szeged, HU, <sup>2</sup>Institut Catala d' Oncologia, L'Hospitalet de Llobregat, ES, <sup>3</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>4</sup>GEICAM, San Sebastian de los Reyes, ES, <sup>5</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>6</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>8</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>9</sup>Hospital Universitario Miguel Servet, Zaragoza, ES, <sup>10</sup>Complejo Hospitalario A Coruña, A Coruña, ES, <sup>11</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>12</sup>Centro Oncológico de

Galicia, A Coruña, ES, <sup>13</sup>Hospital Donostia, San Sebastian, ES, <sup>14</sup>Institute of oncology , Sheba medical center, Tel-Hashomer, IL, <sup>15</sup>Pfizer Inc, San Francisco, US, <sup>16</sup>Pfizer, Milan, IT, <sup>17</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>18</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES

- 12:00 - 12:00 **144P - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) &#x2b; fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)**
- P. Fasching<sup>1</sup>, P. Neven<sup>2</sup>, G. Jerusalem<sup>3</sup>, J.T. Beck<sup>4</sup>, A. Chan<sup>5</sup>, M. De Laurentiis<sup>6</sup>, G. Bianchi<sup>7</sup>, M. Martin Jimenez<sup>8</sup>, S. Chia<sup>9</sup>, A. Gaur<sup>10</sup>, M. Sondhi<sup>10</sup>, K. Rodriguez-Lorenc<sup>11</sup>, B. Lanoue<sup>11</sup>, D. Chandiwana<sup>11</sup>, A. Nusch<sup>12</sup>, <sup>1</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>2</sup>Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, BE, <sup>3</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>4</sup>Highlands Oncology Group, Fayetteville, US, <sup>5</sup>Breast Cancer Centre WA & Curtin University, Perth, AU, <sup>6</sup>Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, IT, <sup>7</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>8</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>9</sup>University of British Columbia, Vancouver, CA, <sup>10</sup>Novartis Pharma MCH, East Hanover, US, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>Practice for Hematology and Internal Oncology, Velbert, DE
- 12:00 - 12:00 **146P - Safety and metabolic effects of fasting-mimicking diet in breast cancer patients**
- C. Vernieri<sup>1</sup>, A. Raimondi<sup>1</sup>, F. Ligorio<sup>1</sup>, E. Zattarin<sup>1</sup>, F. Nichetti<sup>2</sup>, S. Manglaviti<sup>1</sup>, G. Bianchi<sup>1</sup>, G. Capri<sup>1</sup>, L. Rivoltini<sup>2</sup>, F.G.M. De Braud<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 12:00 - 12:00 **147P - Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours**
- M. Takahashi<sup>1</sup>, Y.-J. Bang<sup>2</sup>, M. Karayama<sup>3</sup>, J. Watanabe<sup>4</sup>, H. Minami<sup>5</sup>, N. Yamamoto<sup>6</sup>, I. Kinoshita<sup>7</sup>, C.C. Lin<sup>8</sup>, Y.-H. Im<sup>9</sup>, T. Fujiki<sup>10</sup>, I. Achiwa<sup>10</sup>, E. Kamiyama<sup>11</sup>, Y. Okuda<sup>12</sup>, C. Lee<sup>13</sup>, S. Takahashi<sup>14</sup>, <sup>1</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Hamamatsu University School of Medicine, Hamamatsu, JP, <sup>4</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>5</sup>Kobe University Hospital, Kobe, JP, <sup>6</sup>National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, <sup>7</sup>Hokkaido University, Sapporo, JP, <sup>8</sup>National Taiwan University Hospital (NTUH), Taipei, TW, <sup>9</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Daiichi Sankyo Co., Ltd., Tokyo, JP, <sup>11</sup>Daiichi Sankyo Co, Ltd, Tokyo, JP, <sup>12</sup>Daiichi Sankyo Co, Ltd., Tokyo, JP, <sup>13</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>14</sup>Cancer Institute Hospital of JFCR, Tokyo, JP
- 12:00 - 12:00 **148P - Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A&#xa0;nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)**
- M. Brandão<sup>1</sup>, C. De Angelis<sup>1</sup>, P. Vuylsteke<sup>2</sup>, R. Gelber<sup>3</sup>, N. Van Damme<sup>4</sup>, E. Van Eycken<sup>4</sup>,

J. Verbeeck<sup>4</sup>, L. Van Walle<sup>4</sup>, C. Colpaert<sup>5</sup>, M. Lambertini<sup>6</sup>, F. Poggio<sup>6</sup>, D. Verhoeven<sup>7</sup>, A. Barbeaux<sup>8</sup>, F. Duhoux<sup>9</sup>, K. Punie<sup>5</sup>, H. Wildiers<sup>5</sup>, C. Caballero<sup>10</sup>, A. Awada<sup>1</sup>, M. Piccart<sup>1</sup>, E. De Azambuja<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Princess Marina Hospital, Gaborone, BW, <sup>3</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>4</sup>Belgian Cancer Registry, Brussels, BE, <sup>5</sup>UZ Leuven, Leuven, BE, <sup>6</sup>University of Genova, Genova, IT, <sup>7</sup>University of Antwerp, Antwerp, BE, <sup>8</sup>CHR Verviers East Belgium, Verviers, BE, <sup>9</sup>Université Catholique de Louvain, Brussels, BE, <sup>10</sup>Breast International Group, Brussels, BE

12:00 - 12:00

**149P - Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores**

K. Riecke<sup>1</sup>, V. Mueller<sup>1</sup>, T. Neunhöffer<sup>2</sup>, R. Weide<sup>3</sup>, M. Schmidt<sup>4</sup>, T.-W. Park-Simon<sup>5</sup>, C. Mundhenke<sup>6</sup>, A. Polasik<sup>7</sup>, T. Hesse<sup>8</sup>, K. Lübke<sup>9</sup>, E. Laakmann<sup>1</sup>, M. Thill<sup>10</sup>, P. Fasching<sup>11</sup>, C. Denkert<sup>12</sup>, T. Fehm<sup>13</sup>, V. Nekljudova<sup>14</sup>, J. Rey<sup>14</sup>, S. Loibl<sup>15</sup>, I. Witzel<sup>16</sup>, <sup>1</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>2</sup>Frauenärzte am Dom, Mainz, DE, <sup>3</sup>Praxis für Hämatologie und Onkologie, Koblenz, DE, <sup>4</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>5</sup>Medizinische Hochschule Hannover, Hannover, DE, <sup>6</sup>Klinikum Bayreuth GmbH, Bayreuth, DE, <sup>7</sup>Universitätsklinikum Ulm, Ulm, DE, <sup>8</sup>Agaplesion Diakoniklinikum Rotenburg, Rotenburg, DE, <sup>9</sup>Frauenklinik Hannover, Hannover, DE, <sup>10</sup>Agaplesion Markus Krankenhaus, Frankfurt, DE, <sup>11</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>12</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>13</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>14</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>15</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>16</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

12:00 - 12:00

**150P - Eligibility of real-world patients with metastatic breast cancer in clinical trials**

A. Batra<sup>1</sup>, S. Kong<sup>2</sup>, R. Rigo<sup>2</sup>, W. Cheung<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>Tom Baker Cancer Center, Calgary, CA

12:00 - 12:00

**151P - The landscape of patients with metastatic breast cancer enrolled in phase I trials**

A. Marra<sup>1</sup>, C. Criscitiello<sup>2</sup>, S. Morganti<sup>1</sup>, P. Zagami<sup>2</sup>, G. Viale<sup>1</sup>, P. Tarantino<sup>3</sup>, D. Trapani<sup>1</sup>, E. Nicolò<sup>4</sup>, M. Repetto<sup>1</sup>, E. Ferraro<sup>1</sup>, P. D'Amico<sup>1</sup>, M. Locatelli<sup>4</sup>, A. Esposito<sup>5</sup>, G. Curigliano<sup>2</sup>, <sup>1</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>European Institute of Oncology (IEO), Milan, IT, <sup>4</sup>IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, IT, <sup>5</sup>ecancer, Bristol, GB

12:00 - 12:00

**153P - Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials**

M.A. Franzoi<sup>1</sup>, L. Ameye<sup>2</sup>, D. Eiger<sup>1</sup>, M. Piccart<sup>1</sup>, M. Brandão<sup>1</sup>, N. Pondé<sup>3</sup>, C. Desmedt<sup>4</sup>, S. Di Cosimo<sup>5</sup>, M. Paesmans<sup>1</sup>, R. Caparica<sup>1</sup>, N. Kotecki<sup>1</sup>, M. Lambertini<sup>6</sup>, C. De Angelis<sup>2</sup>, A. Awada<sup>1</sup>, E. De Azambuja<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Institut Jules Bordet, Brussels, BE, <sup>3</sup>AC Camargo Cancer Center, São Paulo, BR, <sup>4</sup>KU Leuven, Leuven, BE,



<sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT, <sup>6</sup>University of Genova, Genova, IT

- 12:00 - 12:00 **154P - Survival outcome of indigenous and non-indigenous women of Western Australia with breast cancer in relation to remoteness**  
A. Khan<sup>1</sup>, H. Martin<sup>2</sup>, L. Spalding<sup>3</sup>, A. Redfern<sup>3</sup>, <sup>1</sup>Sir Charles Gairdner Hospital, Nedlands, AU, <sup>2</sup>Fiona Stanley Hospital, Murdoch, AU, <sup>3</sup>University of Western Australia, Perth, AU
- 12:00 - 12:00 **155P - Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients**  
E. Montagna<sup>1</sup>, E. Pagan<sup>2</sup>, G. Canello<sup>1</sup>, C. Sangalli<sup>3</sup>, V. Bagnardi<sup>2</sup>, E. Munzone<sup>1</sup>, M. Iorfida<sup>1</sup>, M. Mazza<sup>1</sup>, S. Dellapasqua<sup>1</sup>, N. Bianco<sup>1</sup>, P. Veronesi<sup>4</sup>, M. Colleoni<sup>1</sup>, <sup>1</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>University of Milan-Bicocca, Milan, IT, <sup>3</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>4</sup>European Institute of Oncology IRCCS, Milan, IT
- 12:00 - 12:00 **156P - Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR<sup>+</sup>/HER2 ABC)**  
H. Rugo<sup>1</sup>, A. Haltner<sup>2</sup>, L. Zhan<sup>3</sup>, A. Tran<sup>2</sup>, E. Bananis<sup>3</sup>, D. Mitra<sup>3</sup>, C. Cameron<sup>2</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Eversana, Nova Scotia, CA, <sup>3</sup>Pfizer Inc, New York, US
- 12:00 - 12:00 **157P - Germline BRCA1/2 (gBRCA1/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): Results from a multi-country real-world study**  
R. Mahtani<sup>1</sup>, A. Niyazov<sup>2</sup>, K. Lewis<sup>3</sup>, R. Wild<sup>4</sup>, A. Rider<sup>3</sup>, B. Arondekar<sup>5</sup>, M.P. Lux<sup>6</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>Pfizer, New York, US, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Cheshire, GB, <sup>5</sup>Pfizer Inc - USA, New York, US, <sup>6</sup>Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE
- 12:00 - 12:00 **158P - Patient (pt) demographics, treatment patterns (tx) and hematologic (heme) toxicities among pts with HER2<sup>+</sup> advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): A multi-country real-world (RW) study**  
R. Mahtani<sup>1</sup>, A. Niyazov<sup>2</sup>, K. Lewis<sup>3</sup>, M. Last<sup>4</sup>, A. Rider<sup>3</sup>, B. Arondekar<sup>5</sup>, M.P. Lux<sup>6</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>Pfizer, New York, US, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Cheshire, GB, <sup>5</sup>Pfizer Inc - USA, New York, US, <sup>6</sup>Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE
- 12:00 - 12:00 **159P - The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)**  
D. Eiger<sup>1</sup>, E. De Azambuja<sup>1</sup>, M. Moreau<sup>1</sup>, J. Bondele<sup>2</sup>, C. Sotiriou<sup>1</sup>, M.A. Franzoi<sup>1</sup>, M.

Brandão<sup>1</sup>, M. Rediti<sup>1</sup>, X. Wang<sup>1</sup>, A. Awada<sup>1</sup>, N. Kotecki<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Université Libre de Bruxelles, Bruxelles, BE

- 12:00 - 12:00 **162P - Overcoming resistance to endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2-) advanced breast cancer: A meta-analysis of randomized clinical trials**  
W. Zhu, B. Xu, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:00 - 12:00 **163P - Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib & fulvestrant vs everolimus & exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR<sup>+</sup>) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)**  
E. Ciruelos<sup>1</sup>, T. Delea<sup>2</sup>, A. Moynahan<sup>2</sup>, I. Mayer<sup>3</sup>, J. Park<sup>4</sup>, D. Chandiwana<sup>5</sup>, A. Ridolfi<sup>6</sup>, I. Lorenzo<sup>7</sup>, H. Rugo<sup>8</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Policy Analysis Inc. (PAI), Brookline, US, <sup>3</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>4</sup>Novartis Pharmaceuticals UK Ltd, Camberley, GB, <sup>5</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>6</sup>Novartis Pharmaceuticals Corporation, Rueil-Malmaison, FR, <sup>7</sup>Novartis Farmaceutica, S.A., Barcelona, ES, <sup>8</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 12:00 - 12:00 **164P - A prospective approach for the evaluation of a one-step RT-qPCR based test for the quantification of HER2 protein in formalin-fixed and paraffin-embedded breast cancer tissues**  
B. Al Banyahyati, MAScIR - Moroccan Foundation for Advanced Science, Innovation and Research, Rabat, MA
- 12:00 - 12:00 **165P - Immune characterization of the de novo oligometastatic breast cancer**  
S. Chretien<sup>1</sup>, L. Buisseret<sup>2</sup>, X. Wang<sup>2</sup>, G. Rouas<sup>2</sup>, N. Kotecki<sup>2</sup>, S. Garaud<sup>2</sup>, A. Mailliez<sup>1</sup>, D. Larsimont<sup>2</sup>, F. Rothé<sup>2</sup>, C. Sotiriou<sup>2</sup>, <sup>1</sup>Centre Oscar Lambret, Lille, FR, <sup>2</sup>Institute Jules Bordet, Brussels, BE
- 12:00 - 12:00 **166P - Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany**  
M. Lux<sup>1</sup>, T. Decker<sup>2</sup>, E. Runkel<sup>3</sup>, A. Niyazov<sup>4</sup>, R. Quek<sup>5</sup>, E. Glastetter<sup>3</sup>, N. Marschner<sup>6</sup>, N. Harbeck<sup>7</sup>, <sup>1</sup>Kooperatives Brustzentrum Paderborn, Paderborn, DE, <sup>2</sup>Onkologie Hamatologie Ravensburg, Ravensburg, DE, <sup>3</sup>Pfizer - Germany, Berlin, DE, <sup>4</sup>Pfizer, New York, US, <sup>5</sup>Medivation Inc. - Pfizer Inc., San Francisco, US, <sup>6</sup>iOMEDICO AG, Freiburg im Breisgau, DE, <sup>7</sup>Ludwig Maximilians University (LMU) Hospital, Munich, DE
- 12:00 - 12:00 **167P - TRIP13 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse**  
Z. Du, Y. Wang, Q. Lv, West China Medical Center of Sichuan University, Chengdu, CN
- 12:00 - 12:00 **168P - Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)**

O. Martinez Saez<sup>1</sup>, A. Menichetti<sup>2</sup>, L. Pare Brunet<sup>3</sup>, G. Griguolo<sup>2</sup>, A. Rodriguez Hernandez<sup>3</sup>, T. Pascual<sup>4</sup>, M.V. Dieci<sup>2</sup>, P.F. Conte<sup>5</sup>, C.A. Giorgi<sup>5</sup>, F. Brasó-Maristany<sup>6</sup>, N. Chic<sup>7</sup>, D. Martínez<sup>6</sup>, A. Rodríguez<sup>1</sup>, F. Schettini<sup>8</sup>, B. Conte<sup>9</sup>, M. Vidal<sup>7</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, A. Prat<sup>3</sup>, V. Guarneri<sup>5</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>5</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>IDIBAPS, Barcelona, ES, <sup>7</sup>Hospital Clinic, Barcelona, ES, <sup>8</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>9</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

- 12:00 - 12:00 **169P - Trastuzumab use among patients with HER2-positive metastatic breast cancer in an electronic health records database**  
N. Lindegger<sup>1</sup>, C. Ike<sup>2</sup>, N. Schwartz<sup>2</sup>, A. Surinach<sup>3</sup>, Y. Liu<sup>3</sup>, K. Debusk<sup>2</sup>, <sup>1</sup>Seattle Genetics - SeaGen International GmbH, Zug, CH, <sup>2</sup>Seattle Genetics, Bothell, US, <sup>3</sup>Genesis Research, Hoboken, US
- 12:00 - 12:00 **170P - 18F-FDG PET/CT features of the metastases from intrinsic NSIBC molecular types and its prognostic value**  
M. Xu, J. Chen, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN
- 12:00 - 12:00 **171P - An outcomes summary of the clinical advances curriculum on CDK4 &#x26; 6 inhibition in breast cancer**  
N. Dorkhom<sup>1</sup>, D. Middleton<sup>2</sup>, P. Guedj<sup>3</sup>, P. Chen<sup>4</sup>, K. Lucero<sup>5</sup>, G. Curigliano<sup>6</sup>, <sup>1</sup>Medscape, Naarden, NL, <sup>2</sup>Medscape education, Chicago, US, <sup>3</sup>Medscape France, Paris, FR, <sup>4</sup>Medscape education, New York, US, <sup>5</sup>Medscape Education, New York, US, <sup>6</sup>IEO - Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **172P - REACHAUT: Real-world study of first-line (1L) ribociclib (RIB)&#xa0;&#x2b;&#xa0;endocrine therapy (ET) in HR&#x2b;, HER2-metastatic breast cancer (MBC)**  
C. Singer<sup>1</sup>, D. Egle<sup>2</sup>, R. Greil<sup>3</sup>, L. Öhler<sup>4</sup>, E. Petru<sup>5</sup>, C. Suppan<sup>6</sup>, M. Marhold<sup>7</sup>, G. Pfeiler<sup>7</sup>, C. Brunner<sup>2</sup>, C. Tinchon<sup>8</sup>, S. Halper<sup>9</sup>, A. Galid<sup>10</sup>, U. Pluschnig<sup>11</sup>, F. Haslbauer<sup>12</sup>, M. Hubalek<sup>13</sup>, A. Redl<sup>14</sup>, J. Flatschacher<sup>15</sup>, M. Hennebelle<sup>15</sup>, B. Mraz<sup>15</sup>, R. Bartsch<sup>7</sup>, <sup>1</sup>Comprehensive Cancer center, Medical University of Vienna, Vienna, AT, <sup>2</sup>Medical University of Innsbruck, Innsbruck, AT, <sup>3</sup>Paracelsus Medical University Salzburg, salzburg, AT, <sup>4</sup>St Joseph Hospital, Vienna, AT, <sup>5</sup>Medical University of Graz, Graz, AT, <sup>6</sup>Medical University of Graz, Graz, AT, <sup>7</sup>Medical University of Vienna, Vienna, AT, <sup>8</sup>Leoben State Hospital, Leoben, AT, <sup>9</sup>Landesklinikum Wiener Neustadt (Wiener Neustadt Hospital), Wiener Neustadt, AT, <sup>10</sup>Breast Center Hanusch KH, Vienna, AT, <sup>11</sup>Klinikum Klagenfurt, Klagenfurt, AT, <sup>12</sup>Saizkammergut Klinikum Vocklabruck, Vocklabruck, AT, <sup>13</sup>Brustzentrum Schwaz, Schwaz, AT, <sup>14</sup>Datamedrix GmbH, Wien, AT, <sup>15</sup>Novartis Pharma GmbH, Vienna, AT
- 12:00 - 12:00 **173P - Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data**  
D. Skrobo<sup>1</sup>, N. Walsh<sup>2</sup>, C. Quinn<sup>1</sup>, J. Walshe<sup>1</sup>, L.M. Smyth<sup>1</sup>, G. Gullo<sup>1</sup>, J. Crown<sup>1</sup>, <sup>1</sup>St Vincents University Hospital, Dublin, IE, <sup>2</sup>National Institute for Cellular Biotechnology,



Dublin, IE

- 12:00 - 12:00 **174P - Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer**  
G. Vidal<sup>1</sup>, K. Debusk<sup>2</sup>, S. Gautam<sup>3</sup>, A. Vlahiotis<sup>3</sup>, M. Fisher<sup>3</sup>, S. Pulgar<sup>2</sup>, <sup>1</sup>West Cancer Center and Research Institute, Germantown, US, <sup>2</sup>Seattle Genetics, Bothell, US, <sup>3</sup>Concerto HealthAI, Memphis, US
- 12:00 - 12:00 **175P - Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR<sup>+</sup>/HER2-advanced or metastatic breast cancer in Italy and Germany**  
S. De Placido, Md<sup>1</sup>, S. Brucker, Md<sup>2</sup>, E. Law, Pharmd, PhD<sup>3</sup>, M. Ajmera, PhD<sup>4</sup>, D. Mitra, Ma<sup>3</sup>, K. Davis, Ma<sup>4</sup>, N. Harbeck, Md<sup>5</sup>, M. De Laurentiis, Md<sup>6</sup>, <sup>1</sup>University of Naples Federico II, Napoli, IT, <sup>2</sup>Tübingen University Hospital, Tübingen,, DE, <sup>3</sup>Pfizer Inc, New York, US, <sup>4</sup>RTI Health Solutions, Research Triangle Park, US, <sup>5</sup>Brustzentrum der Universität München (LMU), München, DE, <sup>6</sup>National Cancer Institute "Fondazione Pascale", Napoli, IT
- 12:00 - 12:00 **176P - Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices**  
A. Brufsky<sup>1</sup>, X. Liu<sup>2</sup>, B. Li<sup>2</sup>, L. Mcroy<sup>3</sup>, R. Layman<sup>4</sup>, <sup>1</sup>Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Pfizer Inc - USA, New York, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **177P - Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Germany: Results from the IRIS study**  
G. Taylor-Stokes<sup>1</sup>, L. Zhan<sup>2</sup>, K. Mycock<sup>3</sup>, G. Milligan<sup>1</sup>, A. Ghale<sup>1</sup>, D. Mitra<sup>2</sup>, <sup>1</sup>Adelphi Group, Bollington, GB, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Adelphi Real World - Adelphi Group, Bollington, GB
- 12:00 - 12:00 **178P - Risks of distant metastasis of different breast cancer subtypes after surgery: A cohort study in indigenous Indonesian population**  
H. Sakti<sup>1</sup>, W. Avanti<sup>1</sup>, L. Choridah<sup>1</sup>, E.K.D. Dwianingsih<sup>1</sup>, W. Harahap<sup>2</sup>, T. Aryandono<sup>1</sup>, S. Anwar<sup>1</sup>, <sup>1</sup>Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>2</sup>Dr M Jamil Hospital / Faculty of Medicine Universitas Andalas,, Padang, ID
- 12:00 - 12:00 **179TiP - EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER<sup>+</sup>/HER2- advanced breast cancer following CDK4/6 inhibitor therapy**  
A. Bardia<sup>1</sup>, J. Lu<sup>2</sup>, V. Kaklamani<sup>3</sup>, J. Jung<sup>4</sup>, A. Anderson-Villaluz<sup>4</sup>, M. Conlan<sup>5</sup>, F.-C. Bidard<sup>6</sup>, J. Cortés<sup>7</sup>, P. Aftimos<sup>8</sup>, <sup>1</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>2</sup>USC Norris Comprehensive Cancer Center, Los Angeles, US, <sup>3</sup>UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, <sup>4</sup>Radius Health, Inc., Waltham, US, <sup>5</sup>Radius Health Inc, Waltham, US, <sup>6</sup>Institut Curie, Paris, FR, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Institute Jules Bordet, Brussels, BE

- 12:00 - 12:00 **180TiP - Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial**
- E. Ciruelos<sup>1</sup>, P. Villagrasa<sup>2</sup>, M. Oliveira<sup>3</sup>, S. Pernas Simon<sup>4</sup>, J. Cortés<sup>5</sup>, S. Vazquez<sup>6</sup>, N. Martínez<sup>7</sup>, A. Perelló<sup>8</sup>, B. Bermejo De Las Heras<sup>9</sup>, E. Martínez<sup>10</sup>, I. Garau Llinas<sup>11</sup>, M. Mele Olive<sup>12</sup>, A. Montaña<sup>13</sup>, E. Vega<sup>14</sup>, B. Cantos<sup>15</sup>, M.J. Echarri<sup>16</sup>, T. Pascual<sup>17</sup>, P. Celiz<sup>18</sup>, X. González-Farré<sup>19</sup>, A. Prat<sup>20</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>SOLTI, Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, <sup>7</sup>Ramon y Cajal Hospital, Madrid, ES, <sup>8</sup>Hospital Universitari Son Espases, Palma de Mallorca, ES, <sup>9</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>10</sup>Consortio Hospitalario Provincial de Castellón, Castelló de la Plana, ES, <sup>11</sup>Hospital Son Llatzer, Palma de Mallorca, ES, <sup>12</sup>Hospital Universitari Sant Joan de Reus, Reus, ES, <sup>13</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>14</sup>Centro Integral Oncológico Clara Campal, Madrid, ES, <sup>15</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>16</sup>Hospital Severo Ochoa, Leganes, ES, <sup>17</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>18</sup>SOLTI HQ, Barcelona, ES, <sup>19</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>20</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **181TiP - Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)**
- P. Schmid<sup>1</sup>, H. Rugo<sup>2</sup>, J. Cortés<sup>3</sup>, P. Blum<sup>4</sup>, K. Crossley<sup>5</sup>, D. Massey<sup>4</sup>, H. Burris, Iii<sup>6</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Boehringer Ingelheim International GmbH, Biberach, DE, <sup>5</sup>Boehringer Ingelheim Ltd, Bracknell, GB, <sup>6</sup>Sarah Cannon Research Institute, Nashville, US
- 12:00 - 12:00 **182TiP - Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAM) or homologous recombination deficient (HRD), hormone receptor (HR+)/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy**
- S. Blanch<sup>1</sup>, J.M. Pérez-García<sup>2</sup>, J. Balmaña<sup>3</sup>, A. Prat<sup>4</sup>, J.E. Alés-Martínez<sup>5</sup>, J. De La Haba<sup>6</sup>, E. Alba<sup>7</sup>, P. Palacios-Ozores<sup>8</sup>, M. Ramos<sup>9</sup>, L. Lema<sup>10</sup>, J.Á. García Sáenz<sup>11</sup>, M. Sampayo-Cordero<sup>12</sup>, A. Malfettone<sup>12</sup>, J. Cortés<sup>3</sup>, A. Llombart Cussac<sup>13</sup>, <sup>1</sup>Instituto Valenciano de Oncología, Valencia, ES, <sup>2</sup>IOB, Institute of Oncology, QuironSalud Group; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, Madrid and Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>Hospital Nuestra Señora de Sonsoles, Ávila, ES, <sup>6</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>7</sup>Hospital Virgen de la Victoria, Málaga, ES, <sup>8</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>9</sup>Centro Oncológico de Galicia, A Coruña, ES, <sup>10</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>11</sup>Hospital Clínico San Carlos, Madrid, ES, <sup>12</sup>MedSIR - Medica Scientia Innovation Research, Barcelona, ES, <sup>13</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES

- 12:00 - 12:00 **Supportive care and survivorship**
- 12:00 - 12:00 **186P - Using a new controlled thermotherapy (Hilotherapy) during chemotherapy prevents chemotherapy induced polyneuropathy (CIPN)**  
T. Schaper, B. Gross, L. Franzmann, M. Darsow, Luisenkrankenhaus GmbH & Co KG, Düsseldorf, DE
- 12:00 - 12:00 **187P - Patient-reported outcomes near end-of-life in patients with breast cancer**  
A. Batra<sup>1</sup>, C. Cuthbert<sup>2</sup>, R. Rigo<sup>3</sup>, A. Harper<sup>4</sup>, D. Boyne<sup>4</sup>, L. Yang<sup>4</sup>, W. Cheung<sup>3</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>University of Calgary, Calgary, CA, <sup>3</sup>Tom Baker Cancer Center, Calgary, CA, <sup>4</sup>Alberta Health Services, Calgary, CA
- 12:00 - 12:00 **188P - Impact of HIV infection (HIV) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis**  
M. Brandão<sup>1</sup>, M. Bruzzone<sup>2</sup>, M.A. Franzoi<sup>1</sup>, C. De Angelis<sup>1</sup>, D. Eiger<sup>1</sup>, R. Caparica<sup>1</sup>, N. Dauby<sup>3</sup>, M. Ceppi<sup>2</sup>, M. Piccart<sup>1</sup>, C. Carrilho<sup>4</sup>, N. Lunet<sup>5</sup>, L. Buisseret<sup>6</sup>, E. De Azambuja<sup>1</sup>, M. Lambertini<sup>2</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>University of Genova, Genova, IT, <sup>3</sup>Centre Hospitalier Universitaire Saint-Pierre, Bruxelles, BE, <sup>4</sup>Faculty of Medicine University Eduardo Mondlane, Maputo, MZ, <sup>5</sup>Instituto de Saúde Pública da Universidade do Porto, Porto, PT, <sup>6</sup>Institut Jules Bordet, Brussels, BE
- 12:00 - 12:00 **189P - Recommendation for 'a start to move' program: A 8-week program of incremental physical activity in sedentary breast cancer survivors**  
K. Mazzocco<sup>1</sup>, M. Masiero<sup>1</sup>, M. Mazza<sup>2</sup>, D. Radice<sup>1</sup>, P. Maisonneuve<sup>1</sup>, G. Pravettoni<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **190P - Phyllodes tumour of the breast: 10 years of experience in a Mexican oncology reference center**  
M.I. Contreras Salcido, J. González Vela, J. Lara Campos, E. Llerena Hernandez, D. Hernández Barajas, O. Vidal Gutiérrez, A. Adriana González Gutiérrez, R. Martínez Granados, M. Ponce Camacho, M. Molina Ayala, Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, MX
- 12:00 - 12:00 **192P - Strategies and results of oncofertility counselling in young breast cancer patients**  
J. Kufel-Grabowska<sup>1</sup>, M. Litwiniuk<sup>2</sup>, S. Marszałek<sup>3</sup>, M. Górecki<sup>1</sup>, M. Malinowska<sup>4</sup>, J. Doś<sup>3</sup>, A. Marszałek<sup>2</sup>, W. Suchorska<sup>5</sup>, M. Lesiak<sup>6</sup>, E. Straburzynska-Migaj<sup>7</sup>, A. Nowak<sup>6</sup>, A. Bartczak-Rutkowska<sup>7</sup>, M. Dudek<sup>6</sup>, P. Nowaczyk<sup>1</sup>, P. Jedrzejczak<sup>6</sup>, <sup>1</sup>Wielkopolskie Centrum Onkologii, Poznan, PL, <sup>2</sup>Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>3</sup>Wielkopolskie Centrum Onkologii i Uniwersytet Medyczny w Poznaniu, Poznan, PL, <sup>4</sup>wielkopolskie Centrum Onkologii, Poznan, PL, <sup>5</sup>wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>6</sup>University of Medical Sciences in Poznan, Poznan, PL, <sup>7</sup>university of Medical Sciences in Poznan, Poznan, PL



- 12:00 - 12:00    **194P - Follow up after breast cancer in real life**  
J. Zaluska-Kusz, M. Litwiniuk, Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL
- 12:00 - 12:00    **196P - Menopausal symptoms in premenopausal patients with luminal early breast cancer developing chemotherapy-induced amenorrhea**  
A. Zribi, I. Ben Abdallah, S. Ben Nasr, J. Ayari, S. Fendri, M. Balti, A. Haddaoui, Hopital Militaire de Tunis, Tunis, TN
- 12:00 - 12:00    **197P - Epirubicin-induced cardiotoxicity: Use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines**  
I. Ben Abdallah, S. Ben Nasr, C. Chourabi, S. Fendri, M. Balti, A. Zribi, W. Fehri, A. Haddaoui, Hopital Militaire de Tunis, Tunis, TN
- 12:00 - 12:00    **198P - Comparative study between the clinical effect of palonosetron and granisetron as antiemetic therapy for patients receiving highly emetogenic chemotherapy regimens**  
M. Mahrous, Egypt Air Hospital, Cairo, EG
- 12:00 - 12:00    **199TiP - A single-arm, open label, single center study to evaluate the safety and clinical outcome of using FR-Mask in breast cancer patients with radiation-irritated skin**  
C.-N. Chu<sup>1</sup>, S.-C. Wu<sup>2</sup>, D.-T. Bau<sup>3</sup>, <sup>1</sup>China Medical University Hospital, Taichung City, TW, <sup>2</sup>China Medical University Hospital, Taichung, TW, <sup>3</sup>China Medical University, Taichung, TW
- 12:15 - 12:45    Type: Keynote** **Channel**  
**Title: Keynote lecture: Breast cancer treatment and research in the Covid 19 era** **1**  
Chair(s): Giuseppe Curigliano, IT
- 12:15 - 12:15    **Session DOI**
- 12:15 - 12:45    **Breast cancer treatment and research in the Covid 19 era**  
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

12:45 - 14:15	<b>Type: Educational session</b> <b>Title: Metastatic breast cancer: HER2+</b> Chair(s): Suzette Delaloge, FR	<b>Channel 2</b>
12:45 - 12:45	<b>Session DOI</b>	
12:45 - 12:45	<b>Introduction</b>	
12:45 - 13:05	<b>From clinical trials to real life data: Current treatment standards and outcomes among HER2+ metastatic breast cancer patients</b> <u>S. Delaloge</u> , Gustave Roussy, Villejuif, FR	
13:05 - 13:25	<b>New treatment options for triple positive HER2 metastatic breast cancer</b> <u>E. De Azambuja</u> , Institute Jules Bordet, Brussels, BE	
13:25 - 13:45	<b>CNS metastases from HER2+ metastatic breast cancer: Past, present and future</b> <u>T. Bachelot</u> , Centre Léon Bérard, Lyon, FR	
13:45 - 14:05	<b>Biomarkers to inform decisions in HER2+ metastatic breast cancer</b> <u>M.V. Dieci</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
14:05 - 14:15	<b>Live Q&amp;A</b>	

**12:45 - 14:15**    **Type: Educational session**    **Channel 3**  
**Title: Pathology**  
Chair(s): Carsten Denkert, DE

12:45 - 12:45    **Session DOI**

12:45 - 12:45    **Introduction**

C. Denkert, Uniklinikum Giessen und Marburg, Marburg, DE

12:45 - 13:05    **LIN and invasive lobular cancer: What the clinician needs to know**

H. Kreipe, Hannover Medical School, Hannover, DE

13:05 - 13:25    **The right biomarker for the right patient: From immunohistochemistry to predictive molecular pathology of breast cancer**

N. Fusco, IEO - Istituto Europeo di Oncologia, Milan, IT

13:25 - 13:45    **Combined TILs-PDL1 in breast cancer: The new narrative in daily practice**

R. Salgado, St-Augustinus Ziekenhuis, Wilrijk, BE

13:45 - 14:05    **Deep learning and standardisation of breast cancer histology: The future of pathology?**

F. Klauschen, Charité - Universitätsmedizin Berlin, Berlin, DE

**13:00 - 14:15**    **Type: Proffered paper**    **Channel 1**  
**Title: Proffered Paper session 1**  
Chair(s): Sibylle Loibl, DE

13:00 - 13:00    **Session DOI**

13:00 - 13:00    **Introduction**

13:00 - 13:15    **1390 - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)**

R. Dent<sup>1</sup>, M. Oliveira<sup>2</sup>, S. Isakoff<sup>3</sup>, S.-A. Im<sup>4</sup>, M. Espié<sup>5</sup>, S. Blau<sup>6</sup>, A. Tan<sup>7</sup>, C. Saura Manich<sup>8</sup>, M. Wongchenko<sup>9</sup>, N. Xu<sup>9</sup>, D. Bradley<sup>10</sup>, S.-J. Reilly<sup>10</sup>, A. Mani<sup>9</sup>, S.-B. Kim<sup>11</sup>,  
<sup>1</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>Massachusetts General Hospital, Harvard Medical School, Boston, US, <sup>4</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>5</sup>Hospital Saint Louis, Breast Disease Center, Paris, FR, <sup>6</sup>Northwest Medical Specialties, Puyallup, US, <sup>7</sup>Levine Cancer Institute, Atrium Health, Charlotte, US, <sup>8</sup>Vall d'Hebron University Hospital, Barcelona,



ES, <sup>9</sup>Genentech, Inc., South San Francisco, US, <sup>10</sup>Roche Products Ltd, Welwyn Garden City, GB, <sup>11</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

- 13:15 - 13:30 **1400 - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial**  
J.-P. Ayoub<sup>1</sup>, M. Friedlander<sup>2</sup>, V. Dieras<sup>3</sup>, H. Wildiers<sup>4</sup>, B. Arun<sup>5</sup>, H. Han<sup>6</sup>, S. Puhalla<sup>7</sup>, Y. Shparyk<sup>8</sup>, E. Jakobsen<sup>9</sup>, M. Kundu<sup>10</sup>, M. Wu<sup>10</sup>, C. Ratajczak<sup>11</sup>, D. Maag<sup>10</sup>, B. Kaufman<sup>12</sup>, <sup>1</sup>Centre Hospitalier de l'Université de Montréal, Montreal, CA, <sup>2</sup>Prince of Wales Hospital, Randwick, AU, <sup>3</sup>Centre Eugene - Marquis, Rennes, FR, <sup>4</sup>UZ Leuven, Leuven, BE, <sup>5</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>6</sup>Moffitt Cancer Center, Tampa, US, <sup>7</sup>UPMC School of Medicine, Pittsburgh, US, <sup>8</sup>Lviv State Regional Cancer Treatment and Diagnostic Center, Lviv, UA, <sup>9</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>10</sup>AbbVie Inc., North Chicago, US, <sup>11</sup>Abbvie, North Chicago, US, <sup>12</sup>Tel Aviv University, Tel Aviv-Yafo, IL
- 13:30 - 13:45 **Invited discussant abstracts: 1390 and 1400**  
S. Delaloge, Gustave Roussy, Villejuif, FR
- 13:45 - 14:00 **1830 - Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)**  
A. Di Meglio<sup>1</sup>, C. Charles<sup>2</sup>, E. Martin<sup>2</sup>, J. Havas<sup>2</sup>, A. Gbenou<sup>2</sup>, A.-L. Martin<sup>3</sup>, S. Everhard<sup>3</sup>, E. Laas<sup>4</sup>, O. Tredan<sup>5</sup>, L. Vanlemmens<sup>6</sup>, C. Jouannaud<sup>7</sup>, C. Levy<sup>8</sup>, O. Rigal<sup>9</sup>, M. Fournier<sup>10</sup>, P. Soulie<sup>11</sup>, A. Dumas<sup>12</sup>, G. Menvielle<sup>13</sup>, F. André<sup>14</sup>, S. Dauchy<sup>2</sup>, I. Vaz Luis<sup>15</sup>, <sup>1</sup>Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>UNICANCER, Paris, FR, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>Centre Léon Berard, Lyon, FR, <sup>6</sup>Centre Oscar Lambret, Lille, FR, <sup>7</sup>Institut Jean Godinot, Reims, FR, <sup>8</sup>Centre François Baclesse, Caen, FR, <sup>9</sup>Centre Henri Becquerel, Rouen, FR, <sup>10</sup>Institut Bergonié, Bordeaux, FR, <sup>11</sup>Institut de Cancérologie de L'ouest -Paul Papin, Angers, FR, <sup>12</sup>Universite de Paris, ECEVE UMR 1123, INSERM, Paris, FR, <sup>13</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, FR, <sup>14</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>15</sup>Institut Gustave Roussy, Villejuif, PT
- 14:00 - 14:15 **Invited discussant abstract: 1830**  
L. Fallowfield, Sussex Health Outcomes Research & Education in Cancer, Falmer, GB

<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Adjuvant and neoadjuvant early breast cancer: HER2+</b> Chair(s): Valentina Guarneri, IT; Michael Untch, DE	<b>Channel 1</b>
14:30 - 14:30	<b>Session DOI</b>	
14:30 - 14:30	<b>Introduction</b>	
14:30 - 14:50	<b>Current standards for HER2+ EBC</b> <u>S. Tolaney</u> , Dana Farber Cancer Institute, Boston, US	
14:50 - 15:10	<b>Beyond HER2: Dissecting tumour heterogeneity</b> <u>A. Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
15:10 - 15:30	<b>Neoadjuvant approach for treatment escalation and de-escalation</b> <u>V. Guarneri</u> , Istituto Oncologico Veneto IRCCS, Padova, IT	
15:30 - 15:50	<b>A look into the future: Challenges for the regulatory framework</b> <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
15:50 - 16:00	<b>Live Q&amp;A</b>	

**14:30 - 16:00**    **Type: Educational session**    **Channel 2**  
**Title: Targeting DNA repair across subtypes**  
Chair(s): Jennifer Litton, US

14:30 - 14:30    **Session DOI**

14:30 - 14:30    **Introduction**

14:30 - 14:50    **General overview of targeting DNA repair**

J. Litton, The University of Texas MD Anderson Cancer Center, Houston, US

14:50 - 15:10    **PARP inhibition in ER positive disease**

K. Rhiem, University Hospital Cologne, Köln, DE

15:10 - 15:30    **Mechanism of resistance to PARP inhibition**

C. Lord, The Institute of Cancer Research (ICR), London, GB

15:30 - 15:50    **PARP inhibition in immune oncology**

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

15:50 - 16:00    **Live Q&A**



**14:30 - 16:00**    **Type: Educational session**    **Channel 3**  
**Title: Metastatic breast cancer: HER2-/HR+**  
Chair(s): Veronique Dieras, FR

14:30 - 14:30    **Session DOI**

14:30 - 14:30    **Introduction**  
V. Dieras, Centre Eugene - Marquis, Rennes, FR

14:30 - 14:50    **Update CDK4/6 inhibitors: Survival, QoL and toxicity**  
N. Harbeck, Ludwig Maximilians University (LMU) Hospital, Munich, DE

14:50 - 15:10    **What is the right sequence?**  
N. Turner, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

15:10 - 15:30    **Targeting PI3CA/AKT/mTOR pathway**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

15:30 - 15:50    **Is there a role for immunotherapy in the metastatic disease?**  
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

**16:15 - 17:45**    **Type: Proffered paper**    **Channel 1**  
**Title: Proffered Paper session 2**  
Chair(s): Giuseppe Curigliano, IT

16:15 - 16:15    **Session DOI**

16:15 - 16:15    **Introduction**

16:15 - 16:30    **960 - Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE**  
S. Loibl<sup>1</sup>, C.-S. Huang<sup>2</sup>, M. Mano<sup>3</sup>, T. Mamounas<sup>4</sup>, C. Geyer<sup>5</sup>, M. Untch<sup>6</sup>, G. Von Minckwitz<sup>1</sup>, J.-C. Thery<sup>7</sup>, I. Schwaner<sup>8</sup>, S. Limentani<sup>9</sup>, N. Loman<sup>10</sup>, K. Lübke<sup>11</sup>, J. Chang<sup>12</sup>, T. Hatschek<sup>13</sup>, D. Tesarowski<sup>14</sup>, T. Boulet<sup>15</sup>, C. Wiese<sup>16</sup>, C. Song<sup>14</sup>, N. Wolmark<sup>17</sup>, <sup>1</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>2</sup>National Taiwan University Hospital and National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, <sup>3</sup>Hospital Sirio Libanes, Sao Paulo, BR, <sup>4</sup>MD Anderson Cancer Center Orlando, Orlando, US, <sup>5</sup>Massey Cancer Center - McGlothlin Medical Education Ctr., Richmond, US, <sup>6</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>7</sup>CRLCC Henri Becquerel, Rouen, FR, <sup>8</sup>Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, DE, <sup>9</sup>Novant Health, Charlotte, US, <sup>10</sup>Skane University

Hospital, Lund, SE, <sup>11</sup>Frauenklinik Hannover, Hannover, DE, <sup>12</sup>Houston Methodist Cancer Center, Houston, US, <sup>13</sup>Karolinska University Hospital, Solna, SE, <sup>14</sup>Genentech, Inc., South San Francisco, US, <sup>15</sup>F. Hoffmann-La Roche, Basel, CH, <sup>16</sup>F. Hoffmann-La Roche AG, Basel, CH, <sup>17</sup>Allegheny General Hospital, Pittsburgh, US

16:30 - 16:45

**970 - PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels**

T. Hatschek<sup>1</sup>, A. Andersson<sup>2</sup>, J. Bjöhle<sup>3</sup>, A. Bosch<sup>4</sup>, L. Carlsson<sup>5</sup>, A. Dreifaldt<sup>6</sup>, Z. Einbeigi<sup>7</sup>, E. Elinder<sup>8</sup>, H. Fredholm<sup>3</sup>, E. Isaksson-Friman<sup>9</sup>, M. Hellström<sup>10</sup>, H. Johansson<sup>10</sup>, T. Lekberg<sup>10</sup>, H. Lindman<sup>11</sup>, I. Zerdes<sup>12</sup>, T. Foukakis<sup>13</sup>, J. Hartman<sup>8</sup>, Y. Brandberg<sup>14</sup>, J. Bergh<sup>15</sup>, <sup>1</sup>Karolinska Solna - Karolinska Universitetssjukhuset, Solna, SE, <sup>2</sup>Umeå University Hospital, Umeå, SE, <sup>3</sup>Karolinska University Hospital, Solna, SE, <sup>4</sup>Lund University, Lund, SE, <sup>5</sup>Länssjukhuset Sundsvall, Sundsvall, SE, <sup>6</sup>Örebro University Hospital, Örebro, SE, <sup>7</sup>Sahlgrenska University Hospital, Göteborg, SE, <sup>8</sup>Södersjukhuset, Stockholm, SE, <sup>9</sup>S:t Görän, Stockholm, SE, <sup>10</sup>Karolinska University Hospital, Stockholm, SE, <sup>11</sup>University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE, <sup>12</sup>Nya Karolinska Solna, Godsmottagning, Solna, SE, <sup>13</sup>Karolinska Universitetssjukhuset - Radiumhemmet, Solna, SE, <sup>14</sup>Karolinska Institutet, Stockholm, SE, <sup>15</sup>Karolinska Institutet - Bioclinicum, Solna, SE

16:45 - 17:00

**Invited discussant abstracts: 960 and 970**

V. Guarneri, Istituto Oncologico Veneto IRCCS, Padova, IT

17:00 - 17:15

**1380 - CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses**

G. Jerusalem<sup>1</sup>, Y.H. Park<sup>2</sup>, T. Yamashita<sup>3</sup>, S. Hurvitz<sup>4</sup>, S. Chen<sup>5</sup>, J. Cathcart<sup>6</sup>, C. Lee<sup>6</sup>, C. Perrin<sup>7</sup>, <sup>1</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>4</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>5</sup>Daiichi Sankyo Inc., Basking Ridge, US, <sup>6</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR

17:15 - 17:30

**1370 - Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)**

G. Curigliano<sup>1</sup>, R. Murthy<sup>2</sup>, S. Loi<sup>3</sup>, A. Okines<sup>4</sup>, E. Paplomata<sup>5</sup>, E. Hamilton<sup>6</sup>, S. Hurvitz<sup>7</sup>, D. Cameron<sup>8</sup>, V. Borges<sup>9</sup>, P. Bedard<sup>10</sup>, M. Oliveira<sup>11</sup>, E. Jakobsen<sup>12</sup>, T. Bachelot<sup>13</sup>, S. Shachar<sup>14</sup>, V. Mueller<sup>15</sup>, L. Carey<sup>16</sup>, S. Loibl<sup>17</sup>, W. Feng<sup>18</sup>, L.N. Walker<sup>19</sup>, E. Winer<sup>20</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>4</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>5</sup>Winship Cancer Institute of Emory University, Atlanta, US, <sup>6</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>7</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>8</sup>Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, <sup>9</sup>University of Colorado Hospital, Aurora, US, <sup>10</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>11</sup>Vall d`Hebron University Hospital, Barcelona, ES, <sup>12</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>13</sup>Centre Léon Bérard, Lyon, FR, <sup>14</sup>Rambam Health Care Campus, Haifa, IL, <sup>15</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>16</sup>UNC - The University of

North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, <sup>17</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>18</sup>Seattle Genetics, Bothell, US, <sup>19</sup>Seattle Genetics, Inc., Seattle, US, <sup>20</sup>Dana Farber Cancer Institute, Boston, US

17:30 - 17:45 **Invited discussant abstracts: 1380 and 1370**

A. Llombart Cussac, Hospital Universitario Arnau de Vilanova, Lleida, ES

**16:15 - 17:45** **Type: Educational session** **Channel 2**  
**Title: Translational oncology**  
Chair(s): Carlos Caldas, GB

16:15 - 16:15 **Session DOI**

16:15 - 16:15 **Introduction**

16:15 - 16:35 **Breast cancer molecular stratification**

C. Caldas, Cancer Research UK & University of Cambridge UK, Cambridge, GB

16:35 - 16:55 **Molecular pathology of breast cancer**

H. Ali, University of Cambridge, Cambridge, GB

16:55 - 17:15 **Monitoring breast cancer with ctDNA**

M. Murtaza, The Translational Genomics Research Institute (TGen), Phoenix, US

17:15 - 17:35 **Targeting HRD in breast cancer**

J. Jonkers, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

17:35 - 17:45 **Live Q&A**



**16:15 - 17:45**    **Type: Educational session**    **Channel 3**  
**Title: Innovative approaches in diagnostic and therapy for breast cancer**  
Chair(s): Philippe Bedard, CA

16:15 - 16:15    **Session DOI**

16:15 - 16:15    **Introduction**

P. Bedard, Princess Margaret Cancer Center, Toronto, CA

16:15 - 16:35    **ctDNA as a selective and response biomarker for early phase trials in breast cancer (ECT and ctDNA)**

M. Oliveira, Vall d`Hebron University Hospital, Barcelona, ES

16:35 - 16:55    **The importance of molecular screening programmes (tissue biopsy)**

P. Bedard, Princess Margaret Cancer Center, Toronto, CA

16:55 - 17:15    **Adoptive cellular therapy for breast cancer**

J. Specht, University of Washington Seattle Cancer Care Alliance, Seattle, US

17:15 - 17:35    **Novel antibody drug conjugates and beyond**

P.F. Conte, Istituto Oncologico Veneto IRCCS, Padova, IT

**18:00 - 19:30**    **Type: Educational session**    **Channel 1**  
**Title: Mechanisms of endocrine resistance**  
Chair(s): Pedram Razavi, US

18:00 - 18:00    **Session DOI**

18:00 - 18:00    **Introduction**

18:00 - 18:20    **ER mutations as a mechanism of resistance**  
R. Jeselsohn, Dana Farber Cancer Institute, Boston, US

18:20 - 18:40    **Resistance to CDK4/6 inhibitors**  
P. Razavi, Memorial Sloan Kettering Cancer Center, New York, US

18:40 - 19:00    **PI3K alterations as a mechanism of escape**  
M. Scaltriti, Memorial Sloan-Kettering Cancer Center, New York, US

19:00 - 19:20    **Novel SERDs and activity in endocrine therapy resistant cancers**  
A. Bardia, Massachusetts General Hospital Cancer Center, Boston, US

19:20 - 19:30    **Live Q&A**

**18:00 - 19:20**    **Type: Mini oral**    **Channel 2**  
**Title: Mini Oral session**  
Chair(s): Fatima Cardoso, PT; Michael Untch, DE; Christos Sotiriou, BE

18:00 - 18:00    **Session DOI**

18:00 - 18:05    **10 - Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with  $\geq 2$  HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial**

C. Saura Manich<sup>1</sup>, A. Vivancos<sup>1</sup>, J. Matito<sup>1</sup>, H. Wildiers<sup>2</sup>, A. Brufsky<sup>3</sup>, M. Oliveira<sup>4</sup>, S. Waters<sup>5</sup>, S. Hurvitz<sup>6</sup>, B. Moy<sup>7</sup>, S.-B. Kim<sup>8</sup>, W. Gradishar<sup>9</sup>, G. Queiroz<sup>10</sup>, E. Cronemberger<sup>11</sup>, J. Bebchuk<sup>12</sup>, K. Keyvanjah<sup>12</sup>, A. Lalani<sup>12</sup>, L. Eli<sup>12</sup>, S. Delaloge<sup>13</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>UZ Leuven, Leuven, BE, <sup>3</sup>Magee-Womens Hospital of UPMC, Pittsburgh, US, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Velindre Cancer Centre Velindre Hospital, Cardiff, GB, <sup>6</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>7</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>8</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>9</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, US, <sup>10</sup>Hospital Araújo Jorge, Goiânia, BR, <sup>11</sup>Lihuili Hospital Ningbo Medical Treatment Center, Ningbo,

CN, <sup>12</sup>Puma Biotechnology Inc., Los Angeles, US, <sup>13</sup>Gustave Roussy, Villejuif, FR

18:05 - 18:10

**20 - ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis**

T. Pascual<sup>1</sup>, M. Oliveira<sup>2</sup>, E. Ciruelos<sup>3</sup>, M. Bellet Ezquerro<sup>4</sup>, C. Saura Manich<sup>5</sup>, J. Gavila Gregori<sup>6</sup>, S. Pernas Simon<sup>7</sup>, M. Muñoz<sup>8</sup>, M.J. Vidal<sup>8</sup>, M. Margeli Vila<sup>9</sup>, J.M. Cejalvo<sup>10</sup>, B. González-Farré<sup>8</sup>, M. Espinosa-Bravo<sup>11</sup>, J. Ferrero-Cafiero<sup>12</sup>, P. Villagrasa<sup>13</sup>, A. Prat<sup>14</sup>, <sup>1</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>7</sup>Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, <sup>8</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>9</sup>ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>10</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>11</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>12</sup>SOLTI Breast Cancer Research Group, Barcelona, ES, <sup>13</sup>SOLTI, Barcelona, ES, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

18:10 - 18:15

**800 - Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study**

J. O'Shaughnessy<sup>1</sup>, S. Sousa<sup>2</sup>, J. Cruz<sup>3</sup>, L. Fallowfield<sup>4</sup>, P. Auvinen<sup>5</sup>, C. Pulido<sup>6</sup>, A. Cvetanovic<sup>7</sup>, S. Wilks<sup>8</sup>, L. Ribeiro<sup>9</sup>, M. Burotto<sup>10</sup>, D. Klingbiel<sup>11</sup>, D. Messeri<sup>11</sup>, A. Alexandrou<sup>12</sup>, P. Trask<sup>13</sup>, J. Fredriksson<sup>14</sup>, L. Stamatovic<sup>15</sup>, <sup>1</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>2</sup>Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PT, <sup>3</sup>Hospital Universitario de Canarias, S/C Tenerife, ES, <sup>4</sup>Sussex Health Outcomes Research & Education in Cancer, Falmer, GB, <sup>5</sup>Kuopio University Hospital, Kuopio, FI, <sup>6</sup>Centro de Oncologia, Lisbon, PT, <sup>7</sup>Medical Faculty, Nis, RS, <sup>8</sup>Texas Oncology, San Antonio TX, US, <sup>9</sup>Centro Hospitalar Universitário Lisboa Norte, Lisbon, PT, <sup>10</sup>Bradford Hill, Santiago, CL, <sup>11</sup>F. Hoffman-La Roche Ltd, Basel, CH, <sup>12</sup>Roche Products Ltd, Welwyn Garden City, GB, <sup>13</sup>Genentech Inc, San Francisco CA, US, <sup>14</sup>F. Hoffmann-La Roche AG, Basel, CH, <sup>15</sup>Institute for Oncology and Radiology of Serbia, Belgrade, RS

18:15 - 18:30

**Invited discussant abstracts: 10, 20 and 800**

M. Untch, Helios Klinikum Berlin Buch, Berlin, DE

18:30 - 18:35

**980 - The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)**

N. Abuhadra<sup>1</sup>, R. Sun<sup>2</sup>, J. Litton<sup>3</sup>, G. Rauch<sup>3</sup>, A.M. Thompson<sup>1</sup>, B. Lim<sup>3</sup>, B. Adrada<sup>3</sup>, E. Mittendorf<sup>4</sup>, S. Damodaran<sup>5</sup>, R. Pitpitan<sup>3</sup>, B. Arun<sup>5</sup>, J. White<sup>3</sup>, E. Ravenberg<sup>3</sup>, L. Santiago<sup>3</sup>, A. Sahin<sup>3</sup>, R. Murthy<sup>2</sup>, N. Ueno<sup>3</sup>, N. Ibrahim<sup>3</sup>, S. Moulder<sup>3</sup>, L. Huo<sup>3</sup>, <sup>1</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>Brigham and Women's Hospital, Boston, US, <sup>5</sup>The M. D. Anderson Cancer Center, Houston, US



- 18:35 - 18:40 **30 - Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer**  
W. Jacot<sup>1</sup>, H. Savage<sup>2</sup>, S. Dent<sup>3</sup>, J. Cortés<sup>4</sup>, Y.-H. Im<sup>5</sup>, V. Dieras<sup>6</sup>, N. Harbeck<sup>7</sup>, I. Krop<sup>8</sup>, J. Chen<sup>2</sup>, E. Sokol<sup>9</sup>, F. Schimmoller<sup>10</sup>, J. Hsu<sup>2</sup>, M. De Laurentiis<sup>11</sup>, T. Wilson<sup>2</sup>, <sup>1</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>2</sup>Genentech, San Francisco, US, <sup>3</sup>University of Ottawa, Ottawa, CA, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>6</sup>Centre Eugene - Marquis, Rennes, FR, <sup>7</sup>Ludwig Maximilians University (LMU) Hospital, Munich, DE, <sup>8</sup>Dana-Farber Cancer Institute, Boston, US, <sup>9</sup>Foundation Medicine, Massachusetts, US, <sup>10</sup>Genentech, Inc., South San Francisco, US, <sup>11</sup>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT
- 18:40 - 18:45 **1840 - The risk of late breast cancer recurrence in Denmark during 17 years of follow-up**  
R. Pedersen<sup>1</sup>, B. Öztürk<sup>2</sup>, L. Mellekjær<sup>3</sup>, S. Friis<sup>3</sup>, B. Ejlersen<sup>4</sup>, T. Lash<sup>5</sup>, M. Nørgaard<sup>2</sup>, D. Cronin-Fenton<sup>2</sup>, <sup>1</sup>Aarhus University, Aarhus, DK, <sup>2</sup>Aarhus University Hospital, Aarhus N, DK, <sup>3</sup>Danish Cancer Society Research Center, Copenhagen, DK, <sup>4</sup>Rigshospitalet, University of Copenhagen, Copenhagen, DK, <sup>5</sup>Emory University, Atlanta, US
- 18:45 - 19:00 **Invited discussant abstracts: 980, 30 and 1840**  
C. Sotiriou, Institute Jules Bordet, Brussels, BE
- |                      |  |                  |
|----------------------|--|------------------|
| <b>18:00 - 19:00</b> | <b>Type: Educational session</b><br><b>Title: Survivorship and quality of life</b><br>Chair(s): Lesley Fallowfield, GB | <b>Channel 3</b> |
|----------------------|--|------------------|
- 18:00 - 18:00 **Session DOI**
- 18:00 - 18:00 **Introduction**  
L. Fallowfield, Sussex Health Outcomes Research & Education in Cancer, Falmer, GB
- 18:00 - 18:20 **PROMISing ways to measure QoL**  
D. Cella, Northwestern University, Chicago, US
- 18:20 - 18:40 **bWell: A mobile app for self-monitoring of arm and shoulder exercises following breast cancer treatment**  
H. Harder, BSMS-Brighton and Sussex Medical School - University of Sussex, Brighton, GB
- 18:40 - 19:00 **Risk and uncertainty in breast cancer**  
L. Fallowfield, Sussex Health Outcomes Research & Education in Cancer, Falmer, GB

19:30 - 20:15	<b>Type: Young oncologist session</b> <b>Title: Optimizing the adjuvant treatment of premenopausal patients with HR+/HER2- early breast cancer</b> Chair(s): Matteo Lambertini, IT; Alexios Matikas, SE	<b>Channel</b> <b>2</b>
19:30 - 19:30	<b>Session DOI</b>	
19:30 - 19:35	<b>Clinical case presentation</b> <u>M.A. Franzoi</u> , Institute Jules Bordet, Brussels, BE	
19:35 - 19:45	<b>Tailoring adjuvant chemotherapy</b> <u>A. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
19:45 - 19:55	<b>Tailoring adjuvant endocrine therapy</b> <u>M. Lambertini</u> , University of Genova, Genova, IT	
19:55 - 20:05	<b>Tailoring follow-up and survivorship care</b> <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, PT	
20:05 - 20:15	<b>Discussion</b>	

<b>19:30 - 21:00</b>	<b>Type: Special session</b> <b>Title: Collaborative session ESMO ESO: Breast Cancer in young women: From guidelines to clinical practice</b> Chair(s): Giuseppe Curigliano, IT; Olivia Pagani, CH	<b>Channel 3</b>
19:30 - 19:30	<b>Session DOI</b>	
19:30 - 19:35	<b>Introduction</b> <u>O. Pagani</u> , IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH	
19:35 - 19:55	<b>Young women with advanced breast cancer: anything specific for clinical care and research?</b> <u>O. Pagani</u> , IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH	
19:55 - 20:15	<b>Genetic predisposition in the era of multigene panel testing: impact on clinical management</b> <u>J. Litton</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
20:15 - 20:35	<b>How to address survivorship in clinical research: Focus on HOHO and POSITIVE</b> <u>A. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
20:35 - 20:55	<b>ESO-ESMO BCY Guidelines: updated recommendations for optimal management of young women with breast cancer</b> <u>S. Paluch-Shimon</u> , Shaare Zedek Medical Center, Jerusalem, IL	
20:55 - 21:00	<b>Conclusions</b> <u>S. Paluch-Shimon</u> , Shaare Zedek Medical Center, Jerusalem, IL	



24.05.2020

**12:00 - 12:35**    **Type: Keynote**    **Channel**  
**Title: Keynote lecture 2 - Priorities in breast cancer in the next 10**    **1**  
**years**  
 Chair(s): Sibylle Loibl, DE

12:00 - 12:00    **Session DOI**

12:00 - 12:05    **Introduction**

12:05 - 12:35    **Priorities in breast cancer in the next 10 years**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

**12:00 - 19:30**    **Type: ePoster**    **ePosters**  
**Title: ePoster**

12:00 - 12:00    **Biomarkers and translational research and precision medicine**

12:00 - 12:00    **4P - Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)&#x2b;/HER2&#x2b; breast cancer (BC)**  
T. Pascual<sup>1</sup>, A. Fernandez-Martinez<sup>2</sup>, M. Tanioka<sup>2</sup>, M.V. Dieci<sup>3</sup>, S. Pernas Simon<sup>4</sup>, J. Gavila Gregori<sup>5</sup>, V. Guarneri<sup>6</sup>, J. Cortés<sup>7</sup>, P. Villagrassa<sup>8</sup>, M.J. Vidal<sup>9</sup>, B. Adamo<sup>9</sup>, M. Muñoz<sup>9</sup>, G. Griguolo<sup>3</sup>, A. Llombart Cussac<sup>10</sup>, M. Oliveira<sup>11</sup>, L. Paré<sup>8</sup>, L. Carey<sup>12</sup>, C. Perou<sup>13</sup>, A. Prat<sup>14</sup>, <sup>1</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>2</sup>UNC Lineberger Comprehensive Cancer Center - University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>3</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, <sup>5</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>6</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>SOLTI, Barcelona, ES, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>11</sup>Vall d' Hebron University Hospital, Barcelona, ES, <sup>12</sup>UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, <sup>13</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00    **5P - Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)**  
O. Martinez Saez<sup>1</sup>, T. Pascual<sup>1</sup>, F. Brasó-Maristany<sup>2</sup>, N. Chic<sup>3</sup>, B. González-Farré<sup>1</sup>, E. Sanfeliu<sup>1</sup>, A. Rodríguez<sup>1</sup>, D. Martínez<sup>2</sup>, P. Galván<sup>2</sup>, A. Rodriguez Hernandez<sup>4</sup>, F. Schettini<sup>5</sup>, B. Conte<sup>6</sup>, M.J. Vidal<sup>1</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, R. Moreno<sup>1</sup>, E. Ciruelos<sup>7</sup>, I. Faull<sup>8</sup>, J. Odegaard<sup>9</sup>, A. Prat<sup>4</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>IDIBAPS, Barcelona, ES, <sup>3</sup>Hospital Clinic, Barcelona, ES, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT,

<sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>8</sup>Guardant Health, Barcelona, ES, <sup>9</sup>Guardant Health, Redwood City, US

- 12:00 - 12:00 **6P - Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER<sup>+</sup>/HER2-negative advanced breast cancer (ABC)**
- F. Galardi<sup>1</sup>, C. Biagioni<sup>1</sup>, F. De Luca<sup>1</sup>, G. Curigliano<sup>2</sup>, A.M. Minisini<sup>3</sup>, M. Bonechi<sup>1</sup>, E. Moretti<sup>4</sup>, E. Risi<sup>5</sup>, I. Migliaccio<sup>4</sup>, A. McCartney<sup>4</sup>, M. Benelli<sup>4</sup>, D. Romagnoli<sup>1</sup>, V. Conti<sup>6</sup>, L. Biganzoli<sup>5</sup>, A. Di Leo<sup>5</sup>, L. Malorni<sup>7</sup>, <sup>1</sup>Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, <sup>4</sup>Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, <sup>5</sup>Nuovo Ospedale di Prato, Prato, IT, <sup>6</sup>Children's Hospital A. Meyer, Firenze, ITALY, Firenze, IT, <sup>7</sup>Hospital of Prato, Azienda USL Toscana Centro, Prato, IT
- 12:00 - 12:00 **7P - Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial**
- G. Wan, F. Cao, X. Cai, X. Yu, Z. Zuo, Y. Song, T. Xu, Y. Li, Y. Yu, X. Wang, X. Wang, Hubei University of Medicine, Shiyan, CN
- 12:00 - 12:00 **8P - Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)**
- G. Griguolo<sup>1</sup>, G. Serna<sup>2</sup>, T. Pascual<sup>3</sup>, R. Fasani<sup>2</sup>, N. Chic<sup>4</sup>, L. Paré<sup>5</sup>, S. Pernas<sup>6</sup>, M. Muñoz<sup>3</sup>, M. Oliveira<sup>7</sup>, M. Vidal<sup>4</sup>, A. Llombart Cussac<sup>8</sup>, J. Cortés<sup>9</sup>, P. Galván<sup>10</sup>, B. Bermejo<sup>11</sup>, N. Martínez<sup>12</sup>, R. López<sup>13</sup>, S. Morales<sup>14</sup>, P. Villagrasa<sup>5</sup>, A. Prat<sup>15</sup>, P. Nuciforo<sup>2</sup>, <sup>1</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>4</sup>Hospital Clinic, Barcelona, ES, <sup>5</sup>SOLTI, Barcelona, ES, <sup>6</sup>Institut Catala d'Oncologia, Hospitalet de Llobregat, ES, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>10</sup>IDIBAPS, Barcelona, ES, <sup>11</sup>Hospital Clínico Universitario de Valencia / INCLIVA / CIBERONC, Valencia, ES, <sup>12</sup>Ramon y Cajal Hospital, Madrid, ES, <sup>13</sup>Hospital Clínico Universitario de Santiago / CIBERONC, Santiago de Compostela, ES, <sup>14</sup>Hospital Universitario Arnau de Vilanova, LLEIDA, ES, <sup>15</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **9P - The histopathologic profile of pregnancy associated breast cancer; particularly aggressive breast cancer subtype. Analysis of the Dutch National Registry**
- B. Suelmann<sup>1</sup>, E. Van Der Wall<sup>1</sup>, C. Van Dooijweert<sup>2</sup>, S. Linn<sup>3</sup>, P. Van Diest<sup>2</sup>, <sup>1</sup>UMC-University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>UMC - university medical center Utrecht, Utrecht, NL, <sup>3</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 12:00 - 12:00 **10P - Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer**

F. Le Du<sup>1</sup>, F. Takeo<sup>2</sup>, M. Park<sup>2</sup>, K. Hess<sup>2</sup>, D. Liu<sup>2</sup>, R. Jackson<sup>2</sup>, C. Mylander<sup>3</sup>, M. Rosman<sup>3</sup>, A. Raghavendra<sup>2</sup>, L. Tafra<sup>3</sup>, N. Ueno<sup>2</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Anne Arundel Medical Center, Annapolis, US

12:00 - 12:00

**11P - BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC)**

G. Bianchini<sup>1</sup>, M. De Laurentiis<sup>2</sup>, G. Arpino<sup>3</sup>, A. Zambelli<sup>4</sup>, F. Puglisi<sup>5</sup>, L. Del Mastro<sup>6</sup>, M. Colleoni<sup>7</sup>, F. Montemurro<sup>8</sup>, G. Bianchi<sup>9</sup>, I. Paris<sup>10</sup>, G. Allegrini<sup>11</sup>, L. Amaducci<sup>12</sup>, M. Cazzaniga<sup>13</sup>, M. Orditura<sup>14</sup>, C. Zamagni<sup>15</sup>, S. Bianchetti<sup>16</sup>, D. Castelletti<sup>16</sup>, M. Benelli<sup>17</sup>, M. Callari<sup>18</sup>, L. Malorni<sup>19</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT, <sup>3</sup>Università Federico II, Naples, IT, <sup>4</sup>Presidio Ospedaliero Papa Giovanni XXIII, Bergamo, IT, <sup>5</sup>Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, <sup>9</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>10</sup>Università Cattolica del Sacro Cuore, Rome, IT, <sup>11</sup>Az Osp ULS 5 - Ospedale Pontedera, Pontedera, IT, <sup>12</sup>P.O. Ospedale degli Infermi, Romagna, IT, <sup>13</sup>Azienda Ospedaliera S. Gerardo, Monza, IT, <sup>14</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>15</sup>AOU Policlinico S. Orsola-Malpighi, F. Addarii, Bologna, IT, <sup>16</sup>Novartis Farma Italy, Origgio, IT, <sup>17</sup>Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, <sup>18</sup>University of Cambridge, Li Ka Shing Centre, Cambridge, GB, <sup>19</sup>Hospital of Prato, Azienda USL Toscana Centro, Prato, IT

12:00 - 12:00

**12P - Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R&#x2b;L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial**

N. Chic<sup>1</sup>, B. González-Farré<sup>2</sup>, L. Paré<sup>3</sup>, T. Pascual<sup>4</sup>, C. Saura Manich<sup>5</sup>, C. Hernando Melia<sup>6</sup>, M. Muñoz<sup>2</sup>, P. Fernandez<sup>7</sup>, D. Martínez<sup>8</sup>, E. Sanfeliu<sup>2</sup>, F. Brasó-Maristany<sup>9</sup>, X. González-Farré<sup>10</sup>, M. Oliveira<sup>11</sup>, M. Gil-Gil<sup>12</sup>, P. Celiz<sup>13</sup>, E. Ciruelos<sup>14</sup>, P. Villagrasa<sup>3</sup>, J. Gavila Gregori<sup>15</sup>, A. Prat<sup>16</sup>, <sup>1</sup>Hospital Clinic, Barcelona, ES, <sup>2</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>3</sup>SOLTI, Barcelona, ES, <sup>4</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>7</sup>Hospital Germans Trias i Pujol, Badalona, ES, <sup>8</sup>Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, <sup>9</sup>IDIBAPS, Barcelona, ES, <sup>10</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>11</sup>Vall d' Hebron University Hospital, Barcelona, ES, <sup>12</sup>Institut Catala d' Oncologia, L'Hospitalet de Llobregat, ES, <sup>13</sup>SOLTI HQ, Barcelona, ES, <sup>14</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>15</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>16</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00

**13P - HER2 low testing in breast cancer: How to optimize detection**

F. Cecchi<sup>1</sup>, D. Carrolle<sup>2</sup>, M. Gustavson<sup>1</sup>, S. Sridhar<sup>1</sup>, M. De Los Reyes<sup>1</sup>, S. Thyparambil<sup>3</sup>, A. Bhalkikar<sup>3</sup>, W.-L. Liao<sup>3</sup>, S. Coats<sup>1</sup>, T. Hembrough<sup>1</sup>, <sup>1</sup>AstraZeneca USA, Gaithersburg, US, <sup>2</sup>AstraZeneca USA, cambridge, GB, <sup>3</sup>mProbe, Gaithersburg, US



- 12:00 - 12:00 **14P - Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma**  
N. Palazón Carrión<sup>1</sup>, C. Jiménez Cortegana<sup>2</sup>, M.L. Sánchez León<sup>2</sup>, F. Henao Carrasco<sup>3</sup>, E. Nogales Fernandez<sup>1</sup>, V. Sánchez Margalet<sup>1</sup>, L. De La Cruz Merino<sup>2</sup>, <sup>1</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>2</sup>Hospital Universitario Virgen Macarena, sevilla, la macarena, ES, <sup>3</sup>Hospital Universitario Virgen Macarena, Sevilla, ES
- 12:00 - 12:00 **15P - The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis**  
B. González-Farré<sup>1</sup>, P. Nuciforo<sup>2</sup>, L. Pare Brunet<sup>3</sup>, J. Cortés<sup>4</sup>, A. Llombart Cussac<sup>5</sup>, J. Gavila Gregori<sup>6</sup>, E. Sanfeliu<sup>1</sup>, N. Chic<sup>7</sup>, M. Vidal<sup>7</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, P. Galván<sup>8</sup>, D. Martínez<sup>8</sup>, P. Villagrasa<sup>9</sup>, T. Pascual<sup>1</sup>, A. Prat<sup>3</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>6</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>7</sup>Hospital Clinic, Barcelona, ES, <sup>8</sup>IDIBAPS, Barcelona, ES, <sup>9</sup>SOLTI, Barcelona, ES
- 12:00 - 12:00 **17P - Dysregulation of immune checkpoint proteins in newly diagnosed early breast cancer patients**  
B. Rapoport<sup>1</sup>, A. Theron<sup>2</sup>, H. Steel<sup>2</sup>, S. Nayler<sup>3</sup>, C. Benn<sup>4</sup>, N. Hlatwayo<sup>2</sup>, L. Kwofie<sup>2</sup>, L. Heyman<sup>1</sup>, T. Smit<sup>1</sup>, L. Jooste<sup>1</sup>, F. Moosa<sup>1</sup>, R. Anderson<sup>2</sup>, <sup>1</sup>The Medical Oncology Centre of Rosebank, Johannesburg, ZA, <sup>2</sup>University of Pretoria Faculty of Health Sciences, Pretoria, ZA, <sup>3</sup>Drs Gritzman & Thatcher Inc Laboratories & Wits Donald Gordon Medical Centre, Randburg, ZA, <sup>4</sup>Head of Netcare breast care Centre, Johannesburg, ZA
- 12:00 - 12:00 **18P - Inter-tumour heterogeneity in breast cancers: The dynamic evolution of cancer genome during the metastatic process**  
C. Fumagalli<sup>1</sup>, A. Raghiero<sup>2</sup>, S. Gandini<sup>2</sup>, F. Corso<sup>2</sup>, S. Taormina<sup>2</sup>, E. De Camilli<sup>2</sup>, G. Viale<sup>3</sup>, M. Barberis<sup>3</sup>, E. Guerini Rocco<sup>4</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>European Institute of Oncology, Milan, IT, <sup>3</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup>University of Milan, Milan, IT
- 12:00 - 12:00 **19P - PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study**  
V. Guarneri<sup>1</sup>, M.V. Dieci<sup>2</sup>, G. Bisagni<sup>3</sup>, A. Brandes<sup>4</sup>, A. Frassoldati<sup>5</sup>, L. Cavanna<sup>6</sup>, A. Musolino<sup>7</sup>, F. Giotta<sup>8</sup>, A. Rimanti<sup>9</sup>, O. Garrone<sup>10</sup>, E. Bertone<sup>11</sup>, K. Cagossi<sup>12</sup>, O. Nanni<sup>13</sup>, F. Piacentini<sup>14</sup>, E. Orvieto<sup>15</sup>, M. Curtarello<sup>16</sup>, N. Chic<sup>17</sup>, R. D'Amico<sup>18</sup>, A. Prat<sup>19</sup>, P.F. Conte<sup>1</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>Azienda USL-IRCCS, Reggio Emilia, IT, <sup>4</sup>Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, IT, <sup>5</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>6</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>7</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>8</sup>Istituto Oncologico Bari, Bari, IT, <sup>9</sup>University Hospital of Parma, Parma, IT, <sup>10</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>11</sup>Sant'Anna Hospital, Torino, IT, <sup>12</sup>Ramazzini Hospital, Carpi, IT, <sup>13</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>14</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>15</sup>Ulss 5 Polesana, Rovigo, IT, <sup>16</sup>Veneto Institute of Oncology



IRCCS, padova, IT, <sup>17</sup>Hospital Clinic, Barcelona, ES, <sup>18</sup>University of Modena, Modena, IT, <sup>19</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

- 12:00 - 12:00 **21P - Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)**  
J. Litton<sup>1</sup>, L. Zhao<sup>1</sup>, J. White<sup>1</sup>, B. Arun<sup>2</sup>, E. Ravenberg<sup>1</sup>, X. Song<sup>1</sup>, J. Zhang<sup>1</sup>, S. Moulder<sup>1</sup>,  
<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The M. D. Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **23P - Clinical, pathological and gene expression features of HER2-low breast cancer**  
F. Schettini<sup>1</sup>, N. Chic<sup>2</sup>, F. Brasó-Maristany<sup>3</sup>, L. Paré<sup>4</sup>, T. Pascual<sup>5</sup>, B. Conte<sup>6</sup>, O. Martinez Saez<sup>5</sup>, B. Adamo<sup>5</sup>, M. Vidal<sup>2</sup>, A. Fernandez-Martinez<sup>7</sup>, B. González-Farré<sup>5</sup>, E. Sanfeliu<sup>5</sup>, G. Perrone<sup>8</sup>, P. Villagrasa<sup>4</sup>, J. Gavila Gregori<sup>9</sup>, C. Barrios<sup>10</sup>, A. Lluch<sup>11</sup>, M. Martin Jimenez<sup>12</sup>, S. De Placido<sup>13</sup>, A. Prat<sup>14</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>2</sup>Hospital Clinic, Barcelona, ES, <sup>3</sup>IDIBAPS, Barcelona, ES, <sup>4</sup>SOLTI, Barcelona, ES, <sup>5</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>UNC Lineberger Comprehensive Cancer Center - University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>8</sup>Campus Bio-Medico University, Rome, IT, <sup>9</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>10</sup>Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre, BR, <sup>11</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>12</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>13</sup>University of Naples Federico II, Naples, IT, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **24P - The influence of metabolic syndrome on the risk of breast cancer: A study analysing nationwide data from the Korean National Health Insurance Service**  
K.-T. Hwang, Boramae Medical Center, Seoul, KR
- 12:00 - 12:00 **25P - Breast cancers with heterogeneous HER2 amplification show a diverse distribution of driver and passenger somatic mutations and copy number variations**  
M. Van Bockstal<sup>1</sup>, M.C. Agahozo<sup>2</sup>, R. Van Marion<sup>2</sup>, P. Atmodimedjo<sup>2</sup>, H. Sleddens<sup>2</sup>, W. Dinjens<sup>2</sup>, L. Visser<sup>3</sup>, E. Lips<sup>4</sup>, J. Wesseling<sup>4</sup>, C. Van Deurzen<sup>5</sup>, <sup>1</sup>Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>5</sup>Erasmus University Medical Center, Rotterdam, NL
- 12:00 - 12:00 **28P - Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer**  
R. Erber<sup>1</sup>, A. Hartmann<sup>2</sup>, P. Fasching<sup>3</sup>, R. Stöhr<sup>2</sup>, M. Beckmann<sup>3</sup>, M. Zentgraf<sup>2</sup>, M. Ruebner<sup>4</sup>, H. Huebner<sup>4</sup>, J. Fischer<sup>5</sup>, E. Guerini Rocco<sup>6</sup>, G. Viale<sup>7</sup>, A. Cayre<sup>8</sup>, F. Penault-Llorca<sup>8</sup>, T. Caniego Casa<sup>9</sup>, J. Palacios Calvo<sup>9</sup>, P. Jank<sup>10</sup>, C. Denkert<sup>11</sup>, L. Khoury<sup>12</sup>, T. Mairinger<sup>12</sup>, F. Ferrazzi<sup>2</sup>, <sup>1</sup>Universitaetsklinikum Erlangen - Pathologisches Institut, Erlangen, DE, <sup>2</sup>University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE,

<sup>3</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>4</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, DE, <sup>5</sup>Qualitätssicherungs-Initiative Pathologie QuIP GmbH, Berlin, DE, <sup>6</sup>University of Milan, Milan, IT, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>9</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>10</sup>Uniklinikum Giessen und Marburg (UKGM), Marburg, DE, <sup>11</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>12</sup>MVZ Helios Hospital Emil von Behring GmbH, Berlin, DE

- 12:00 - 12:00 **29P - Key cancer gene expression features of hereditary breast cancer in the Kazakh population**  
N. Omarbayeva<sup>1</sup>, D. Kaidarova<sup>1</sup>, A. Abdrakhmanova<sup>1</sup>, G. Zhunussova<sup>2</sup>, S. Abdikerim<sup>3</sup>, L. Djansugurova<sup>3</sup>, <sup>1</sup>Kazakh Reserch Institute of Oncology & Radiology, Almaty, KZ, <sup>2</sup>Institute of general genetics and cytology, Almaty, KZ, <sup>3</sup>Institute of general genetics and cytology, almaty, KZ
- 12:00 - 12:00 **30P - In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients**  
S. D'Oronzo<sup>1</sup>, D. Lovero<sup>2</sup>, R. Palmirotta<sup>2</sup>, P. Cafforio<sup>2</sup>, J. Brown<sup>3</sup>, S. Wood<sup>4</sup>, M. Cives<sup>5</sup>, M. Tucci<sup>1</sup>, L. Stucci<sup>1</sup>, R. Coleman<sup>3</sup>, F. Silvestris<sup>1</sup>, <sup>1</sup>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, IT, <sup>2</sup>University of Bari Aldo Moro, Bari, IT, <sup>3</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>4</sup>University of Sheffield, Sheffield, GB, <sup>5</sup>University of Bari, Bari, IT
- 12:00 - 12:00 **31P - BRCA1/2 gene mutation detection in 2686 Chinese clinical samples based on NGS HANDLE technology**  
F. Zhang<sup>1</sup>, B. Jin<sup>2</sup>, L. Zhang<sup>2</sup>, A. Zhang<sup>2</sup>, H. Ge<sup>2</sup>, M. Mueser<sup>2</sup>, L. Ruan<sup>2</sup>, <sup>1</sup>AmoyDx Medical Institute, Xiamen, CN, <sup>2</sup>Amoy Diagnostics Co., Ltd., Xiamen, CN
- 12:00 - 12:00 **32P - The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer**  
E. Zattarin<sup>1</sup>, C. Fabbroni<sup>2</sup>, F. Ligorio<sup>1</sup>, F. Nichetti<sup>2</sup>, R. Lobefaro<sup>1</sup>, L. Rivoltini<sup>2</sup>, G. Capri<sup>1</sup>, G. Bianchi<sup>1</sup>, F.G.M. De Braud<sup>1</sup>, C. Vernieri<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 12:00 - 12:00 **33P - Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers**  
A. Quintana<sup>1</sup>, V. Peg<sup>2</sup>, T. Moline<sup>2</sup>, A. Prat<sup>3</sup>, L. Paré<sup>4</sup>, P. Galván<sup>5</sup>, G. Villacampa<sup>2</sup>, R. Dientsmann<sup>2</sup>, J. Perez<sup>6</sup>, E. Muñoz<sup>2</sup>, M. Martí<sup>7</sup>, J. Blanco-Heredia<sup>8</sup>, C. Dos Anjos<sup>8</sup>, M. Vazquez<sup>9</sup>, L. De Mattos<sup>8</sup>, J. Cortés<sup>10</sup>, <sup>1</sup>Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES, <sup>2</sup>HOSPITAL VALL D'HEBRON, BARCELONA, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>SOLTI, Barcelona, ES, <sup>5</sup>IDIBAPS, Barcelona, ES, <sup>6</sup>IOB Institute of Oncology, Quironsalud group, Barcelona, ES, <sup>7</sup>Universidad Autónoma de Barcelona, Bellaterra, ES, <sup>8</sup>Hospital Universitari Trias i Pujol, Badalona, ES, <sup>9</sup>Barcelona Supercomputing Center, Barcelona, ES, <sup>10</sup>Vall d'Hebron University Hospital, Barcelona,

ES

- 12:00 - 12:00 **34P - Comprehensive clinical and molecular portraits of grade 3 ER+ HER2- breast cancer**  
K. Wang<sup>1</sup>, S. Franch-Expósito<sup>2</sup>, L. Li<sup>3</sup>, T. Xiang<sup>4</sup>, J. Wu<sup>3</sup>, G. Ren<sup>4</sup>, <sup>1</sup>The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, CN, <sup>2</sup>Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, <sup>3</sup>Fudan University Shanghai Cancer Center, Fudan University, Shanghai, CN, <sup>4</sup>The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN
- 12:00 - 12:00 **35P - The role of interplay between microRNA-133a and Mre11 in breast cancer**  
L.-C. Kao, F.-M. Chen, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City, TW
- 12:00 - 12:00 **36P - Molecular subtypes in Tunisian breast cancer**  
M. Frikha<sup>1</sup>, S. Zouari<sup>2</sup>, N. Fourati<sup>2</sup>, M. Kallel<sup>2</sup>, F. Elloumi<sup>2</sup>, M. Bahri<sup>2</sup>, W. Siala<sup>2</sup>, T. Boudawara<sup>2</sup>, A. Khanfir<sup>2</sup>, W. Mnejja<sup>1</sup>, J. Daoud<sup>2</sup>, <sup>1</sup>University of Sfax - Hopital Habib Bourguiba, Sfax, TN, <sup>2</sup>Hopital Habib Bourguiba - Sfax University, Sfax, TN
- 12:00 - 12:00 **37P - A pooled analysis of the clinical utility of genomic signatures in young women with breast cancer**  
A. Ferrigno<sup>1</sup>, C. De La Garza-Ramos<sup>2</sup>, M. Lambertini<sup>3</sup>, R. Barragan-Carrillo<sup>4</sup>, H. Azim Jr<sup>2</sup>, C. Villarreal-Garza<sup>1</sup>, <sup>1</sup>Hospital Zambrano Hellion Tecnológico de Monterrey, San Pedro Garza Garcia, MX, <sup>2</sup>Tecnologico de Monterrey, San Pedro Garza Garcia, MX, <sup>3</sup>University of Genova, Genova, IT, <sup>4</sup>National Institute of Medical Sciences and Nutrition, Mexico City, MX
- 12:00 - 12:00 **38P - Morphological heterogeneity in ductal carcinoma in situ of the breast**  
C. Stanciu Pop<sup>1</sup>, M.-C. Nollevaux<sup>1</sup>, M. Berlière<sup>2</sup>, F. Duhoux<sup>3</sup>, M. Van Bockstal<sup>3</sup>, <sup>1</sup>CHU UCL Namur - Site Godinne, Yvoir, BE, <sup>2</sup>Cliniques Universitaires Saint Luc, Belgium, BE, <sup>3</sup>Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE
- 12:00 - 12:00 **39P - Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel**  
I. Alvarez Lopez<sup>1</sup>, E. González<sup>2</sup>, L. Manso<sup>3</sup>, J.L. Alonso<sup>4</sup>, J. Cruz-Hernández<sup>5</sup>, V. Carañana Ballerini<sup>6</sup>, I. Gallegos<sup>7</sup>, M. Quindós Varela<sup>8</sup>, J. Illaramendi<sup>9</sup>, E. Vicente<sup>10</sup>, A.I. Ballesteros Garcia<sup>11</sup>, F. Ayala De La Pena<sup>12</sup>, A. Perelló<sup>13</sup>, J. Vidal<sup>14</sup>, A. Llombart Cussac<sup>14</sup>, <sup>1</sup>Hospital Donostia, San Sebastian, ES, <sup>2</sup>Hospital Universitario Virgen de las Nieves, Granada, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, ES, <sup>5</sup>Salamanca University Healthcare Complex, Salamanca, ES, <sup>6</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>7</sup>Hospital General Segovia, Segovia, ES, <sup>8</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>9</sup>Hospital de Navarra, Pamplona, ES, <sup>10</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>11</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>12</sup>Hospital Universitario Morales Meseguer, Murcia, ES, <sup>13</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>14</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES



- 12:00 - 12:00 **40P - Analysis of clinical pathological association with somatic mutations through next-generation sequencing**  
S. Jung, Kosin Univeristy Gospel Hospital, Busan, KR
- 12:00 - 12:00 **41P - A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)**  
L. Manso<sup>1</sup>, P. Villagrasa<sup>2</sup>, N. Chic<sup>3</sup>, J.M. Cejalvo<sup>4</sup>, Y. Izarzugaza<sup>5</sup>, B. Cantos<sup>6</sup>, S. Blanch<sup>7</sup>, M. Juan<sup>8</sup>, B. González-Farré<sup>9</sup>, R. Laeufle<sup>10</sup>, G. Nuovo<sup>11</sup>, G. Wilkinson<sup>12</sup>, M. Coffey<sup>12</sup>, A. González<sup>8</sup>, D. Martínez<sup>13</sup>, L. Paré<sup>2</sup>, F. Salvador<sup>14</sup>, X. González-Farré<sup>15</sup>, A. Prat<sup>16</sup>, J. Gavila Gregori<sup>17</sup>, <sup>1</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>2</sup>SOLTI, Barcelona, ES, <sup>3</sup>Hospital Clinic, Barcelona, ES, <sup>4</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>5</sup>Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, <sup>6</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, <sup>7</sup>Instituto Valenciano de Oncología, Valencia, ES, <sup>8</sup>Hospital Clinic de Barcelona, Barcelona, ES, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Oncolytics biotech inc, Calgary, CA, <sup>11</sup>Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, Powell OHIO, US, <sup>12</sup>Oncolytics Biotech Inc., Calgary, CA, <sup>13</sup>IDIBAPS, Barcelona, ES, <sup>14</sup>SOLTI HQ, Barcelona, ES, <sup>15</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>16</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>17</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES
- 12:00 - 12:00 **42P - Expression of WNT, Hedgehog and NOTCH signaling pathways in HER-2 overexpressed and triple negative subtypes of breast cancer with high and low content of cancer stem cells**  
S. Demidov<sup>1</sup>, S. Sazonov<sup>2</sup>, A. Brilliant<sup>3</sup>, Y. Brilliant<sup>3</sup>, <sup>1</sup>City Clinical Hospital 40 (Mau Gkb 40)-Surgery Department, Ekaterinburg, RU, <sup>2</sup>Ural State Medical University, Ekaterinburg, RU, <sup>3</sup>Institute of Medical Cell Technologies, Ekaterinburg, RU
- 12:00 - 12:00 **43P - PDL1 protein expression is a prognostic factor in triple negative breast cancer**  
J. Yue<sup>1</sup>, P. Yuan<sup>2</sup>, A. Zhu<sup>2</sup>, N. Hu<sup>2</sup>, X. Wang<sup>2</sup>, W. Wang<sup>3</sup>, Z. Wang<sup>3</sup>, <sup>1</sup>Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>3</sup>Beijing Hospital, National Center of Gerontology, Beijing, CN
- 12:00 - 12:00 **44P - Obesity is associated with a late-stage diagnosis in triple-negative breast cancer**  
A. Aranda-Gutierrez<sup>1</sup>, A. Ferrigno<sup>2</sup>, M. Moncada-Madrado<sup>2</sup>, A. Gomez-Picos<sup>2</sup>, C. De La Garza-Ramos<sup>2</sup>, F. Mesa-Chavez<sup>2</sup>, H. Diaz-Perez<sup>2</sup>, S. Cardona<sup>2</sup>, R. Ortiz-Lopez<sup>3</sup>, C. Villarreal-Garza<sup>2</sup>, <sup>1</sup>Hospital Zambrano Hellion, Monterrey, MX, <sup>2</sup>Hospital Zambrano Hellion Tecnológico de Monterrey, San Pedro Garza Garcia, MX, <sup>3</sup>Tecnologico de Monterrey, Monterrey, MX
- 12:00 - 12:00 **45P - Characterizing the impact of pathogenic BRCA mutations on tissue-specific gene expression and pre-mRNA splicing**  
P. Bak-Gordon, IMM Instituto de Medicina Molecular, Lisbon, PT



- 12:00 - 12:00 **46P - Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore are associated with pathological CR in patients receiving neo-adjuvant chemotherapy**  
B. Rapoport<sup>1</sup>, J. Galon<sup>2</sup>, S. Nayler<sup>3</sup>, B. Mlecnik<sup>2</sup>, A. Fugon<sup>4</sup>, C. Benn<sup>5</sup>, M. Martel<sup>4</sup>, T. Cronje<sup>6</sup>, T. Smit<sup>1</sup>, F. Moosa<sup>1</sup>, L. Jooste<sup>1</sup>, R. Anderson<sup>7</sup>, <sup>1</sup>The Medical Oncology Centre of Rosebank, Johannesburg, ZA, <sup>2</sup>Laboratory of Integrative Cancer Immunology, Paris, FR, <sup>3</sup>Drs Gritzman & Thatcher Inc Laboratories & Wits Donald Gordon Medical Centre, Randburg, ZA, <sup>4</sup>HaliDx, Marseille, FR, <sup>5</sup>Head of Netcare breast care Centre, Johannesburg, ZA, <sup>6</sup>University of Pretoria, Pretoria, ZA, <sup>7</sup>University of Pretoria Faculty of Health Sciences, Pretoria, ZA
- 12:00 - 12:00 **47P - Androgen receptor expression and survival in triple negative breast cancer**  
L. Moyano<sup>1</sup>, J. Soto<sup>1</sup>, M. Garmendia<sup>2</sup>, <sup>1</sup>Instituto Nacional del Cancer, Santiago, CL, <sup>2</sup>Institute of Nutrition and Food Technology, Universidad de Chile., SANTIAGO, CL
- 12:00 - 12:00 **48P - Association of a genomic index of sensitivity to endocrine therapy with disease-free survival in breast cancer**  
P. Singh<sup>1</sup>, I. Bedrosian<sup>1</sup>, M.J. Ha<sup>1</sup>, Y. Shen<sup>1</sup>, L. Du<sup>1</sup>, R. Gould<sup>1</sup>, F. Symmans<sup>2</sup>, <sup>1</sup>University of Texas M.D. Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **49P - BRCA mutation testing rates among breast cancer patients meeting testing criteria: A single-centre experience**  
M. Boianu, N. Daaboul, G. Speranza, C. Prady, S. Soldera, S. Martel, Hopital Charles - Le Moyne, Greenfield Park, CA
- 12:00 - 12:00 **50P - Cardiosafe nano-formulation of doxorubicin allows coadministration with trastuzumab in neoadjuvant setting improving antitumor efficacy and preventing trastuzumab-mediated cardiotoxicity in HER2<sup>+</sup> murine model of breast cancer**  
S. Mazzucchelli<sup>1</sup>, F. Andreati<sup>1</sup>, A. Bonizzi<sup>1</sup>, M. Sevieri<sup>1</sup>, M. Truffi<sup>1</sup>, L. Sitia<sup>1</sup>, R. Ottria<sup>1</sup>, F. Silva<sup>1</sup>, P. Zerbi<sup>1</sup>, D. Prosperi<sup>2</sup>, F. Corsi<sup>1</sup>, <sup>1</sup>Università degli Studi di Milano, Milan, IT, <sup>2</sup>Università degli studi di Milano- Bicocca, Milano, IT
- 12:00 - 12:00 **51P - Evolution of low HER2 expressions between primary and metastatic breast cancer**  
P. Tarantino<sup>1</sup>, E. Nicolò<sup>2</sup>, P. Zagami<sup>3</sup>, F. Giugliano<sup>2</sup>, P. Trillo A.<sup>2</sup>, A. Marra<sup>4</sup>, D. Trapani<sup>4</sup>, S. Morganti<sup>4</sup>, L. Mazzarella<sup>2</sup>, C. Criscitiello<sup>3</sup>, A. Esposito<sup>5</sup>, G. Curigliano<sup>3</sup>, <sup>1</sup>European Institute of Oncology (IEO), Milan, IT, <sup>2</sup>IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, IT, <sup>3</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>5</sup>ecancer, Bristol, GB
- 12:00 - 12:00 **52P - Characterising clinicopathological and biological parameters predictive of outcome for patients diagnosed with invasive lobular carcinoma**  
P. Simpson<sup>1</sup>, A. McCart Reed<sup>1</sup>, J. Kutasovic<sup>1</sup>, C. Coorey<sup>1</sup>, L. Kuo<sup>1</sup>, H. Nguyen<sup>1</sup>, W. Pei<sup>1</sup>, J. Ong<sup>1</sup>, A. Sokolova<sup>1</sup>, E. Evans<sup>2</sup>, A. Porter<sup>2</sup>, S. Lakhani<sup>1</sup>, <sup>1</sup>University of Queensland,

Brisbane, AU, <sup>2</sup>The Wesley Hospital, Brisbane, AU

- 12:00 - 12:00 **53P - Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer**  
S. Pasricha<sup>1</sup>, D. Bansal<sup>1</sup>, A. Jajodia<sup>1</sup>, K. Choudhary<sup>2</sup>, G. Gupta<sup>1</sup>, A. Sharma<sup>1</sup>, A. Sharma<sup>1</sup>, G. Durga<sup>1</sup>, M. Kamboj<sup>1</sup>, A. Kumar<sup>1</sup>, S. Bothra<sup>1</sup>, M. Chllamma<sup>3</sup>, V.P.B. Koyyala<sup>1</sup>, A. Russo<sup>4</sup>, D.C. Doval<sup>1</sup>, A. Mehta<sup>2</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>3</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>4</sup>University of Palermo, Palermo, IT
- 12:00 - 12:00 **54P - Establishment and characterization of luminal A breast PDX models from patients with acquired resistance to CDK 4/6 inhibitors**  
M. Wick, J. Flores, A. Moriarty, M. Beeram, K. Papadopoulos, South Texas Accelerated Research Therapeutics (START), San Antonio, US
- 12:00 - 12:00 **55P - Role of radiomics for predicting immunophenotypes in male breast cancer**  
V.P.B. Koyyala<sup>1</sup>, A. Jajodia<sup>1</sup>, S. Pasricha<sup>1</sup>, A. Gupta<sup>2</sup>, A. Chaturvedi<sup>1</sup>, A. Rao<sup>3</sup>, R. Tripathi<sup>1</sup>, M. Kamboj<sup>1</sup>, M. Mayerhoefer<sup>4</sup>, D. Leithner<sup>5</sup>, H. Prosch<sup>6</sup>, M. Chllamma<sup>7</sup>, M. La Mantia<sup>8</sup>, A. Russo<sup>9</sup>, D.C. Doval<sup>1</sup>, A. Mehta<sup>3</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>The Indian Institute of Information Technology, Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>Medical University of Vienna, vienna, AT, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>Medical University of Vienna, HOUSTON, AT, <sup>7</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>8</sup>University of Palermo, palermo, IT, <sup>9</sup>University of Palermo, Palermo, IT
- 12:00 - 12:00 **57P - Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients**  
P. Tolosa Ortega<sup>1</sup>, J.M. Cejalvo<sup>2</sup>, S. Moragon Terencio<sup>1</sup>, L. Carril-Ajuria<sup>3</sup>, B. Bermejo<sup>4</sup>, Á. Ruiz<sup>3</sup>, C. Hernando Melia<sup>1</sup>, A. Sánchez-Torre<sup>3</sup>, M.T. Martínez<sup>2</sup>, M. Herrera<sup>3</sup>, V. Gambardella<sup>1</sup>, L. Lema<sup>3</sup>, D. Roda<sup>1</sup>, E. Bernal<sup>3</sup>, P. Rentero-Garrido<sup>1</sup>, A. Lluch<sup>2</sup>, E. Ciruelos<sup>5</sup>, A. Cervantes<sup>1</sup>, L. Manso<sup>3</sup>, <sup>1</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>3</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup>Hospital Clínico Universitario de Valencia / INCLIVA / CIBERONC, Valencia, ES, <sup>5</sup>University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **58P - Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients**  
T. De La Motte Rouge<sup>1</sup>, F. Le Du<sup>1</sup>, J. Corne<sup>2</sup>, F. Godey<sup>1</sup>, H. Bourien<sup>1</sup>, A. Brunot<sup>1</sup>, L. Crouzet<sup>1</sup>, C. Perrin<sup>1</sup>, C. Lefeuvre-Plesse<sup>3</sup>, V. Dieras<sup>1</sup>, V. Quillien<sup>1</sup>, <sup>1</sup>Centre Eugène - Marquis, Rennes, FR, <sup>2</sup>Centre Eugène Marquis, RENNES, FR, <sup>3</sup>Centre Eugène Marquis, Rennes, FR
- 12:00 - 12:00 **59P - Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC)**  
S. Di Cosimo<sup>1</sup>, M. Silvestri<sup>1</sup>, M. Dugo<sup>1</sup>, M. Vismara<sup>1</sup>, C. Reduzzi<sup>1</sup>, G. Pruneri<sup>2</sup>, S. Folli<sup>1</sup>, V.

Cappelletti<sup>1</sup>, M.G. Daidone<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale Tumori (INT) Milan, Milan, IT

- 12:00 - 12:00 **60P - Prognosis and survival of single hormone receptor positive breast cancer comparing to double HR positive and triple-negative breast cancers**  
K. Oualla<sup>1</sup>, L. Nouiakh<sup>1</sup>, O. Zouiten<sup>1</sup>, L. Amaadour<sup>2</sup>, Z. Benbrahim<sup>1</sup>, S. Arifi<sup>1</sup>, N. Mellas<sup>2</sup>, <sup>1</sup>CHU - University Hospital of Hassan II, Fez, MA, <sup>2</sup>University Hospital of Hassan II, Fez, MA
- 12:00 - 12:00 **62P - XRCC1 (Arg194Trp), Palb2 T1100T (3300T→G), HMMR (V353A), TNF (aG308A) polymorphisms as diagnostic markers of breast cancer in the Kyrgyz ethnic group**  
A. Semetei Kyzy<sup>1</sup>, E. Makimbetov<sup>2</sup>, J. Isakova<sup>3</sup>, <sup>1</sup>International school of medicine-International University of Kyrgyzstan (IUK), Bishkek, KG, <sup>2</sup>Kyrgyz Russian Slavic University, Bishkek, KG, <sup>3</sup>Research Institute of Molecular Biology and Medicine, Bishkek, KG
- 12:00 - 12:00 **63P - Study of single nucleotide polymorphism of thymocyte selection associated high mobility group box 3 and fibroblast growth factor receptor 2 genes in breast cancer patients**  
A. Alhanafy, M. Hammoudah, A. Dawood, M. Abouelenin, Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG
- 12:00 - 12:00 **64P - Comprehensive genomic analysis of primary triple negative breast cancer prior to neoadjuvant chemotherapy**  
M. Drobnienė<sup>1</sup>, R. Sabaliauskaite<sup>1</sup>, E. Zurauskas<sup>2</sup>, R. Meskauskas<sup>2</sup>, B. Brasiuniene<sup>1</sup>, S. Jarmalaite<sup>1</sup>, <sup>1</sup>National Cancer Institute, Vilnius, LT, <sup>2</sup>National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, LT
- 12:00 - 12:00 **65P - Investigating the molecular connection between hormone receptor status and ploidy management in breast cancer**  
S. Nath, Saroj Gupta Cancer Centre & Research Institute, Kolkata, IN
- 12:00 - 12:00 **66P - Impact of EPclin on adjuvant therapeutic decision-making and comparison of EPclin to PREDICT tool**  
H. Bourien<sup>1</sup>, V. Quillien<sup>1</sup>, F. Godey<sup>1</sup>, C. Perrin<sup>1</sup>, F. Le Du<sup>1</sup>, A. Brunot<sup>1</sup>, L. Crouzet<sup>1</sup>, T. De La Motte Rouge<sup>1</sup>, V. Dieras<sup>1</sup>, C. Lefeuvre-Plesse<sup>2</sup>, <sup>1</sup>Centre Eugène - Marquis, Rennes, FR, <sup>2</sup>Centre Eugène Marquis, Rennes, FR
- 12:00 - 12:00 **67P - Digital analysis of distant and cancer-associated adipocytes in breast cancer**  
E. Isnaldi<sup>1</sup>, F. Richard<sup>1</sup>, M. De Schepper<sup>1</sup>, D. Vincent<sup>2</sup>, S. Leduc<sup>1</sup>, M. Maetens<sup>1</sup>, T. Geukens<sup>1</sup>, G. Floris<sup>3</sup>, G. Rouas<sup>4</sup>, F. Rothé<sup>4</sup>, F. Cardoso<sup>5</sup>, M. Piccart<sup>4</sup>, C. Sotiriou<sup>4</sup>, G. Zoppoli<sup>6</sup>, E. Biganzoli<sup>7</sup>, D. Larsimont<sup>4</sup>, C. Desmedt<sup>8</sup>, <sup>1</sup>KU Leuven - VIB Campus Gasthuisberg, Leuven, BE, <sup>2</sup>Institut Jules Bordet, Bruxelles, BE, <sup>3</sup>UZ Leuven, Leuven, BE, <sup>4</sup>Institute Jules Bordet, Brussels, BE, <sup>5</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>6</sup>University of Genova-DIMI, Genova, IT, <sup>7</sup>University of Milan, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT, <sup>8</sup>KU Leuven, Leuven, BE



- 12:00 - 12:00 **68P - Deciphering the interplay between nuclear RNA export factors and long non-coding RNAs in breast cancer metabolism**  
C. Klec<sup>1</sup>, D. Schwarzenbacher<sup>2</sup>, B. Gottschalk<sup>3</sup>, R. Margit<sup>2</sup>, F. Prinz<sup>2</sup>, T. Bauernhofer<sup>4</sup>, H. Stoeger<sup>5</sup>, W. Graier<sup>3</sup>, M. Pichler<sup>2</sup>, <sup>1</sup>Medical University Graz-Center for Medical Research, Graz, AT, <sup>2</sup>Medical University of Graz, Graz, AT, <sup>3</sup>Gottfried Schatz Research Center, Graz, AT, <sup>4</sup>University Hospital Graz, Graz, AT, <sup>5</sup>LKH-Univ. Klinikum Graz, Graz, AT
- 12:00 - 12:00 **69P - TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2<sup>+</sup> breast cancer patients cohort**  
H. Pla<sup>1</sup>, Á. Díaz-Lagares<sup>2</sup>, A. Hernandez<sup>1</sup>, G. Oliveras<sup>3</sup>, F. Pérez-Bueno<sup>3</sup>, M. Esteller<sup>4</sup>, T. Puig<sup>5</sup>, S. Palomeras<sup>5</sup>, G. Viñas<sup>1</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO), Dr. Josep Trueta Hospital, Girona, ES, <sup>2</sup>Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS), CIBERONC, Santiago de Compostela., ES, <sup>3</sup>Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, ES, <sup>4</sup>Josep Carreras Leukaemia Research Institute (IJC), Badalona, ES, <sup>5</sup>TargetsLab, University of Girona, Girona, ES
- 12:00 - 12:00 **70P - Genetic polymorphisms of ESR1 are associated with hormone resistance to aromatase inhibitors therapy in patients with metastatic luminal breast cancer (MLBC)**  
T. Tarasenko, L. Syvak, N. Verovkina, S. Lyalkin, National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA
- 12:00 - 12:00 **71P - Role of radiomics in predicting molecular phenotypes of female breast cancer**  
A. Jajodia<sup>1</sup>, A. Gupta<sup>2</sup>, A. Mehta<sup>3</sup>, A. Chaturvedi<sup>1</sup>, A. Rao<sup>3</sup>, G. Gupta<sup>3</sup>, D.C. Doval<sup>1</sup>, A. Bp<sup>3</sup>, P. Medisetty<sup>4</sup>, S. Bommera<sup>1</sup>, V.P.B. Koyyala<sup>1</sup>, S. Pasricha<sup>1</sup>, M. Mayerhoefer<sup>5</sup>, H. Prosch<sup>6</sup>, M. Chllamma<sup>7</sup>, M. La Mantia<sup>8</sup>, A. Russo<sup>8</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>The Indian Institute of Information Technology, Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>BSAH - Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, IN, <sup>5</sup>Medical University of Vienna, vienna, AT, <sup>6</sup>Medical University of Vienna, HOUSTON, AT, <sup>7</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>8</sup>University of Palermo, Palermo, IT
- 12:00 - 12:00 **72P - Non-mass like enhancement patterns on MR mammography and their pathological correlation**  
A. Parashar<sup>1</sup>, A. Jajodia<sup>2</sup>, A. Chaturvedi<sup>2</sup>, A. Rao<sup>3</sup>, A. Mehta<sup>3</sup>, D.C. Doval<sup>2</sup>, A. Bp<sup>3</sup>, P. Medisetty<sup>4</sup>, V.P.B. Koyyala<sup>2</sup>, S. Pasricha<sup>2</sup>, M. La Mantia<sup>5</sup>, M. Chllamma<sup>6</sup>, D. Leithner<sup>7</sup>, M. Mayerhoefer<sup>8</sup>, A. Russo<sup>5</sup>, H. Prosch<sup>9</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, <sup>2</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, new delhi, IN, <sup>4</sup>BSAH - Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, IN, <sup>5</sup>University of Palermo, Palermo, IT, <sup>6</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>Medical University of Vienna, vienna, AT, <sup>9</sup>Medical University of Vienna, HOUSTON, AT



- 12:00 - 12:00 **73P - microRNA expression profiles of single hormone receptor-positive breast cancers**  
M. Kunc<sup>1</sup>, M. Popeda<sup>1</sup>, A. Szalkowska<sup>2</sup>, M. Niemira<sup>2</sup>, A. Lacko<sup>3</sup>, B. Radecka<sup>4</sup>, M. Braun<sup>5</sup>, J. Pikiel<sup>6</sup>, M. Litwiniuk<sup>7</sup>, K. Pogoda<sup>8</sup>, A. Sz wajkosz<sup>9</sup>, E. Izycka-Swieszewska<sup>1</sup>, A. Zaczek<sup>1</sup>, W. Biernat<sup>10</sup>, E. Senkus-Konefka<sup>1</sup>, <sup>1</sup>Medical University of Gdansk, Gdansk, PL, <sup>2</sup>Medical University of Bialystok, Bialystok, PL, <sup>3</sup>Wroclaw Medical University, Wroclaw, PL, <sup>4</sup>Opolskie Centrum Onkologii Oddzial Onkologii Klinicznej Tadeusz Koszarowskieg, Opole, PL, <sup>5</sup>Medical University of Lodz, Lodz, PL, <sup>6</sup>Szpital Morski, Gdynia, PL, <sup>7</sup>Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>8</sup>The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>9</sup>Beskid Oncology Center, Bielsko-Biala, PL, <sup>10</sup>Medical University of Gdansk, Gdańsk, PL
- 12:00 - 12:00 **74P - Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy**  
B. Kotowicz<sup>1</sup>, P. Winter<sup>1</sup>, M. Fuksiewicz<sup>1</sup>, A. Jagiello-Gruszfeld<sup>2</sup>, Z. Nowecki<sup>3</sup>, M. Kowalska<sup>4</sup>, <sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>2</sup>Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, <sup>3</sup>Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, <sup>4</sup>National Cancer Institute, Warsaw, PL
- 12:00 - 12:00 **75P - Clinical and pathological feature of primary lung cancer in patients with primary breast cancer**  
T. Zeng, W. Li, Y. Yin, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **76P - Retrospective study about the prevalence of (TILs) tumour infiltrating lymphocytes in non-metastatic triple negative breast cancer patients and its prognostic value**  
A. Kamal, H. Elghazaly, M. El-Mahdy, A. Adel, N. Abdel-Kader, Mataria Teaching Hospital, Cairo, EG
- 12:00 - 12:00 **79P - Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastatic breast cancer patients**  
C. Suppan<sup>1</sup>, Q. Zhou<sup>2</sup>, R. Graf<sup>2</sup>, V. Klocker<sup>3</sup>, A. Terbuch<sup>3</sup>, N. Dandachi<sup>3</sup>, E. Heitzer<sup>2</sup>, M. Balic<sup>4</sup>, <sup>1</sup>Medical University of Graz, Graz, AT, <sup>2</sup>Medical University of Graz, Graz, AT, <sup>3</sup>LKH-Univ. Klinikum Graz, Graz, AT, <sup>4</sup>LKH-Univ.Klinikum Graz - Universitätsklinik für Innere Medizin, Graz, AT
- 12:00 - 12:00 **Early Breast cancer: Adjuvant therapy**
- 12:00 - 12:00 **82P - A multinational study of real-world treatment patterns among patients with early stage HR&#x2b;/HER2- breast cancer (BC)**  
C. Criscitiello<sup>1</sup>, D. Spurden<sup>2</sup>, A. Rider<sup>3</sup>, R. Williams<sup>4</sup>, M. Corsaro<sup>5</sup>, J. Pike<sup>4</sup>, E. Law<sup>6</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Pfizer UK, Tadworth, GB, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Bollington, GB, <sup>5</sup>Pfizer, Milan, IT, <sup>6</sup>Pfizer Inc, New York, US

- 12:00 - 12:00 **83P - Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2<sup>+</sup>; HR<sup>+</sup> breast cancer after trastuzumab-based therapy on patient outcomes**  
M. Martin Jimenez<sup>1</sup>, M. Gnant<sup>2</sup>, B. Ejlersen<sup>3</sup>, J. Mansi<sup>4</sup>, M. Ruiz-Borrego<sup>5</sup>, E. Jakobsen<sup>6</sup>, C.K. Osborne<sup>7</sup>, R. Birhiray<sup>8</sup>, B. Zhang<sup>9</sup>, A. Wong<sup>9</sup>, B. Moy<sup>10</sup>, F. Holmes<sup>11</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>2</sup>Medizinische Universität Wien, Vienna, AT, <sup>3</sup>Rigshospitalet, University of Copenhagen, Copenhagen, DK, <sup>4</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>5</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>6</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>7</sup>Baylor College of Medicine, Houston, US, <sup>8</sup>Hematology / Oncology of Indiana, Indianapolis, US, <sup>9</sup>PUMA Biotechnology, Los Angeles, US, <sup>10</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>11</sup>Texas Oncology, Fort Worth, US
- 12:00 - 12:00 **84P - Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials**  
E. Aravantinou Fatorou<sup>1</sup>, G.-A. Koliou<sup>2</sup>, F. Zagouri<sup>2</sup>, L. Kostadima<sup>2</sup>, H. Gogas<sup>2</sup>, D. Pectasides<sup>2</sup>, I. Binas<sup>2</sup>, A. Koutras<sup>2</sup>, G. Aravantinos<sup>2</sup>, A. Psyrris<sup>2</sup>, G.L. Lazaridis<sup>2</sup>, D. Bafaloukos<sup>2</sup>, E. Saloustros<sup>2</sup>, C. Karanikiotis<sup>2</sup>, I.B. Bombolaki<sup>2</sup>, E. Razis<sup>2</sup>, A. Koumariou<sup>2</sup>, P. Papakostas<sup>2</sup>, P. Kosmidis<sup>2</sup>, G. Fountzilas<sup>3</sup>, <sup>1</sup>251 Hellenic Airforce General Hospital, Athens, GR, <sup>2</sup>Hellenic Cooperative Oncology Group ( HeCOG), Athens, GR, <sup>3</sup>Papageorgiou Hospital - Aristotle University of Thessaloniki, Thessaloniki, GR
- 12:00 - 12:00 **85P - Racial differences in predictive value of 21-gene recurrence score assay: A population-based study using the SEER database**  
J. Jung<sup>1</sup>, H. Kim<sup>2</sup>, K.-T. Hwang<sup>3</sup>, <sup>1</sup>Seoul Medical Center, Seoul, KR, <sup>2</sup>Seoul Metropolitan Government Seoul National Hospital Boramae Medical Center, Seoul, KR, <sup>3</sup>Boramae Medical Center, Seoul, KR
- 12:00 - 12:00 **86P - Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2<sup>+</sup> early breast cancer (BC) treated within the GAIN-2 trial**  
M. Reinisch<sup>1</sup>, M. Untch<sup>2</sup>, T. Reimer<sup>3</sup>, R. Mahlberg<sup>4</sup>, M. Aydogdu<sup>5</sup>, T. Hitschold<sup>6</sup>, C. Jackisch<sup>7</sup>, F. Marmé<sup>8</sup>, H.-J. Lück<sup>9</sup>, E. Ladda<sup>10</sup>, S. Schmatloch<sup>11</sup>, M. Schmidt<sup>12</sup>, P. Klare<sup>13</sup>, B. Sinn<sup>14</sup>, E. Stickeler<sup>15</sup>, S. Seiler<sup>16</sup>, J. Rey<sup>16</sup>, N. Klutinus<sup>17</sup>, V. Möbus<sup>18</sup>, S. Loibl<sup>16</sup>, <sup>1</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>2</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>3</sup>Klinikum Südstadt Rostock, Rostock, DE, <sup>4</sup>Klinikum Mutterhaus der Borromäerinnen, Trier, DE, <sup>5</sup>Klinikum Bremen-Mitte, Bremen, DE, <sup>6</sup>Klinikum Worms, Worms, DE, <sup>7</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>8</sup>UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>9</sup>Gynäkologisch-onkologische Praxis, Hamburg, DE, <sup>10</sup>Onkologische Praxis Neumarkt, Neumarkt, DE, <sup>11</sup>Elisabeth Krankenhaus Kassel, Kassel, DE, <sup>12</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>13</sup>Praxisklinik Berlin, Berlin, DE, <sup>14</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>15</sup>Universitätsklinikum Aachen (UKA), Aachen, Germany, DE, <sup>16</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>17</sup>HELIOS Klinikum Pforzheim, Pforzheim, DE, <sup>18</sup>Universitätsklinikum Frankfurt, Frankfurt, DE

- 12:00 - 12:00 **87P - Patient-reported and cancer-specific health-related quality of life among patients with early stage HR<sup>+</sup>/HER2- breast cancer (BC)**  
C. Criscitiello<sup>1</sup>, D. Spurden<sup>2</sup>, A. Rider<sup>3</sup>, R. Williams<sup>4</sup>, M. Corsaro<sup>5</sup>, J. Pike<sup>4</sup>, E. Law<sup>6</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Pfizer UK, Tadworth, GB, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Bollington, GB, <sup>5</sup>Pfizer, Milan, IT, <sup>6</sup>Pfizer Inc, New York, US
- 12:00 - 12:00 **88P - Latent class analysis (LCA) to identify and describe clinically relevant subgroups in a multinational study of patients with HR<sup>+</sup>/HER2- early breast cancer (eBC)**  
A. Rider<sup>1</sup>, D. Spurden<sup>2</sup>, R. Williams<sup>3</sup>, M. Corsaro<sup>4</sup>, J. Pike<sup>3</sup>, E. Law<sup>5</sup>, C. Criscitiello<sup>6</sup>, <sup>1</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>2</sup>Pfizer UK, Tadworth, GB, <sup>3</sup>Adelphi Real World, Bollington, GB, <sup>4</sup>Pfizer, Milan, IT, <sup>5</sup>Pfizer Inc, New York, US, <sup>6</sup>IEO - Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **89P - Tamoxifen versus aromatase inhibitors as adjuvant therapy in premenopausal women with hormone receptor-positive breast cancer: Effects on sexuality and the female reproductive system**  
A. Skolariki<sup>1</sup>, A. Boutis<sup>1</sup>, E. Kosmidis<sup>2</sup>, <sup>1</sup>Theagenio Cancer Hospital, Thessaloniki, GR, <sup>2</sup>Aristotle University of Thessaloniki, Thessaloniki, GR
- 12:00 - 12:00 **90P - Patient-reported outcomes among patients with HR<sup>+</sup>/HER2- early breast cancer: A systematic literature review**  
E. Salvo<sup>1</sup>, J. Cueto<sup>2</sup>, E. Law<sup>2</sup>, C. Aniceto Da Silva<sup>1</sup>, C. Cameron<sup>3</sup>, I. Samjoo<sup>1</sup>, <sup>1</sup>Eversana, Burlington, CA, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Eversana, Nova Scotia, CA
- 12:00 - 12:00 **91P - Gene expression profiling in localised luminal N<sup>+</sup> breast cancer: Efficacy and utility of 50 gene expression platform in adjuvant treatment decision making**  
P. Tolosa Ortega<sup>1</sup>, A. Sánchez-Torre<sup>2</sup>, L. Carril-Ajuria<sup>2</sup>, M. Herrera<sup>2</sup>, Á. Ruiz<sup>2</sup>, E. Bernal<sup>2</sup>, L. Lema<sup>2</sup>, L. Manso<sup>2</sup>, E. Ciruelos<sup>3</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **93P - Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer**  
B. Liu<sup>1</sup>, X. Guan<sup>2</sup>, Y. Wang<sup>2</sup>, X. Sun<sup>3</sup>, Z. Yi<sup>2</sup>, W. Wang<sup>2</sup>, L. Li<sup>2</sup>, J. Zhai<sup>2</sup>, H. Li<sup>4</sup>, F. Ma<sup>2</sup>, <sup>1</sup>CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>3</sup>Cancer Hospital of Huanxing, Beijing, CN, <sup>4</sup>Beijing Anzhen Hospital, Capital Medical University, Beijing, CN
- 12:00 - 12:00 **94P - Integration of clinicopathological and genomic data and adjuvant treatment decisions in premenopausal women with recurrence scores between 16 and 25**  
M. Alsendi<sup>1</sup>, M. Lucas<sup>1</sup>, W. Darwish<sup>2</sup>, M. Higgins<sup>3</sup>, C. Kelly<sup>3</sup>, <sup>1</sup>The Mater Misericordiae University Hospital, Dublin, IE, <sup>2</sup>Letterkenny General Hospital, Letterkenny, IE, <sup>3</sup>Mater Misericordiae hospital, Dublin, IE



- 12:00 - 12:00 **95TiP - Gruppo Italiano Mammella (GIM) 10 &#x2013; CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR&#x2b;) early breast cancer (EBC)**
- M. Lambertini<sup>1</sup>, V. Guarneri<sup>2</sup>, E.R. Caremoli<sup>3</sup>, A. Rocca<sup>4</sup>, F. Montemurro<sup>5</sup>, M. De Laurentiis<sup>6</sup>, M. Giordano<sup>7</sup>, S. De Placido<sup>8</sup>, G. Bisagni<sup>9</sup>, O. Garrone<sup>10</sup>, A. Ferzi<sup>11</sup>, F. Giovanardi<sup>12</sup>, F. Cognetti<sup>13</sup>, L. Amaducci<sup>14</sup>, A. Bernardo<sup>15</sup>, L. Livi<sup>16</sup>, C. Bighin<sup>17</sup>, F. Poggio<sup>1</sup>, A. Ballestrero<sup>18</sup>, L. Del Mastro<sup>19</sup>, <sup>1</sup>University of Genova, Genova, IT, <sup>2</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>ASST Papa Giovanni XXIII, Bergamo, IT, <sup>4</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>5</sup>Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, <sup>6</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, IT, <sup>7</sup>Ospedale Sant'Anna, Como, IT, <sup>8</sup>University of Naples Federico II, Naples, IT, <sup>9</sup>Azienda USL-IRCCS, Reggio Emilia, IT, <sup>10</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>11</sup>Ospedale Civile, Legnano, IT, <sup>12</sup>AUSL.RE, Guastalla, IT, <sup>13</sup>Istituto Nazionale Tumori Regina Elena, Roma, IT, <sup>14</sup>P.O. Ospedale degli Infermi, Romagna, IT, <sup>15</sup>Fondazione S. Maugeri IRCCS, Pavia, IT, <sup>16</sup>AUC Careggi, Florence, IT, <sup>17</sup>IRCCS Ospedale Policlinico San Martino - University of Genova, Genova, IT, <sup>18</sup>Università degli Studi di Genova and Ospedale Policlinico San Martino IRCCS, Genova, IT, <sup>19</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 12:00 - 12:00 **Early Breast cancer: Neoadjuvant therapy**
- 12:00 - 12:00 **99P - Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer**
- G. Vernaci<sup>1</sup>, E. Cumerlato<sup>2</sup>, G. Griguolo<sup>3</sup>, D. Massa<sup>2</sup>, A. Menichetti<sup>3</sup>, F. Miglietta<sup>3</sup>, G. Tasca<sup>3</sup>, E. Savarino<sup>2</sup>, P.F. Conte<sup>1</sup>, V. Guarneri<sup>1</sup>, M.V. Dieci<sup>3</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>University of Padova, Padova, IT, <sup>3</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 12:00 - 12:00 **101P - Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[&#x2b;] early breast cancer (EBC). A substudy of the PHERGain trial**
- A. Llombart Cussac<sup>1</sup>, A. Prat<sup>2</sup>, J.M. Pérez-García<sup>3</sup>, J. Mateos<sup>4</sup>, T. Pascual<sup>5</sup>, S. Escrivà-De-Romani<sup>6</sup>, A. Stradella<sup>7</sup>, M. Ruiz-Borrego<sup>8</sup>, B. Bermejo De Las Heras<sup>9</sup>, M. Keyaerts<sup>10</sup>, M. Sampayo-Cordero<sup>11</sup>, A. Malfettone<sup>11</sup>, R. Cortés<sup>12</sup>, P. Galván<sup>13</sup>, J. Cortés<sup>14</sup>, G. Gebhart<sup>10</sup>, <sup>1</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>2</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>3</sup>IOB, Institute of Oncology, QuironSalud Group; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, Madrid and Barcelona, ES, <sup>4</sup>IEC, Barcelona, ES, <sup>5</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>6</sup>Hospital Universitari Vall Hebrón, Barcelona, ES, <sup>7</sup>ICO l'Hospitalet, Barcelona, ES, <sup>8</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>9</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>10</sup>Institute Jules Bordet, Brussels, BE, <sup>11</sup>MedSIR - Medica Scientia Innovation Research, Barcelona, ES, <sup>12</sup>Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, ES, <sup>13</sup>IDIBAPS, Barcelona, ES, <sup>14</sup>Vall d'Hebron University Hospital, Barcelona, ES



- 12:00 - 12:00 **102P - Predictive models associated with the presence of pathological complete response following neoadjuvant chemotherapy for breast cancer**  
Y. Xie, West China Medical Center of Sichuan University, Chengdu, CN
- 12:00 - 12:00 **103P - Loss of HER2 after neoadjuvant treatment of HER2+ early breast cancer**  
S. Morales<sup>1</sup>, A. Gasol Cudos<sup>2</sup>, A. Rodriguez Galindo<sup>1</sup>, A. Velasco<sup>1</sup>, C. Canosa Morales<sup>1</sup>, D.-R. Sánchez Guzmán<sup>1</sup>, J. Melé Olivé<sup>1</sup>, <sup>1</sup>Hospital Universitario Arnau de Vilanova, LLEIDA, ES, <sup>2</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES
- 12:00 - 12:00 **104P - Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)**  
W. Rhodes<sup>1</sup>, S. Gautam<sup>1</sup>, A. Haiderali<sup>2</sup>, M. Huang<sup>3</sup>, J. Sieluk<sup>4</sup>, K. Skinner<sup>1</sup>, L. Schwartzberg<sup>5</sup>, <sup>1</sup>Concerto HealthAI, Memphis, US, <sup>2</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>3</sup>Merck & Co., Inc. - Upper Gwynedd Site, North Wales, US, <sup>4</sup>MSD - Merck Sharp & Dohme, North Wales, US, <sup>5</sup>West Cancer Center, Germantown, US
- 12:00 - 12:00 **105P - Lower-dose apatinib combined with nanoparticle albumin-bound paclitaxel and carboplatin as a neoadjuvant regimen for triple negative breast cancer: A prospective, single-arm, phase II study**  
Y. Yin, W. Li, X. Zha, J. Wang, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **107P - Preservation of ovarian function with goserelin in young breast cancer patients: Does it hamper the effect of neoadjuvant chemotherapy?**  
S.Y. Wang, S. Wang, Peking University People's Hospital, Beijing, CN
- 12:00 - 12:00 **109P - Role of MRI and histopathological classification in pre-treatment identification of non-responders to neoadjuvant chemotherapy in breast cancer**  
B. Vertakova Krakovska<sup>1</sup>, L. Vanovcanova<sup>2</sup>, V. Lehotska<sup>2</sup>, I. Waczulikova<sup>3</sup>, K. Gocarova<sup>1</sup>, <sup>1</sup>Oncological Institute of St. Elizabeth-Onkologický ústav sv. Alžbety, s.r.o., Bratislava, SK, <sup>2</sup>Comenius University, Medical Faculty, Bratislava, SK, <sup>3</sup>Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava, Bratislava, SK
- 12:00 - 12:00 **110P - Primary endocrine therapy of breast cancer: Is there a good radiological technique to define pathological response?**  
J. Lopez Velazco<sup>1</sup>, M. Otaño<sup>2</sup>, L. Larburu<sup>2</sup>, A. Lahuerta<sup>2</sup>, K. Elorriaga<sup>2</sup>, V. Segur<sup>2</sup>, J.C. Irizabal<sup>2</sup>, A. Martinez<sup>2</sup>, L. Jáuregui<sup>2</sup>, J.A. Alberro<sup>2</sup>, L. Álvarez<sup>2</sup>, I. Etxabe<sup>2</sup>, M. Huarte<sup>2</sup>, M. M. Caffarel<sup>3</sup>, A. Urruticoechea Ribate<sup>2</sup>, <sup>1</sup>Onkologiko Donostia - Kutxa Fundaziona, San Sebastian, ES, <sup>2</sup>Onkologiko Donostia - Kutxa Fundaziona, DONOSTIA, ES, <sup>3</sup>Instituto de Investigación Sanitaria Biodonostia, DONOSTIA, ES
- 12:00 - 12:00 **111P - Evaluating the protective effect of metformine on cancer: A retrospective cohort analysis**  
N. Honoré<sup>1</sup>, A. Van Der Elst<sup>1</sup>, D. D'Augusto<sup>2</sup>, E. Seront<sup>3</sup>, <sup>1</sup>UCLouvain Brussels Woluwe, Brussels, BE, <sup>2</sup>Jolimont Group, La Louvière, BE, <sup>3</sup>Centre Hospitalier Jolimont-Lobbès,

Haine Saint Paul, BE

- 12:00 - 12:00 **112TiP - SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR $\times$ 2b;)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)**  
E. Ciruelos<sup>1</sup>, X. González-Farré<sup>2</sup>, A. Perelló<sup>3</sup>, E. Alba<sup>4</sup>, P. Palacios-Ozores<sup>5</sup>, J. Salvador-Bofil<sup>6</sup>, M. Merino<sup>7</sup>, P. Villagrasa<sup>8</sup>, P. Celiz<sup>9</sup>, T. Pascual<sup>10</sup>, A. Prat<sup>11</sup>, S. Pernas Simon<sup>12</sup>,  
1University Hospital 12 De Octubre, Madrid, ES, 2Hospital General de Catalunya, San Cugat del Valles, ES, 3Hospital Universitari Son Espases, Palma de Mallorca, ES, 4Hospital Virgen de la Victoria, Málaga, ES, 5Complejo Hospitalario de Pontevedra, Pontevedra, ES, 6Hospital Virgen del Rocío, Sevilla, ES, 7Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, ES, 8SOLTI, Barcelona, ES, 9SOLTI HQ, Barcelona, ES, 10Lineberger Comprehensive Cancer Center, Chapel Hill, US, 11Hospital Clinic y Provincial de Barcelona, Barcelona, ES, 12Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES
- 12:00 - 12:00 **Early Breast cancer: Surgery and radiotherapy**
- 12:00 - 12:00 **113P - Impact of local recurrence on disease-specific survival in breast cancer patients who underwent breast-conserving surgery**  
D. Tiezzi<sup>1</sup>, L. De Mattos<sup>2</sup>, L. Orlandini<sup>1</sup>, F.J. Candido Dos Reis<sup>3</sup>, H. Carrara<sup>1</sup>, O. Rueda<sup>4</sup>, C. Caldas<sup>4</sup>, J. Andrade<sup>1</sup>,  
1Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, BR, 2Hospital Universitari Trias i Pujol, Badalona, ES, 3Ribeirão Preto Medical School, Ribeirão Preto, BR, 4Cancer Research UK & University of Cambridge UK, Cambridge, GB
- 12:00 - 12:00 **114P - Non-metastatic metaplastic breast cancer; clinicopathological characteristics and treatment outcomes: A single institution experience**  
A. Erjan, A. Dayyat, KHCC - King Hussein Cancer Center, Amman, JO
- 12:00 - 12:00 **115P - Factors associated with mastectomy in women with small residual tumour after neoadjuvant chemotherapy for breast cancer**  
E. Bernell<sup>1</sup>, A. Duinmeijer<sup>2</sup>, R. Altena<sup>2</sup>, T. Foukakis<sup>2</sup>, H. Fredholm<sup>2</sup>,  
1Karolinska Institutet, Stockholm, SE, 2Karolinska Institutet, Karolinska University hospital, Stockholm, SE
- 12:00 - 12:00 **116P - Is young age an independent adverse prognostic factor in carcinoma breast? A single institute retrospective comparative study from South India**  
A. K P, RCC - Regional Cancer Centre, Thiruvananthapuram, IN
- 12:00 - 12:00 **117P - Pregnancy-associated breast cancer (PABC): Demographics and outcome analysis from a lower and middle income country (LMIC)**  
J. Bajpai<sup>1</sup>, S. Dandekar<sup>2</sup>, V. Simha<sup>3</sup>, T. Shylasree<sup>2</sup>, R. Sarin<sup>2</sup>, V. Bansal<sup>4</sup>, J. Ghosh<sup>2</sup>, S. Rath<sup>2</sup>, N. Nair<sup>2</sup>, S. Gulia<sup>2</sup>, A. Patil<sup>5</sup>, S. Gupta<sup>6</sup>,  
1Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, 2Tata Memorial Centre, Mumbai, IN, 3PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN, 4Wadia Hospital, Mumbai, IN, 5Tata Memorial Centre, Mumbai, IR, 6Tata Memorial Hospital

Centre, Mumbai, IN

- 12:00 - 12:00 **118P - Should DIBH (deep inspiration breath-hold) be the standard of care in LBC (left breast cancer)?**  
M.G. Garcia Alvarez<sup>1</sup>, C. Peraza Fernandez<sup>1</sup>, C. Rodrigues<sup>2</sup>, M. Mateos Dominguez<sup>1</sup>, M. Montijano Linde<sup>1</sup>, I. Marrone<sup>1</sup>, L. Tinoco Gil<sup>1</sup>, E. López Ramirez<sup>3</sup>, <sup>1</sup>GenesisCare, H. San Francisco de Asís, Madrid, ES, <sup>2</sup>Genesiscare, Windsor, GB, <sup>3</sup>Genesiscare, Madrid, ES
- 12:00 - 12:00 **120P - Synchronous breast cancers with dissimilar radiological appearances**  
S. Ganeswaran<sup>1</sup>, A. Palmer<sup>2</sup>, E. Millar<sup>3</sup>, <sup>1</sup>St George Hospital, Kogarah, AU, <sup>2</sup>BreastScreen NSW South Eastern Sydney Illawarra, Kogarah, AU, <sup>3</sup>NSW Health Pathology, Kogarah, AU
- 12:00 - 12:00 **121P - Can axillary surgery be avoided in patients with breast pathologic complete response after neoadjuvant systemic therapy? A real-world study in China**  
R. Chen, Y. Li, S. Li, Q. Zhu, X. Shi, X. Zha, J. Wang, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **122P - A comparison of margin involvement and re-excision rates with the use of KliniTray versus standard suture specimen orientation in wide local excision surgery for breast cancer**  
T. Clarke<sup>1</sup>, K. Edwards<sup>2</sup>, J. Piper<sup>2</sup>, <sup>1</sup>York Hospital, York, GB, <sup>2</sup>York District Hospital, York, GB
- 12:00 - 12:00 **123P - Cosmetic outcome after vacuum-assisted excision is good and independent of the amount of resected tissue**  
E. Van De Voort, T. Klem, G. Struik, A. Ghandi, R. Sinke, SFVG - St Franciscus Gasthuis, Rotterdam, NL
- 12:00 - 12:00 **125P - Prognostic factors in phyllodes tumours (PT) of the breast: A single-institution cohort**  
E. Di Liso<sup>1</sup>, M. Bottosso<sup>2</sup>, V. Tsvetkova<sup>3</sup>, M. Lo Mele<sup>4</sup>, M.V. Dieci<sup>5</sup>, C. Falci<sup>6</sup>, G. Faggioni<sup>5</sup>, G. Tasca<sup>5</sup>, C.A. Giorgi<sup>6</sup>, T. Giarratano<sup>6</sup>, E. Mioranza<sup>7</sup>, A.P. Dei Tos<sup>8</sup>, V. Guarneri<sup>6</sup>, P.F. Conte<sup>6</sup>, <sup>1</sup>Istituto Oncologico Veneto, padova, IT, <sup>2</sup>Istituto Oncologico Veneto, PADOVA, IT, <sup>3</sup>University of Study of Verona, Verona, IT, <sup>4</sup>University of Study of Padua, Padova, IT, <sup>5</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>7</sup>Istituto Oncologico Veneto IRCCS, PADOVA, IT, <sup>8</sup>University of Padua, School of Medicine, Padova, IT
- 12:00 - 12:00 **126TiP - Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG 101 - TAXIS): A multicenter randomized phase III trial**  
W. Weber<sup>1</sup>, G. Henke<sup>2</sup>, K. Ribic<sup>3</sup>, S. Hayoz<sup>4</sup>, S. Seiler<sup>5</sup>, C. Maddox<sup>6</sup>, T. Ruhstaller<sup>7</sup>, D. Zwahlen<sup>8</sup>, S. Muenst<sup>1</sup>, M. Ackerknecht<sup>1</sup>, F. Fitzal<sup>9</sup>, Z. Matrai<sup>10</sup>, M. Újhelyi<sup>11</sup>, C. Kurzeder<sup>1</sup>, L. Lelièvre<sup>12</sup>, C. Tausch<sup>13</sup>, J. Heil<sup>14</sup>, M. Knauer<sup>7</sup>, <sup>1</sup>University Hospital Basel, Basel, CH, <sup>2</sup>University Hospital St. Gallen, St. Gallen, CH, <sup>3</sup>SAKK Coordinating Center,



Switzerland, Bern, CH, <sup>4</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>5</sup>SAKK Coordinating Center, Bern, CH, <sup>6</sup>ETOP - European Thoracic Oncology Platform, Bern, CH, <sup>7</sup>Brustzentrum Ostschweiz AG, St. Gallen, CH, <sup>8</sup>Cantonal Hospital Winterthur, Winterthur, CH, <sup>9</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>10</sup>National Institute of Oncology Hungary, Budapest, HU, <sup>11</sup>National Institute of Oncology, Hungary, Budapest, HU, <sup>12</sup>Centre du sein CHUV, Lausanne, CH, <sup>13</sup>Brust-Zentrum, Zurich, CH, <sup>14</sup>University Hospital Heidelberg, Heidelberg, DE

12:00 - 12:00 **Immunotherapy**

12:00 - 12:00 **129P - Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort**

Y. Novik<sup>1</sup>, N. Klar<sup>2</sup>, S. Zamora<sup>1</sup>, M. Kwa<sup>1</sup>, J. Speyer<sup>1</sup>, R. Oratz<sup>1</sup>, F. Muggia<sup>3</sup>, M. Meyers<sup>1</sup>, T. Hochman<sup>4</sup>, J. Goldberg<sup>4</sup>, S. Adams<sup>5</sup>, <sup>1</sup>NYU Cancer Institute NYU Medical School, New York, US, <sup>2</sup>NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, US, <sup>3</sup>Private Practice - Dr. Franco Muggia, Mamaroneck, US, <sup>4</sup>NYU Langone Medical Center, New York City, US, <sup>5</sup>NYU Cancer Institute NYU Medical School, New York City, US

12:00 - 12:00 **131P - Abrogation of paclitaxel chemo-resistance via epigenetic immune checkpoints regulation in triple negative breast cancer**

S. El Shihy<sup>1</sup>, R. Abdeltawab<sup>2</sup>, H. El Tayebi<sup>3</sup>, <sup>1</sup>GUC - German University in Cairo, Cairo, EG, <sup>2</sup>Ain Shams University, Cairo, EG, <sup>3</sup>GUC - German University in Cairo, New Cairo, EG

12:00 - 12:00 **132P - MALAT-1 ruling the miR-182/PIG-C/MSLN triad in triple negative breast cancer**

A. Samir<sup>1</sup>, F. Barsoum<sup>1</sup>, R. Abdeltawab<sup>2</sup>, H. El Tayebi<sup>3</sup>, <sup>1</sup>GUC - German University in Cairo, Cairo, DE, <sup>2</sup>Ain Shams University, Cairo, EG, <sup>3</sup>GUC - German University in Cairo, New Cairo, EG

12:00 - 12:00 **133TiP - A phase II trial of nivolumab &#x2b; palbociclib &#x2b; anastrozole in postmenopausal women with ER&#x2b;/HER2&#x2013; primary breast cancer: CheckMate 7A8**

S. Tolaney<sup>1</sup>, G. Jerusalem<sup>2</sup>, R. Salgado<sup>3</sup>, X. Liu<sup>4</sup>, T. Chen<sup>4</sup>, H. Zhang<sup>4</sup>, M. Roberts<sup>4</sup>, D. Zardavas<sup>4</sup>, A. Prat<sup>5</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>3</sup>St-Augustinus Ziekenhuis, Wilrijk, BE, <sup>4</sup>Bristol-Myers Squibb, Lawrence, US, <sup>5</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **134TiP - A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER&#x2b;/HER2&#x2013; primary breast cancer: CheckMate 7FL**

G. Curigliano<sup>1</sup>, H. Mcarthur<sup>2</sup>, N. Harbeck<sup>3</sup>, L. Pusztai<sup>4</sup>, S. Delaloge<sup>5</sup>, K. Letrent<sup>6</sup>, T. Chen<sup>6</sup>, B. Li<sup>6</sup>, K. Tatsuoka<sup>6</sup>, D. Zardavas<sup>6</sup>, S. Loi<sup>7</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>Ludwig Maximilians University (LMU) Hospital, Munich, DE, <sup>4</sup>Yale School of Medicine, New Haven, US, <sup>5</sup>Gustave Roussy, Villejuif, FR, <sup>6</sup>Bristol-Myers Squibb, Lawrence, US, <sup>7</sup>Peter MacCallum



Cancer Centre, Melbourne, AU

- 12:00 - 12:00 **135TiP - GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer**  
L. Voorwerk<sup>1</sup>, H. Horlings<sup>1</sup>, M. Dongen<sup>2</sup>, I. Kemper<sup>2</sup>, I. Mandjes<sup>2</sup>, J. Boers<sup>3</sup>, C. Schröder<sup>3</sup>, V. Tjan-Heijnen<sup>4</sup>, A. Jager<sup>5</sup>, T. Schumacher<sup>6</sup>, C. Blank<sup>2</sup>, K. De Visser<sup>1</sup>, S. Linn<sup>6</sup>, M. Kok<sup>6</sup>, <sup>1</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>4</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>5</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>6</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 12:00 - 12:00 **Metastatic Breast cancer**
- 12:00 - 12:00 **141P - Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer**  
P. Schmid<sup>1</sup>, A. Haiderali<sup>2</sup>, J. Mejia<sup>3</sup>, Z. Guo<sup>3</sup>, X. Zhou<sup>3</sup>, A. Martin-Nguyen<sup>4</sup>, J. Cortés<sup>5</sup>, E. Winer<sup>6</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>3</sup>Merck, North Wales, US, <sup>4</sup>MSD-Merck Sharp & Dohme, Kenilworth, US, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Dana Farber Cancer Institute, Boston, US
- 12:00 - 12:00 **142P - Quality-adjusted survival with ribociclib plus fulvestrant (R&#x2b;F) versus placebo plus fulvestrant (P&#x2b;F) in postmenopausal women (PMW) HR&#x2b;/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial**  
G. Jerusalem<sup>1</sup>, T. Delea<sup>2</sup>, M. Martin Jimenez<sup>3</sup>, M. De Laurentiis<sup>4</sup>, A. Nusch<sup>5</sup>, J.T. Beck<sup>6</sup>, A. Chan<sup>7</sup>, S.-A. Im<sup>8</sup>, P. Neven<sup>9</sup>, A. Lonshteyn<sup>2</sup>, D. Chandiwana<sup>10</sup>, B. Lanoue<sup>10</sup>, P. Fasching<sup>11</sup>, <sup>1</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>2</sup>Policy Analysis Inc. (PAI), Brookline, US, <sup>3</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, IT, <sup>5</sup>Practice for Hematology and Internal Oncology, Velbert, DE, <sup>6</sup>Highlands Oncology Group, Fayetteville, US, <sup>7</sup>Breast Cancer Centre WA & Curtin University, Perth, AU, <sup>8</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>9</sup>Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, BE, <sup>10</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>11</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE
- 12:00 - 12:00 **143P - Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study**  
Z. Kahan<sup>1</sup>, M. Gil-Gil<sup>2</sup>, M. Ruiz-Borrego<sup>3</sup>, E. Carrasco<sup>4</sup>, E. Ciruelos<sup>5</sup>, M. Muñoz<sup>6</sup>, B. Bermejo De Las Heras<sup>7</sup>, M. Margeli Vila<sup>8</sup>, A. Anton<sup>9</sup>, M. Casas<sup>4</sup>, L. Calvo<sup>10</sup>, J. De La Haba<sup>11</sup>, M. Ramos<sup>12</sup>, I. Alvarez Lopez<sup>13</sup>, E. Gal-Yam<sup>14</sup>, E. Gautier<sup>15</sup>, M. Corsaro<sup>16</sup>, G. Rodrigálvarez<sup>4</sup>, C. Zielinski<sup>17</sup>, M. Martin Jimenez<sup>18</sup>, <sup>1</sup>University of Szeged, Szeged, HU,

<sup>2</sup>Institut Catala d' Oncologia, L'Hospitalet de Llobregat, ES, <sup>3</sup>Hospital Universitario Virgen del Rocio, Sevilla, ES, <sup>4</sup>GEICAM, San Sebastian de los Reyes, ES, <sup>5</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>6</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>8</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>9</sup>Hospital Universitario Miguel Servet, Zaragoza, ES, <sup>10</sup>Complejo Hospitalario A Coruña, A Coruña, ES, <sup>11</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>12</sup>Centro Oncológico de Galicia, A Coruña, ES, <sup>13</sup>Hospital Donostia, San Sebastian, ES, <sup>14</sup>Institute of oncology , Sheba medical center, Tel-Hashomer, IL, <sup>15</sup>Pfizer Inc, San Francisco, US, <sup>16</sup>Pfizer, Milan, IT, <sup>17</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>18</sup>Hospital General Universitario Gregorio Marañon, Madrid, ES

12:00 - 12:00

**144P - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) &#x2b; fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)**

P. Fasching<sup>1</sup>, P. Neven<sup>2</sup>, G. Jerusalem<sup>3</sup>, J.T. Beck<sup>4</sup>, A. Chan<sup>5</sup>, M. De Laurentiis<sup>6</sup>, G. Bianchi<sup>7</sup>, M. Martin Jimenez<sup>8</sup>, S. Chia<sup>9</sup>, A. Gaur<sup>10</sup>, M. Sondhi<sup>10</sup>, K. Rodriguez-Lorenc<sup>11</sup>, B. Lanoue<sup>11</sup>, D. Chandiwana<sup>11</sup>, A. Nusch<sup>12</sup>, <sup>1</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>2</sup>Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, BE, <sup>3</sup>Centre Hospitalier Universitaire Liège and Liege University, Liège, BE, <sup>4</sup>Highlands Oncology Group, Fayetteville, US, <sup>5</sup>Breast Cancer Centre WA & Curtin University, Perth, AU, <sup>6</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, IT, <sup>7</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>8</sup>Hospital General Universitario Gregorio Marañon, Madrid, ES, <sup>9</sup>University of British Columbia, Vancouver, CA, <sup>10</sup>Novartis Pharma MCH, East Hanover, US, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>Practice for Hematology and Internal Oncology, Velbert, DE

12:00 - 12:00

**146P - Safety and metabolic effects of fasting-mimicking diet in breast cancer patients**

C. Vernieri<sup>1</sup>, A. Raimondi<sup>1</sup>, F. Ligorio<sup>1</sup>, E. Zattarin<sup>1</sup>, F. Nichetti<sup>2</sup>, S. Manglaviti<sup>1</sup>, G. Bianchi<sup>1</sup>, G. Capri<sup>1</sup>, L. Rivoltini<sup>2</sup>, F.G.M. De Braud<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:00 - 12:00

**147P - Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours**

M. Takahashi<sup>1</sup>, Y.-J. Bang<sup>2</sup>, M. Karayama<sup>3</sup>, J. Watanabe<sup>4</sup>, H. Minami<sup>5</sup>, N. Yamamoto<sup>6</sup>, I. Kinoshita<sup>7</sup>, C.C. Lin<sup>8</sup>, Y.-H. Im<sup>9</sup>, T. Fujiki<sup>10</sup>, I. Achiwa<sup>10</sup>, E. Kamiyama<sup>11</sup>, Y. Okuda<sup>12</sup>, C. Lee<sup>13</sup>, S. Takahashi<sup>14</sup>, <sup>1</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Hamamatsu University School of Medicine, Hamamatsu, JP, <sup>4</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>5</sup>Kobe University Hospital, Kobe, JP, <sup>6</sup>National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, <sup>7</sup>Hokkaido University, Sapporo, JP, <sup>8</sup>National Taiwan University Hospital (NTUH), Taipei, TW, <sup>9</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Daiichi Sankyo Co., Ltd., Tokyo, JP, <sup>11</sup>Daiichi Sankyo Co, Ltd, Tokyo, JP, <sup>12</sup>Daiichi Sankyo Co, Ltd., Tokyo, JP, <sup>13</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>14</sup>Cancer Institute Hospital of JFCR, Tokyo, JP

- 12:00 - 12:00 **148P - Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)**
- M. Brandão<sup>1</sup>, C. De Angelis<sup>1</sup>, P. Vuylsteke<sup>2</sup>, R. Gelber<sup>3</sup>, N. Van Damme<sup>4</sup>, E. Van Eycken<sup>4</sup>, J. Verbeeck<sup>4</sup>, L. Van Walle<sup>4</sup>, C. Colpaert<sup>5</sup>, M. Lambertini<sup>6</sup>, F. Poggio<sup>6</sup>, D. Verhoeven<sup>7</sup>, A. Barbeaux<sup>8</sup>, F. Duhoux<sup>9</sup>, K. Punie<sup>5</sup>, H. Wildiers<sup>5</sup>, C. Caballero<sup>10</sup>, A. Awada<sup>1</sup>, M. Piccart<sup>1</sup>, E. De Azambuja<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Princess Marina Hospital, Gaborone, BW, <sup>3</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>4</sup>Belgian Cancer Registry, Brussels, BE, <sup>5</sup>UZ Leuven, Leuven, BE, <sup>6</sup>University of Genova, Genova, IT, <sup>7</sup>University of Antwerp, Antwerp, BE, <sup>8</sup>CHR Verviers East Belgium, Verviers, BE, <sup>9</sup>Université Catholique de Louvain, Brussels, BE, <sup>10</sup>Breast International Group, Brussels, BE
- 12:00 - 12:00 **149P - Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores**
- K. Riecke<sup>1</sup>, V. Mueller<sup>1</sup>, T. Neunhöffer<sup>2</sup>, R. Weide<sup>3</sup>, M. Schmidt<sup>4</sup>, T.-W. Park-Simon<sup>5</sup>, C. Mundhenke<sup>6</sup>, A. Polasik<sup>7</sup>, T. Hesse<sup>8</sup>, K. Lübke<sup>9</sup>, E. Laakmann<sup>1</sup>, M. Thill<sup>10</sup>, P. Fasching<sup>11</sup>, C. Denkert<sup>12</sup>, T. Fehm<sup>13</sup>, V. Nekljudova<sup>14</sup>, J. Rey<sup>14</sup>, S. Loibl<sup>15</sup>, I. Witzel<sup>16</sup>, <sup>1</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>2</sup>Frauenärzte am Dom, Mainz, DE, <sup>3</sup>Praxis für Hämatologie und Onkologie, Koblenz, DE, <sup>4</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>5</sup>Medizinische Hochschule Hannover, Hannover, DE, <sup>6</sup>Klinikum Bayreuth GmbH, Bayreuth, DE, <sup>7</sup>Universitätsklinikum Ulm, Ulm, DE, <sup>8</sup>Agaplesion Diakoniklinikum Rotenburg, Rotenburg, DE, <sup>9</sup>Frauenklinik Hannover, Hannover, DE, <sup>10</sup>Agaplesion Markus Krankenhaus, Frankfurt, DE, <sup>11</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMM, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen—Nuremberg, Erlangen, DE, <sup>12</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>13</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>14</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>15</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>16</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
- 12:00 - 12:00 **150P - Eligibility of real-world patients with metastatic breast cancer in clinical trials**
- A. Batra<sup>1</sup>, S. Kong<sup>2</sup>, R. Rigo<sup>2</sup>, W. Cheung<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>Tom Baker Cancer Center, Calgary, CA
- 12:00 - 12:00 **151P - The landscape of patients with metastatic breast cancer enrolled in phase I trials**
- A. Marra<sup>1</sup>, C. Criscitiello<sup>2</sup>, S. Morganti<sup>1</sup>, P. Zagami<sup>2</sup>, G. Viale<sup>1</sup>, P. Tarantino<sup>3</sup>, D. Trapani<sup>1</sup>, E. Nicolò<sup>4</sup>, M. Repetto<sup>1</sup>, E. Ferraro<sup>1</sup>, P. D'Amico<sup>1</sup>, M. Locatelli<sup>4</sup>, A. Esposito<sup>5</sup>, G. Curigliano<sup>2</sup>, <sup>1</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>European Institute of Oncology (IEO), Milan, IT, <sup>4</sup>IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, IT, <sup>5</sup>ecancer, Bristol, GB
- 12:00 - 12:00 **153P - Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A**



**pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials**

M.A. Franzoi<sup>1</sup>, L. Ameye<sup>2</sup>, D. Eiger<sup>1</sup>, M. Piccart<sup>1</sup>, M. Brandão<sup>1</sup>, N. Pondé<sup>3</sup>, C. Desmedt<sup>4</sup>, S. Di Cosimo<sup>5</sup>, M. Paesmans<sup>1</sup>, R. Caparica<sup>1</sup>, N. Kotecki<sup>1</sup>, M. Lambertini<sup>6</sup>, C. De Angelis<sup>2</sup>, A. Awada<sup>1</sup>, E. De Azambuja<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Institut Jules Bordet, Brussels, BE, <sup>3</sup>AC Camargo Cancer Center, São Paulo, BR, <sup>4</sup>KU Leuven, Leuven, BE, <sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT, <sup>6</sup>University of Genova, Genova, IT

12:00 - 12:00

**154P - Survival outcome of indigenous and non-indigenous women of Western Australia with breast cancer in relation to remoteness**

A. Khan<sup>1</sup>, H. Martin<sup>2</sup>, L. Spalding<sup>3</sup>, A. Redfern<sup>3</sup>, <sup>1</sup>Sir Charles Gairdner Hospital, Nedlands, AU, <sup>2</sup>Fiona Stanley Hospital, Murdoch, AU, <sup>3</sup>University of Western Australia, Perth, AU

12:00 - 12:00

**155P - Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients**

E. Montagna<sup>1</sup>, E. Pagan<sup>2</sup>, G. Canello<sup>1</sup>, C. Sangalli<sup>3</sup>, V. Bagnardi<sup>2</sup>, E. Munzone<sup>1</sup>, M. Iorfida<sup>1</sup>, M. Mazza<sup>1</sup>, S. Dellapasqua<sup>1</sup>, N. Bianco<sup>1</sup>, P. Veronesi<sup>4</sup>, M. Colleoni<sup>1</sup>, <sup>1</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>University of Milan-Bicocca, Milan, IT, <sup>3</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>4</sup>European Institute of Oncology IRCCS, Milan, IT

12:00 - 12:00

**156P - Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR<sup>+</sup>/HER2<sup>-</sup> ABC)**

H. Rugo<sup>1</sup>, A. Haltner<sup>2</sup>, L. Zhan<sup>3</sup>, A. Tran<sup>2</sup>, E. Bananis<sup>3</sup>, D. Mitra<sup>3</sup>, C. Cameron<sup>2</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Eversana, Nova Scotia, CA, <sup>3</sup>Pfizer Inc, New York, US

12:00 - 12:00

**157P - Germline BRCA1/2 (gBRCA1/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): Results from a multi-country real-world study**

R. Mahtani<sup>1</sup>, A. Niyazov<sup>2</sup>, K. Lewis<sup>3</sup>, R. Wild<sup>4</sup>, A. Rider<sup>3</sup>, B. Arondekar<sup>5</sup>, M.P. Lux<sup>6</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>Pfizer, New York, US, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Cheshire, GB, <sup>5</sup>Pfizer Inc - USA, New York, US, <sup>6</sup>Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE

12:00 - 12:00

**158P - Patient (pt) demographics, treatment patterns (tx) and hematologic (heme) toxicities among pts with HER2<sup>+</sup> advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): A multi-country real-world (RW) study**

R. Mahtani<sup>1</sup>, A. Niyazov<sup>2</sup>, K. Lewis<sup>3</sup>, M. Last<sup>4</sup>, A. Rider<sup>3</sup>, B. Arondekar<sup>5</sup>, M.P. Lux<sup>6</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>Pfizer, New York, US, <sup>3</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>4</sup>Adelphi Real World, Cheshire, GB, <sup>5</sup>Pfizer Inc - USA, New York, US, <sup>6</sup>Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St.



Louise, Paderborn, DE

- 12:00 - 12:00 **159P - The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)**  
D. Eiger<sup>1</sup>, E. De Azambuja<sup>1</sup>, M. Moreau<sup>1</sup>, J. Bondele<sup>2</sup>, C. Sotiriou<sup>1</sup>, M.A. Franzoi<sup>1</sup>, M. Brandão<sup>1</sup>, M. Rediti<sup>1</sup>, X. Wang<sup>1</sup>, A. Awada<sup>1</sup>, N. Kotecki<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Université Libre de Bruxelles, Bruxelles, BE
- 12:00 - 12:00 **162P - Overcoming resistance to endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2-) advanced breast cancer: A meta-analysis of randomized clinical trials**  
W. Zhu, B. Xu, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:00 - 12:00 **163P - Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib & fulvestrant vs everolimus & exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR<sup>+</sup>) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)**  
E. Ciruelos<sup>1</sup>, T. Delea<sup>2</sup>, A. Moynahan<sup>2</sup>, I. Mayer<sup>3</sup>, J. Park<sup>4</sup>, D. Chandiwana<sup>5</sup>, A. Ridolfi<sup>6</sup>, I. Lorenzo<sup>7</sup>, H. Rugo<sup>8</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Policy Analysis Inc. (PAI), Brookline, US, <sup>3</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>4</sup>Novartis Pharmaceuticals UK Ltd, Camberley, GB, <sup>5</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>6</sup>Novartis Pharmaceuticals Corporation, Rueil-Malmaison, FR, <sup>7</sup>Novartis Farmaceutica, S.A., Barcelona, ES, <sup>8</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 12:00 - 12:00 **164P - A prospective approach for the evaluation of a one-step RT-qPCR based test for the quantification of HER2 protein in formalin-fixed and paraffin-embedded breast cancer tissues**  
B. Al Banyahyati, MAScIR - Moroccan Foundation for Advanced Science, Innovation and Research, Rabat, MA
- 12:00 - 12:00 **165P - Immune characterization of the de novo oligometastatic breast cancer**  
S. Chretien<sup>1</sup>, L. Buisseret<sup>2</sup>, X. Wang<sup>2</sup>, G. Rouas<sup>2</sup>, N. Kotecki<sup>2</sup>, S. Garaud<sup>2</sup>, A. Mailliez<sup>1</sup>, D. Larsimont<sup>2</sup>, F. Rothé<sup>2</sup>, C. Sotiriou<sup>2</sup>, <sup>1</sup>Centre Oscar Lambret, Lille, FR, <sup>2</sup>Institute Jules Bordet, Brussels, BE
- 12:00 - 12:00 **166P - Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany**  
M. Lux<sup>1</sup>, T. Decker<sup>2</sup>, E. Runkel<sup>3</sup>, A. Niyazov<sup>4</sup>, R. Quek<sup>5</sup>, E. Glastetter<sup>3</sup>, N. Marschner<sup>6</sup>, N. Harbeck<sup>7</sup>, <sup>1</sup>Kooperatives Brustzentrum Paderborn, Paderborn, DE, <sup>2</sup>Onkologie Hamatologie Ravensburg, Ravensburg, DE, <sup>3</sup>Pfizer - Germany, Berlin, DE, <sup>4</sup>Pfizer, New York, US, <sup>5</sup>Medivation Inc. - Pfizer Inc., San Francisco, US, <sup>6</sup>iOMEDICO AG, Freiburg im Breisgau, DE, <sup>7</sup>Ludwig Maximilians University (LMU) Hospital, Munich, DE
- 12:00 - 12:00 **167P - TRIP13 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse**

Z. Du, Y. Wang, Q. Lv, West China Medical Center of Sichuan University, Chengdu, CN

12:00 - 12:00 **168P - Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)**

O. Martinez Saez<sup>1</sup>, A. Menichetti<sup>2</sup>, L. Pare Brunet<sup>3</sup>, G. Griguolo<sup>2</sup>, A. Rodriguez Hernandez<sup>3</sup>, T. Pascual<sup>4</sup>, M.V. Dieci<sup>2</sup>, P.F. Conte<sup>5</sup>, C.A. Giorgi<sup>5</sup>, F. Brasó-Maristany<sup>6</sup>, N. Chic<sup>7</sup>, D. Martínez<sup>6</sup>, A. Rodríguez<sup>1</sup>, F. Schettini<sup>8</sup>, B. Conte<sup>9</sup>, M. Vidal<sup>7</sup>, B. Adamo<sup>1</sup>, M. Muñoz<sup>1</sup>, A. Prat<sup>3</sup>, V. Guarneri<sup>5</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>5</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>IDIBAPS, Barcelona, ES, <sup>7</sup>Hospital Clinic, Barcelona, ES, <sup>8</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>9</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

12:00 - 12:00 **169P - Trastuzumab use among patients with HER2-positive metastatic breast cancer in an electronic health records database**

N. Lindegger<sup>1</sup>, C. Ike<sup>2</sup>, N. Schwartz<sup>2</sup>, A. Surinach<sup>3</sup>, Y. Liu<sup>3</sup>, K. Debusk<sup>2</sup>, <sup>1</sup>Seattle Genetics - SeaGen International GmbH, Zug, CH, <sup>2</sup>Seattle Genetics, Bothell, US, <sup>3</sup>Genesis Research, Hoboken, US

12:00 - 12:00 **170P - 18F-FDG PET/CT features of the metastases from intrinsic NSIBC molecular types and its prognostic value**

M. Xu, J. Chen, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN

12:00 - 12:00 **171P - An outcomes summary of the clinical advances curriculum on CDK4 &#x26; 6 inhibition in breast cancer**

N. Dorkhom<sup>1</sup>, D. Middleton<sup>2</sup>, P. Guedj<sup>3</sup>, P. Chen<sup>4</sup>, K. Lucero<sup>5</sup>, G. Curigliano<sup>6</sup>, <sup>1</sup>Medscape, Naarden, NL, <sup>2</sup>Medscape education, Chicago, US, <sup>3</sup>Medscape France, Paris, FR, <sup>4</sup>Medscape education, New York, US, <sup>5</sup>Medscape Education, New York, US, <sup>6</sup>IEO - Istituto Europeo di Oncologia, Milan, IT

12:00 - 12:00 **172P - REACHAUT: Real-world study of first-line (1L) ribociclib (RIB)&#xa0;&#x2b;&#xa0;endocrine therapy (ET) in HR&#x2b;, HER2-metastatic breast cancer (MBC)**

C. Singer<sup>1</sup>, D. Egle<sup>2</sup>, R. Greil<sup>3</sup>, L. Öhler<sup>4</sup>, E. Petru<sup>5</sup>, C. Suppan<sup>6</sup>, M. Marhold<sup>7</sup>, G. Pfeiler<sup>7</sup>, C. Brunner<sup>2</sup>, C. Tinchon<sup>8</sup>, S. Halper<sup>9</sup>, A. Galid<sup>10</sup>, U. Pluschnig<sup>11</sup>, F. Haslbauer<sup>12</sup>, M. Hubalek<sup>13</sup>, A. Redl<sup>14</sup>, J. Flatschacher<sup>15</sup>, M. Hennebelle<sup>15</sup>, B. Mraz<sup>15</sup>, R. Bartsch<sup>7</sup>, <sup>1</sup>Comprehensive Cancer center, Medical University of Vienna, Vienna, AT, <sup>2</sup>Medical University of Innsbruck, Innsbruck, AT, <sup>3</sup>Paracelsus Medical University Salzburg, salzburg, AT, <sup>4</sup>St Joseph Hospital, Vienna, AT, <sup>5</sup>Medical University of Graz, Graz, AT, <sup>6</sup>Medical University of Graz, Graz, AT, <sup>7</sup>Medical University of Vienna, Vienna, AT, <sup>8</sup>Leoben State Hospital, Leoben, AT, <sup>9</sup>Landesklinikum Wiener Neustadt (Wiener Neustadt Hospital), Wiener Neustadt, AT, <sup>10</sup>Breast Center Hanusch KH, Vienna, AT, <sup>11</sup>Klinikum Klagenfurt, Klagenfurt, AT, <sup>12</sup>Saizkammergut Klinikum Vocklabruck, Vocklabruck, AT, <sup>13</sup>Brustzentrum Schwaz, Schwaz, AT, <sup>14</sup>Datamedrix GmbH, Wien, AT, <sup>15</sup>Novartis Pharma

GmbH, Vienna, AT

- 12:00 - 12:00 **173P - Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data**  
D. Skrobo<sup>1</sup>, N. Walsh<sup>2</sup>, C. Quinn<sup>1</sup>, J. Walshe<sup>1</sup>, L.M. Smyth<sup>1</sup>, G. Gullo<sup>1</sup>, J. Crown<sup>1</sup>, <sup>1</sup>St Vincents University Hospital, Dublin, IE, <sup>2</sup>National Institute for Cellular Biotechnology, Dublin, IE
- 12:00 - 12:00 **174P - Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer**  
G. Vidal<sup>1</sup>, K. Debusk<sup>2</sup>, S. Gautam<sup>3</sup>, A. Vlahiotis<sup>3</sup>, M. Fisher<sup>3</sup>, S. Pulgar<sup>2</sup>, <sup>1</sup>West Cancer Center and Research Institute, Germantown, US, <sup>2</sup>Seattle Genetics, Bothell, US, <sup>3</sup>Concerto HealthAI, Memphis, US
- 12:00 - 12:00 **175P - Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR<sup>+</sup>/HER2-advanced or metastatic breast cancer in Italy and Germany**  
S. De Placido, Md<sup>1</sup>, S. Brucker, Md<sup>2</sup>, E. Law, Pharmd, Phd<sup>3</sup>, M. Ajmera, Phd<sup>4</sup>, D. Mitra, Ma<sup>3</sup>, K. Davis, Ma<sup>4</sup>, N. Harbeck, Md<sup>5</sup>, M. De Laurentiis, Md<sup>6</sup>, <sup>1</sup>University of Naples Federico II, Napoli, IT, <sup>2</sup>Tübingen University Hospital, Tübingen,, DE, <sup>3</sup>Pfizer Inc, New York, US, <sup>4</sup>RTI Health Solutions, Research Triangle Park, US, <sup>5</sup>Brustzentrum der Universität München (LMU), München, DE, <sup>6</sup>National Cancer Institute "Fondazione Pascale", Napoli, IT
- 12:00 - 12:00 **176P - Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices**  
A. Brufsky<sup>1</sup>, X. Liu<sup>2</sup>, B. Li<sup>2</sup>, L. Mcroy<sup>3</sup>, R. Layman<sup>4</sup>, <sup>1</sup>Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Pfizer Inc - USA, New York, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **177P - Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Germany: Results from the IRIS study**  
G. Taylor-Stokes<sup>1</sup>, L. Zhan<sup>2</sup>, K. Mycock<sup>3</sup>, G. Milligan<sup>1</sup>, A. Ghale<sup>1</sup>, D. Mitra<sup>2</sup>, <sup>1</sup>Adelphi Group, Bollington, GB, <sup>2</sup>Pfizer Inc, New York, US, <sup>3</sup>Adelphi Real World - Adelphi Group, Bollington, GB
- 12:00 - 12:00 **178P - Risks of distant metastasis of different breast cancer subtypes after surgery: A cohort study in indigenous Indonesian population**  
H. Sakti<sup>1</sup>, W. Avanti<sup>1</sup>, L. Choridah<sup>1</sup>, E.K.D. Dwianingsih<sup>1</sup>, W. Harahap<sup>2</sup>, T. Aryandono<sup>1</sup>, S. Anwar<sup>1</sup>, <sup>1</sup>Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>2</sup>Dr M Jamil Hospital / Faculty of Medicine Universitas Andalas,, Padang, ID
- 12:00 - 12:00 **179TiP - EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER<sup>+</sup>/HER2- advanced breast cancer following CDK4/6 inhibitor therapy**



A. Bardia<sup>1</sup>, J. Lu<sup>2</sup>, V. Kaklamani<sup>3</sup>, J. Jung<sup>4</sup>, A. Anderson-Villaluz<sup>4</sup>, M. Conlan<sup>5</sup>, F.-C. Bidard<sup>6</sup>, J. Cortés<sup>7</sup>, P. Aftimos<sup>8</sup>, <sup>1</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>2</sup>USC Norris Comprehensive Cancer Center, Los Angeles, US, <sup>3</sup>UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, <sup>4</sup>Radius Health, Inc., Waltham, US, <sup>5</sup>Radius Health Inc, Waltham, US, <sup>6</sup>Institut Curie, Paris, FR, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Institute Jules Bordet, Brussels, BE

12:00 - 12:00 **180TiP - Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2<sup>+</sup>/HR<sup>+</sup>) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial**

E. Ciruelos<sup>1</sup>, P. Villagrasa<sup>2</sup>, M. Oliveira<sup>3</sup>, S. Pernas Simon<sup>4</sup>, J. Cortés<sup>5</sup>, S. Vazquez<sup>6</sup>, N. Martínez<sup>7</sup>, A. Perelló<sup>8</sup>, B. Bermejo De Las Heras<sup>9</sup>, E. Martínez<sup>10</sup>, I. Garau Llinas<sup>11</sup>, M. Mele Olive<sup>12</sup>, A. Montaña<sup>13</sup>, E. Vega<sup>14</sup>, B. Cantos<sup>15</sup>, M.J. Echarri<sup>16</sup>, T. Pascual<sup>17</sup>, P. Celiz<sup>18</sup>, X. González-Farré<sup>19</sup>, A. Prat<sup>20</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>SOLTI, Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, <sup>7</sup>Ramon y Cajal Hospital, Madrid, ES, <sup>8</sup>Hospital Universitari Son Espases, Palma de Mallorca, ES, <sup>9</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>10</sup>Consortio Hospitalario Provincial de Castellón, Castelló de la Plana, ES, <sup>11</sup>Hospital Son Llatzer, Palma de Mallorca, ES, <sup>12</sup>Hospital Universitari Sant Joan de Reus, Reus, ES, <sup>13</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>14</sup>Centro Integral Oncológico Clara Campal, Madrid, ES, <sup>15</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>16</sup>Hospital Severo Ochoa, Leganes, ES, <sup>17</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>18</sup>SOLTI HQ, Barcelona, ES, <sup>19</sup>Hospital General de Catalunya, San Cugat del Valles, ES, <sup>20</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **181TiP - Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)**

P. Schmid<sup>1</sup>, H. Rugo<sup>2</sup>, J. Cortés<sup>3</sup>, P. Blum<sup>4</sup>, K. Crossley<sup>5</sup>, D. Massey<sup>4</sup>, H. Burris, Iii<sup>6</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Boehringer Ingelheim International GmbH, Biberach, DE, <sup>5</sup>Boehringer Ingelheim Ltd, Bracknell, GB, <sup>6</sup>Sarah Cannon Research Institute, Nashville, US

12:00 - 12:00 **182TiP - Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR<sup>+</sup>)/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy**

S. Blanch<sup>1</sup>, J.M. Pérez-García<sup>2</sup>, J. Balmaña<sup>3</sup>, A. Prat<sup>4</sup>, J.E. Alés-Martínez<sup>5</sup>, J. De La Haba<sup>6</sup>, E. Alba<sup>7</sup>, P. Palacios-Ozores<sup>8</sup>, M. Ramos<sup>9</sup>, L. Lema<sup>10</sup>, J.Á. García Sáenz<sup>11</sup>, M. Sampayo-Cordero<sup>12</sup>, A. Malfettone<sup>12</sup>, J. Cortés<sup>3</sup>, A. Llombart Cussac<sup>13</sup>, <sup>1</sup>Instituto Valenciano de Oncología, Valencia, ES, <sup>2</sup>IOB, Institute of Oncology, QuironSalud Group; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, Madrid

and Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>Hospital Nuestra Señora de Sonsoles, Ávila, ES, <sup>6</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>7</sup>Hospital Virgen de la Victoria, Málaga, ES, <sup>8</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>9</sup>Centro Oncológico de Galicia, A Coruña, ES, <sup>10</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>11</sup>Hospital Clínico San Carlos, Madrid, ES, <sup>12</sup>MedSIR - Medica Scientia Innovation Research, Barcelona, ES, <sup>13</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES

- 12:00 - 12:00 **Supportive care and survivorship**
- 12:00 - 12:00 **186P - Using a new controlled thermotherapy (Hilotherapy) during chemotherapy prevents chemotherapy induced polyneuropathy (CIPN)**  
T. Schaper, B. Gross, L. Franzmann, M. Darsow, Luisenkrankenhaus GmbH & Co KG, Düsseldorf, DE
- 12:00 - 12:00 **187P - Patient-reported outcomes near end-of-life in patients with breast cancer**  
A. Batra<sup>1</sup>, C. Cuthbert<sup>2</sup>, R. Rigo<sup>3</sup>, A. Harper<sup>4</sup>, D. Boyne<sup>4</sup>, L. Yang<sup>4</sup>, W. Cheung<sup>3</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>University of Calgary, Calgary, CA, <sup>3</sup>Tom Baker Cancer Center, Calgary, CA, <sup>4</sup>Alberta Health Services, Calgary, CA
- 12:00 - 12:00 **188P - Impact of HIV infection (HIV) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis**  
M. Brandão<sup>1</sup>, M. Bruzzone<sup>2</sup>, M.A. Franzoi<sup>1</sup>, C. De Angelis<sup>1</sup>, D. Eiger<sup>1</sup>, R. Caparica<sup>1</sup>, N. Dauby<sup>3</sup>, M. Ceppi<sup>2</sup>, M. Piccart<sup>1</sup>, C. Carrilho<sup>4</sup>, N. Lunet<sup>5</sup>, L. Buisseret<sup>6</sup>, E. De Azambuja<sup>1</sup>, M. Lambertini<sup>2</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>University of Genova, Genova, IT, <sup>3</sup>Centre Hospitalier Universitaire Saint-Pierre, Bruxelles, BE, <sup>4</sup>Faculty of Medicine University Eduardo Mondlane, Maputo, MZ, <sup>5</sup>Instituto de Saúde Pública da Universidade do Porto, Porto, PT, <sup>6</sup>Institut Jules Bordet, Brussels, BE
- 12:00 - 12:00 **189P - Recommendation for 'a start to move' program: A 8-week program of incremental physical activity in sedentary breast cancer survivors**  
K. Mazzocco<sup>1</sup>, M. Masiero<sup>1</sup>, M. Mazza<sup>2</sup>, D. Radice<sup>1</sup>, P. Maisonneuve<sup>1</sup>, G. Pravettoni<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **190P - Phyllodes tumour of the breast: 10 years of experience in a Mexican oncology reference center**  
M.I. Contreras Salcido, J. González Vela, J. Lara Campos, E. Llerena Hernandez, D. Hernández Barajas, O. Vidal Gutiérrez, A. Adriana González Gutiérrez, R. Martínez Granados, M. Ponce Camacho, M. Molina Ayala, Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, MX
- 12:00 - 12:00 **192P - Strategies and results of oncofertility counselling in young breast cancer patients**  
J. Kufel-Grabowska<sup>1</sup>, M. Litwiniuk<sup>2</sup>, S. Marszałek<sup>3</sup>, M. Górecki<sup>1</sup>, M. Malinowska<sup>4</sup>, J. Doś<sup>3</sup>,

A. Marszalek<sup>2</sup>, W. Suchorska<sup>5</sup>, M. Lesiak<sup>6</sup>, E. Straburzynska-Migaj<sup>7</sup>, A. Nowak<sup>6</sup>, A. Bartczak-Rutkowska<sup>7</sup>, M. Dudek<sup>6</sup>, P. Nowaczyk<sup>1</sup>, P. Jedrzejczak<sup>6</sup>, <sup>1</sup>Wielkopolskie Centrum Onkologii, Poznan, PL, <sup>2</sup>Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>3</sup>Wielkopolskie Centrum Onkologii i Uniwersytet Medyczny w Poznaniu, Poznan, PL, <sup>4</sup>wielkopolskie Centrum Onkologii, Poznan, PL, <sup>5</sup>wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL, <sup>6</sup>University of Medical Sciences in Poznan, Poznan, PL, <sup>7</sup>university of Medical Sciences in Poznan, Poznan, PL

- 12:00 - 12:00 **194P - Follow up after breast cancer in real life**  
J. Zaluska-Kusz, M. Litwiniuk, Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL
- 12:00 - 12:00 **196P - Menopausal symptoms in premenopausal patients with luminal early breast cancer developing chemotherapy-induced amenorrhea**  
A. Zribi, I. Ben Abdallah, S. Ben Nasr, J. Ayari, S. Fendri, M. Balti, A. Haddaoui, Hopital Militaire de Tunis, Tunis, TN
- 12:00 - 12:00 **197P - Epirubicin-induced cardiotoxicity: Use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines**  
I. Ben Abdallah, S. Ben Nasr, C. Chourabi, S. Fendri, M. Balti, A. Zribi, W. Fehri, A. Haddaoui, Hopital Militaire de Tunis, Tunis, TN
- 12:00 - 12:00 **198P - Comparative study between the clinical effect of palonosetron and granisetron as antiemetic therapy for patients receiving highly emetogenic chemotherapy regimens**  
M. Mahrous, Egypt Air Hospital, Cairo, EG
- 12:00 - 12:00 **199TiP - A single-arm, open label, single center study to evaluate the safety and clinical outcome of using FR-Mask in breast cancer patients with radiation-irritated skin**  
C.-N. Chu<sup>1</sup>, S.-C. Wu<sup>2</sup>, D.-T. Bau<sup>3</sup>, <sup>1</sup>China Medical University Hospital, Taichung City, TW, <sup>2</sup>China Medical University Hospital, Taichung, TW, <sup>3</sup>China Medical University, Taichung, TW

**12:45 - 14:15** **Type: Proffered paper** **Channel 1**  
**Title: Proffered papers 3 - Best abstracts**  
Chair(s): Giuseppe Curigliano, IT

12:45 - 12:45 **Session DOI**

12:45 - 12:45 **Introduction**

12:45 - 13:00 **1270 - Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo**



T. Karn<sup>1</sup>, C. Denkert<sup>2</sup>, K. Weber<sup>3</sup>, U. Holtrich<sup>4</sup>, C. Hanusch<sup>5</sup>, B. Sinn<sup>6</sup>, B. Higgs<sup>7</sup>, P. Jank<sup>8</sup>, J. Huober<sup>9</sup>, J.-U. Blohmer<sup>10</sup>, W. Schmitt<sup>6</sup>, S. Wu<sup>7</sup>, M. Van Mackelenbergh<sup>11</sup>, C. Schem<sup>12</sup>, E. Stickeler<sup>13</sup>, C. Jackisch<sup>14</sup>, M. Untch<sup>15</sup>, A. Schneeweiss<sup>16</sup>, S. Loibl<sup>3</sup>,

<sup>1</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>2</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>3</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>4</sup>Goethe University, Frankfurt, DE, <sup>5</sup>Rotkreuzklinikum München, München, DE, <sup>6</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>7</sup>Medimmune + LAP&P, Gaithersburg, US, <sup>8</sup>Uniklinikum Giessen und Marburg (UKGM), Marburg, DE, <sup>9</sup>Universitätsfrauenklinik Ulm, Ulm, DE, <sup>10</sup>St. Gertrauden-Krankenhaus, Berlin, DE, <sup>11</sup>University Hospital Kiel, Kiel, DE, <sup>12</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>13</sup>Universitätsklinikum Aachen (UKA), Aachen, Germany, DE, <sup>14</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>15</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>16</sup>University Hospital Heidelberg, Heidelberg, DE

13:00 - 13:15 **1280 - PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIRO2-IMMUNO randomized phase II trial**

T. Bachelot<sup>1</sup>, T. Filleron<sup>2</sup>, F. Dalenc<sup>2</sup>, I. Bieche<sup>3</sup>, I. Gaberis<sup>4</sup>, E. Rouleau<sup>4</sup>, A. Tran-Dien<sup>4</sup>, J. Adam<sup>5</sup>, A. Lusque<sup>2</sup>, M. Jimenez<sup>6</sup>, A. Jacquet<sup>6</sup>, F. André<sup>4</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>3</sup>Institut Curie, PARIS, FR, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>UNICANCER, Paris, FR

13:15 - 13:35 **Invited discussant abstracts: 1270 and 1280**

L. Pusztai, Yale School of Medicine, New Haven, US

13:35 - 13:50 **LBA1 - Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)**

K. Jhaveri<sup>1</sup>, D. Juric<sup>2</sup>, Y.-S. Yap<sup>3</sup>, S. Cresta<sup>4</sup>, R. Layman<sup>5</sup>, F. Duhoux<sup>6</sup>, C. Terret<sup>7</sup>, S. De Vita<sup>8</sup>, N. Kundamal<sup>9</sup>, W. He<sup>8</sup>, A. Balbin<sup>8</sup>, Q. Sheng<sup>8</sup>, A. Crystal<sup>8</sup>, G. Curigliano<sup>10</sup>, <sup>1</sup>Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>6</sup>Université Catholique de Louvain, Brussels, BE, <sup>7</sup>Centre Léon Bérard, Lyon, FR, <sup>8</sup>Novartis Institutes for Biomedical Research, Massachusetts, US, <sup>9</sup>Novartis Institutes for Biomedical Research, East Hanover, US, <sup>10</sup>IEO - Istituto Europeo di Oncologia, Milan, IT

13:50 - 14:05 **Invited discussant of LBA**

S. Cinieri, Ospedale A. Perrino, Brindisi, IT

**12:45 - 14:15**    **Type: Educational session**    **Channel 2**  
**Title: Surgery session**  
Chair(s): Tibor Kovacs, GB

12:45 - 12:45    **Session DOI**

12:45 - 12:45    **Introduction**

12:45 - 13:05    **The role of AI in surgical education and surgery planning**  
P. Gouveia, Champalimaud Foundation - Champalimaud Clinical Centre, Lisbon, PT

13:05 - 13:25    **The role of surgery in metastatic breast cancer**  
M. Knauer, Brustzentrum Ostschweiz AG, St. Gallen, CH

13:25 - 13:45    **The role of the surgical oncologist in breast cancer trials**  
M.-J. Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

13:45 - 13:55    **Live Q&A**

**12:45 - 14:15**    **Type: Educational session**    **Channel 3**  
**Title: Risk stratification according to genomic classifier**  
 Chair(s): Christos Sotiriou, BE

12:45 - 12:45    **Session DOI**

12:45 - 12:45    **Introduction**

C. Sotiriou, Institute Jules Bordet, Brussels, BE

12:45 - 13:05    **Clinical utility of gene expression classifiers in early breast cancer**

C. Sotiriou, Institute Jules Bordet, Brussels, BE

13:05 - 13:25    **Gene panels versus whole genome sequencing: Ready for clinical practice?**

M. Arnedos, Institut Gustave Roussy, Villejuif, FR

13:25 - 13:45    **What is the role of liquid biopsy for precision medicine?**

M. Ignatiadis, Institute Jules Bordet, Brussels, BE

13:45 - 14:05    **Single cell omics analysis: Promises and future applications**

J. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, US

**12:45 - 13:30**    **Type: Industry Satellite Symposia**    **Industry satellites**  
**Title: Daiichi Sankyo 2 - Industry Satellite Symposium: CME**    **(On Demand)**  
**Webinar Supported by Daiichi Sankyo**

12:45 - 13:00    **Novel Anti-HER2-Directed ADCs**

A. Brufsky, Magee-Womens Hospital of UPMC, Pittsburgh, US

13:00 - 13:15    **Novel Targeted Therapies for MBC - Tyrosine kinase inhibitors**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

13:15 - 13:30    **Novel Anti-HER2 Monoclonal Antibody**

T. Bachelot, Centre Léon Bérard, Lyon, FR

13:30 - 13:45    **Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments**

T. Bachelot, Centre Léon Bérard, Lyon, FR



<b>14:30 - 15:45</b>	<b>Type: Educational session</b> <b>Title: Special subtypes in breast cancer</b> Chair(s): Giuseppe Viale, IT	<b>Channel 1</b>
14:30 - 14:30	<b>Session DOI</b>	
14:30 - 14:30	<b>Introduction</b>	
14:30 - 14:50	<b>Sarcoma of the breast</b> <u>P. Dubsy</u> , Hirslanden-Klinik St. Anna, Luzern, CH	
14:50 - 15:10	<b>Medullary type carcinoma</b> <u>W. Weichert</u> , Technische Universität München-Institute of Pathology, Munich, DE	
15:10 - 15:30	<b>Apocrine? Metaplastic and adenoid cystic</b> <u>G. Viale</u> , Istituto Europeo di Oncologia, Milan, IT	
15:30 - 15:45	<b>Discussion and Conclusions</b>	

**14:30 - 15:45**    **Type: Educational session**    **Channel 2**  
**Title: Management of brain metastases in breast cancer**  
Chair(s): Volkmar Mueller, DE

14:30 - 14:30    **Session DOI**

14:30 - 14:30    **Introduction**

V. Mueller, Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE

14:30 - 14:50    **CNS metastases in ER-positive breast cancer patients**

I. Witzel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

14:50 - 15:10    **Medical treatment of HER2-positive patients**

M. Oliveira, Vall d`Hebron University Hospital, Barcelona, ES

15:10 - 15:30    **CNS metastases from triple negative MBC, Current treatment, Future prospect**

T. Bachelot, Centre Léon Bérard, Lyon, FR

15:30 - 15:45    **Live Q&A**

**14:30 - 15:45**    **Type: Educational session**    **Channel 3**  
**Title: Role of loco regional treatment: Now and tomorrow**  
Chair(s): Philip Poortmans, FR

14:30 - 14:30    **Session DOI**

14:30 - 14:30    **Introduction**

P. Poortmans, Dr. Bernard Verbeeten Instituut, Tilburg, FR

14:30 - 14:50    **Medical oncology treatment**

G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

14:50 - 15:10    **Radiation**

P. Poortmans, Dr. Bernard Verbeeten Instituut, Tilburg, FR

15:10 - 15:30    **Surgeon**

M. Morrow, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

**15:00 - 15:45**    **Type: Industry Satellite Symposia**    **Industry satellites (On Demand)**  
**Title: Novartis - Industry Satellite Symposium: The Power of Choice in HR+, HER2-Advanced Breast Cancer: A Case Continuum**  
Chair(s): Dejan Juric, US

15:00 - 15:05    **Panel discussion**  
D. Juric<sup>1</sup>, F. Cardoso<sup>2</sup>, H.-C. Kolberg<sup>3</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>3</sup>Marienhospital Bottrop, Bottrop, DE

15:05 - 15:10    **Panel discussion**  
D. Juric<sup>1</sup>, F. Cardoso<sup>2</sup>, H.-C. Kolberg<sup>3</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>3</sup>Marienhospital Bottrop, Bottrop, DE

**15:45 - 16:30**    **Type: Industry Satellite Symposia**    **Industry satellites (On Demand)**  
**Title: Pfizer - Industry Satellite Symposium: Optimising breast cancer outcomes: Clinical and real-world experience lead to strength in numbers**  
Chair(s): Nadia Harbeck, DE

15:45 - 16:10    **From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment**  
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US



**16:00 - 17:30**    **Type: Educational session**    **Channel 1**  
**Title: Immuno-oncology**  
Chair(s): Peter Schmid, GB

16:00 - 16:00    **Session DOI**

16:00 - 16:00    **Introduction**

16:00 - 16:20    **Immunotherapy in metastatic breast cancer**  
J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES

16:20 - 16:40    **Immunotherapy in early breast cancer**  
P. Schmid, Barts Cancer Institute-Queen Mary University of London, London, GB

16:40 - 17:00    **Managing side effects of immunotherapy**  
C. Criscitiello, IEO - Istituto Europeo di Oncologia, Milan, IT

17:00 - 17:20    **Selecting patients for immunotherapy - PDL1 and beyond**  
G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT

17:20 - 17:30    **Live Q&A**

**16:00 - 17:30**    **Type: Educational session**    **Channel 2**  
**Title: Precision medicine**  
Chair(s): Nicholas Turner, GB

16:00 - 16:00    **Session DOI**

16:00 - 16:00    **Introduction**

16:00 - 16:20    **Selecting PI3 kinase pathway inhibitors for advanced breast cancer**  
V. Dieras, Centre Eugene - Marquis, Rennes, FR

16:20 - 16:40    **Resistance to CDK4/6 inhibitors beyond progression**  
L. Malorni, Hospital of Prato, Azienda USL Toscana Centro, Prato, IT

16:40 - 17:00    **Utility of liquid biopsies in clinical practice**  
N. Turner, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

17:00 - 17:20    **Personalising immunotherapy - beyond PDL1 expression**  
M. Kok, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

17:20 - 17:30    **Live Q&A**

**16:00 - 17:30**    **Type: Educational session**    **Channel 3**  
**Title: Early breast cancer: TNBC**  
Chair(s): Miguel Martin Jimenez, ES

16:00 - 16:05    **Session DOI**

16:05 - 16:10    **Introduction**

M. Martin Jimenez, Hospital General Universitario Gregorio Marañón, Madrid, ES

16:10 - 16:30    **Utility of til's in predicting pathological response to neoadjuvant chemotherapy in TNBC**

C. Denkert, Uniklinikum Giessen und Marburg, Marburg, DE

16:30 - 16:50    **Utility of genomic assays in predicting pathological response to neoadjuvant chemotherapy in TNBC**

A. Llombart Cussac, Hospital Universitario Arnau de Vilanova, Lleida, ES

16:50 - 17:10    **Role of anthracyclines as adjuvant therapy in TNBC**

M. Martin Jimenez, Hospital General Universitario Gregorio Marañón, Madrid, ES

17:10 - 17:30    **Role of platinum salts and alkylating agents as adjuvant therapy in TNBC**

F. Marmé, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE

17:45 - 19:15	<b>Type: Educational session</b> <b>Title: Precision medicine in metastatic triple negative breast cancer</b> Chair(s): Fabrice André, FR	<b>Channel 1</b>
17:45 - 17:45	<b>Session DOI</b>	
17:45 - 17:45	<b>Introduction</b>	
17:45 - 18:05	<b>How to predict sensitivity to anti-PD(L)1?</b> <u>S. Loi</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
18:05 - 18:25	<b>What is the target population of PARP inhibitors?</b> <u>C. Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, ES	
18:25 - 18:45	<b>Dissecting PI3K/AKT/mTOR pathway in mTNBC</b> <u>R. Kristeleit</u> , UCL Cancer Institute/Paul O'Gorman Building, London, GB	
18:45 - 19:05	<b>How to integrate predictors in a single algorithm?</b> <u>J. Reis-Filho</u> , Memorial Sloan Kettering Cancer Center, New York, US	
19:05 - 19:15	<b>Live Q&amp;A</b>	



17:45 - 19:15	<b>Type: Educational session</b> <b>Title: Designing innovative clinical trials in breast cancer</b> Chair(s): Giuseppe Curigliano, IT	<b>Channel 2</b>
17:45 - 17:45	<b>Session DOI</b>	
17:45 - 17:45	<b>Introduction</b>	
17:45 - 18:05	<b>Window of opportunity trials across subtypes</b> <u>E. Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, US	
18:05 - 18:25	<b>Long term vs surrogate vs endpoint</b> <u>S. Michiels</u> , Gustave Roussy, Villejuif, FR	
18:25 - 18:45	<b>Methology of early drugs development : a break with the past</b> <u>A. Awada</u> , Institute Jules Bordet, Brussels, BE	
18:45 - 19:05	<b>Decision making process for patients involved in clinical trials</b> <u>G. Pravettoni</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
19:05 - 19:15	<b>Live Q&amp;A</b>	

<b>17:45 - 19:15</b>	<b>Type: Special session</b> <b>Title: Collaborative session ESMO-SIOG - Older patients and breast cancer</b> Chair(s): Laura Biganzoli, IT; Giuseppe Curigliano, IT	<b>Channel 3</b>
17:45 - 17:45	<b>Session DOI</b>	
17:45 - 17:50	<b>Introduction</b> <u>L. Biganzoli</u> , Nuovo Ospedale di Prato, Prato, IT	
17:50 - 18:15	<b>Consolidation radiation therapy in inoperable elderly patients after "neo-adjuvant" therapy</b> <u>P. Poortmans</u> , Dr. Bernard Verbeeten Instituut, Tilburg, FR	
18:15 - 18:40	<b>Highlights of the new SIOG EUSOMA guidelines for breast cancer in the elderly</b> <u>L. Biganzoli</u> , Nuovo Ospedale di Prato, Prato, IT	
18:40 - 19:05	<b>Bone health in the elderly: ESMO and SIOG guidelines</b> <u>M. Aapro</u> , Clinique de Genolier, Genolier, CH	
19:05 - 19:15	<b>Take home message</b> <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
<b>19:15 - 19:20</b>	<b>Type: Opening/closure</b> <b>Title: Closure of the meeting</b>	<b>Channel 1</b>